US20050009864A1 - Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them - Google Patents

Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them Download PDF

Info

Publication number
US20050009864A1
US20050009864A1 US10/866,843 US86684304A US2005009864A1 US 20050009864 A1 US20050009864 A1 US 20050009864A1 US 86684304 A US86684304 A US 86684304A US 2005009864 A1 US2005009864 A1 US 2005009864A1
Authority
US
United States
Prior art keywords
atoms
methyl
tetrahydro
dichloro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/866,843
Inventor
Armin Hofmeister
Uwe Heinelt
Hans-Jochen Lang
Markus Bleich
Klaus Wirth
Michael Gekle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to US10/866,843 priority Critical patent/US20050009864A1/en
Publication of US20050009864A1 publication Critical patent/US20050009864A1/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to compounds of the formula I wherein:
  • compounds of the formula I are chosen from:
  • compounds of the formula I are chosen from:
  • compounds of the formula I are chosen from:
  • compounds of the invention are chosen from the following:
  • compounds of the invention are chosen from the following:
  • the invention encompasses the use of the compounds of the formula I for the treatment of disorders which can be influenced by inhibition of the sodium-proton exchange of subtype III (NHE3), in which:
  • the use of the compounds of the formula I for the treatment of disorders which can be influenced by inhibition of the sodium-proton exchange of subtype III (NHE3) are chosen from:
  • the use of the compounds of the formula I for the treatment of disorders which can be influenced by inhibition of the sodium-proton exchange of subtype III (NHE3) are chosen from:
  • the invention encompasses the use of the compounds of the formula I for the treatment of disorders which can be influenced by inhibition of the sodium-proton exchange of subtype III (NHE3), chosen from:
  • the invention encompasses the use of the compounds of the formula I for the treatment of disorders which can be influenced by inhibition of the sodium-proton exchange of subtype III (NHE3), chosen from:
  • the compounds of the formula I contain one or more centers of asymmetry, these may have both the S and the R configuration.
  • the compounds may be in the form of optical isomers, of diastereomers, of racemates or of mixtures thereof.
  • the defined alkyl radicals and partly or completely fluorinated alkyl radicals may be both straight-chain and branched.
  • Groups C a H 2a-1 and their analogs as far as C yy H 2yy-1 mean either the corresponding alkenyls, cycloalkyls, cycloalkylalkyls or alkylcycloalkyls.
  • heteroaryls are, for example, 2- or 3-thienyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 1,2,3-triazol-1-, -4- or 5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 1,2,3-oxadiazol-4- or 5-yl, 1,2,4-oxadiazol-3-or 5-yl, 1,3,4-oxadiazol-2-yl or -5-yl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or 5-yl, 2-, 3- or
  • the 5- or 6-membered heterocycles are chosen.
  • imidazolyl, pyrazolyl, pyrrolyl, triazolyl, tetrazolyl, thiazolyl and oxazolyl are chosen.
  • the terminal CH 3 groups in an alkyl chain are also regarded as CH 2 units and are in this connection viewed as CH 2 groups.
  • the substances described herein can be prepared, for example, starting from the benzylamine precursors IV. These in turn can, if not obtainable commercially, be synthesized by standard processes from the corresponding benzyl chlorides or bromides III.
  • the benzylamines IV obtained in this way may be alkylated in a manner known to the skilled worker with the appropriately substituted alpha-bromoacetophenone compounds V.
  • the alpha-bromacetophenone compounds V may be obtained from the corresponding acetophenone precursors by bromination in processes known from the literature.
  • the desired tetrahydroisoquinolines I may be obtained by known processes by reduction of the carbonyl group in VI and subsequent acid-catalyzed cyclization of the corresponding alcohols VII (cf. Tetrahedron Lett.; 1989, 30, 5837; Org. Prep. Proced. Int.; 1995, 27, 513).
  • the desired compounds of the formula I may be prepared for example from the iodides VIII by halogen/metal exchange and subsequent nucleophilic attack of the intermediate organolithium species on the carbonyl group (cf. Chem. Pharm. Bull.; 1995, 43,1543).
  • the tertiary alcohols synthesized in this way may be converted by known methods into other derivatives.
  • Alkyl-branched analogs (i) may be prepared by alkylating the corresponding diphenylacetic esters X in the alpha position by known methods.
  • the desired product XI may be converted by standard processes into the corresponding amides XII, which may be converted into the desired tetrahydroisoquinolines I in a Pictet-Spengler-analogous reaction (cf. Tetrahedron; 1987, 43, 439; Chem. Pharm. Bull.; 1985, 33, 340).
  • treating or treatment includes the treating of, for example, a patient inflicted with a disease or condition, as well as the prevention, prophylaxis, or protective treatment of a patient. Treatment also includes treating a subject susceptible to or predisposed to developing a disease or condition, which could include patients in whom a disease or condition has not yet presented as well as patients in whom the disease has been successfully treated but could redevelop or reoccur.
  • the compounds of the formula I may be excellent inhibitors of the sodium-hydrogen exchanger (NHE)—especially of the sodium of the sodium-hydrogen exchanger of subtype 3 (NHE3).
  • the compounds may be suitable for the treatment of disorders caused by oxygen deficiency.
  • the compounds may be, as a result of their pharmacological properties, suitable as antiarrhythmic medicaments with a cardioprotective component for prophylaxis of infarction and for treatment of infarction, and for the treatment of angina pectoris, in which connection they may also inhibit or reduce in a preventive manner the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the induction of ischemia-induced cardiac arrhythmias.
  • the compounds of the formula I which are used according to the invention may, as a result of inhibition of the cellular Na + /H + exchange mechanism, be used as medicaments for the treatment of all acute or chronic damage induced by ischemia or disorders induced primarily or secondarily thereby.
  • This relates to the possible use thereof as medicaments for surgical interventions, e.g. in organ transplantations, in which cases the compounds may be used, for exmple, both to protect the organs in the donor before and during removal, to protect removed organs for example on treatment with or storage thereof in physiological bath fluids, as well as during the transfer into the recipient organism.
  • the compounds may in some embodiments likewise be valuable medicaments with a protective action during the performance of angioplastic surgical interventions, for example on the heart as well as peripheral vessels.
  • the compounds may also be suitable as medicaments for the treatment of ischemias of the nervous system, especially of the CNS, in which connection they may be suitable for example for the treatment of stroke or of cerebral edema.
  • the compounds of the formula I which are used according to the invention may likewise be suitable for the treatment of types of shock, such as, for example, of allergic, cardiogenic, hypovolemic and bacterial shock.
  • the compounds may induce an improvement in the respiratory drive and may therefore be used to treat respiratory conditions associated with the following clinical conditions and diseases: disturbance of central respiratory drive (e.g. central sleep apnea, sudden infant death, postoperative hypoxia), muscle-related breathing disorders, breathing disorders after long-term ventilation, breathing disorders associated with altitude adaptation, obstructive and mixed type of sleep apnea, acute and chronic pulmonary disorders with hypoxia and hypercapnia.
  • disturbance of central respiratory drive e.g. central sleep apnea, sudden infant death, postoperative hypoxia
  • muscle-related breathing disorders e.g. central breathing apnea, sudden infant death, postoperative hypoxia
  • breathing disorders after long-term ventilation e.g. central sleep apnea, sudden infant death, postoperative hypoxia
  • breathing disorders after long-term ventilation e.g. central sleep apnea, sudden infant death, postoperative hypoxia
  • muscle-related breathing disorders e.g. central breathing disorders, breathing disorders after long-term ventilation
  • the compounds additionally may in some embodiments increase the tone of the muscles of the upper airways, so that snoring is suppressed.
  • a combination of an NHE inhibitor with a carbonic anhydrase inhibitor e.g. acetazolamide
  • the latter inducing metabolic acidosis and thus itself increasing respiratory activity may in some embodiments prove to be advantageous due to an enhanced effect and reduced use of active ingredient.
  • the compounds used according to the invention have a mild laxative effect and accordingly may be used advantageously as laxatives or if there is a risk of constipation, in which case the compounds may prevent the ischemic damage associated with constipation in the intestinal region.
  • the compounds of the formula I used according to the invention may demonstrate a strong inhibitory effect on the proliferation of cells, for example of fibroblast cell proliferation and the proliferation of smooth muscular muscle cells.
  • the compounds of the formula I may therefore is some embodiments be suitable as valuable therapeutic agents for diseases in which cell proliferation represents a primary or secondary cause, and may therefore be used as antiatherosclerotic agents, agents to prevent late complications of diabetes, cancers, fibrotic disorders such as pulmonary fibrosis, hepatic fibrosis or renal fibrosis, organ hypertrophies and hyperplasias, in particular for prostate hyperplasia or prostate hypertrophy.
  • the compounds used according to the invention may be effective inhibitors of the cellular sodium-proton antiporter (Na/H exchanger) which is elevated in numerous disorders (essential hypertension, atherosclerosis, diabetes, etc.), also in those cells which are readily amenable to measurements, such as, for example, in erythrocytes, platelets or leukocytes.
  • the compounds used according to the invention in some embodiments therefore may be suitable as excellent and simple scientific tools, for example in their use as diagnostic agents for determining and distinguishing different types of hypertension, but also of atherosclerosis, of diabetes, proliferative disorders etc.
  • the compounds of the formula I may also be suitable for preventive therapy to prevent the development of high blood pressure, for example of essential hypertension.
  • NHE inhibitors may show a beneficial effect on serum lipoproteins. It is generally acknowledged that blood lipid levels which are too high, so-called hyperlipoproteinemias, represent a considerable risk factor for the development of arteriosclerotic vascular lesions, especially coronary heart disease. The reduction of elevated serum lipoproteins therefore may have exceptional importance for the prophylaxis and regression of atherosclerotic lesions.
  • the compounds used according to the invention may therefore in some embodiments be used for the prophylaxis and regression of atherosclerotic lesions by eliminating a causal risk factor.
  • compounds of the formula I may be valuable medicaments for the prevention and treatment of coronary vasospasms, of atherogenesis and of atherosclerosis, of left-ventricular hypertrophy and of dilated cardiomyopathy, and thrombotic disorders.
  • the compounds of the invention may therefore be used for producing a medicament for the prevention and treatment of sleep apneas and muscle-related respiratory disorders; for producing a medicament for the prevention and treatment of snoring; for producing a medicament for lowering blood pressure; for producing a medicament for the prevention and treatment of disorders induced by ischemia and reperfusion of central and peripheral organs, such as acute renal failure, stroke, endogenous states of shock, intestinal disorders etc.; for producing a medicament for the treatment of late damage from diabetes and chronic renal disorders, in particular of all inflammations of the kidneys (nephritides) which are associated with increased protein/albumin excretion; for producing a medicament for the treatment of infection by ectoparasites in human and veterinary medicine; for producing a medicament for the treatment of said disorders in combinations with hypotensive substances, preferably with angiotensin converting enzyme (ACE) inhibitors, with diuretics and saluretics such as furosemide, hydrochlorothiazide, pseudoaldoster
  • At least one sodium-proton exchange inhibitors of the formula I is administered as a medicament for lowering elevated blood lipid levels, including as the combination of sodium-proton exchange inhibitors with hypotensive medicaments and/or medicaments with hypolipidemic activity.
  • Medicaments which comprise a compound of the invention can in this connection may be administered orally, parenterally, intravenously, rectally, transdermally or by inhalation, the preferred administration being dependent on the particular characteristics of the disorder.
  • the compounds of the invention may moreover may be used alone or together with pharmaceutical excipients, both in veterinary medicine and in human medicine.
  • excipients suitable for the desired pharmaceutical formulation are familiar to the skilled worker on the basis of his expert knowledge.
  • solvents, gel formers, suppository bases, tablet excipients, and other active ingredient carriers it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavorings, preservatives, solubilizers or colors.
  • the active compounds may be mixed with additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into suitable dosage forms such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily solutions.
  • suitable dosage forms such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily solutions.
  • inert carriers which can be used include, for example, gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. It is moreover possible for the preparation to take place both as dry granules and as wet granules.
  • suitable oily carriers or solvents are vegetable or animal oils such as sunflower oil or fish liver oil.
  • the active compounds used may be converted, if desired with the substances customary for this purpose, such as solubilizers, emulsifiers or other excipients, into a solution, suspension or emulsion.
  • suitable solvents are: water, physiological saline or alcohols, e.g. ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else a mixture of the various solvents mentioned.
  • Compounds of the invention are also suitable as a pharmaceutical formulation for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active ingredient of the formula I in a pharmaceutically acceptable solvent such as, in particular, ethanol or water, or a mixture of such solvents.
  • a pharmaceutically acceptable solvent such as, in particular, ethanol or water, or a mixture of such solvents.
  • the formulation may, if required, also contain other pharmaceutical excipients such as surfactants, emulsifiers and stabilizers, and a propellant gas.
  • Such a preparation normally contains the active ingredient in a concentration of about 0.1 to 10, in particular of about 0.3 to 3, % by weight.
  • the dosage of the active ingredient of the coumpounds of the invention to be administered, and the frequency of administration, depend on the potency and duration of action of the compounds used; additionally also on the nature and severity of the disorder to be treated and on the sex, age, weight and individual responsiveness of the mammal to be treated.
  • the daily dose of a compound of the formula I for a patient weighing about 75 kg is at least 0.001 mg/kg, preferably 0.001 mg/kg, to a maximum of 10 mg/kg, preferably 1 mg/kg, of body weight.
  • a compound of the formula I for a patient weighing about 75 kg is at least 0.001 mg/kg, preferably 0.001 mg/kg, to a maximum of 10 mg/kg, preferably 1 mg/kg, of body weight.
  • higher and, in particular, more frequent dosages may also be necessary, e.g. up to 4 single doses a day. Up to 200 mg a day may be necessary, in particular on i.v. administration, for example for a patient with infarction in the intensive care unit.
  • R t retention times (R t ) indicated below relate to LCMS measurements with the following parameters:
  • Method A stationary phase: Merck Purospher 3 ⁇ 2 ⁇ 55 mm mobile phase: 95% H 2 O (0.05% TFA) ⁇ 95% acetonitrile; 4 min; 95% acetonitrile; 1.5 min ⁇ 5% acetonitrile; 1 min; 0.5 ml/min, 30° C.
  • Method B stationary phase: Merck Purospher 3 ⁇ 2 ⁇ 55 mm mobile Phase: 0 min 90% H 2 O (0.05% TFA) 2.5 min-95% acetoni- trile; 95% acetonitrile to 3.3 min; 10% acetonitrile 3.4 min; 1 ml/min.
  • Method B1 stationary phase: YMC, J'sphere ODS H80 4 ⁇ 2 ⁇ 20 mm mobile phase: 0 min 90% H 2 O (0.05% TFA) 1,9 min-95% acetoni- trile; 95% acetonitrile bis 2,4 min; 10% acetonitrile 2,45 min; 1 ml/min.
  • Method C stationary phase: Merck LiChroCart 55-2 Purospher STAR RP 18e solvent: solvent A: acetonitrile/water 90:10 + 0.5% HCOOH solvent B: acetonitrile/water 10:90 + 0.5% HCOOH flow rate: 0.75 ml/min time[min] solvent B[%] 0.00 95.0 0.50 95.0 1.75 5.0 4.25 5.0 4.50 95.0 5.00 95.0 stop time: 6.20 min temperature: 40° C.
  • Method D stationary phase: Merck RP18 Purospher Star, 55 ⁇ 2 mm, 3 ⁇ KorngröBe solvent: Solvent A: acetonitrile + 0.08% HCOOH Solvent B: water + 0.1% HCOOH Flow rate 0.45 ml/min time [min] solvent B[%] 0 95 5 5 7 5 8 95 9 5 temperature: room temperature
  • the starting compound (0.256 mol) was introduced into 300 ml of acetic acid and, at 60° C, a solution of 39.9 g of bromine (1.0 eq) in 60 ml of acetic acid was added dropwise. After 1.5 h, the reaction mixture was allowed to cool to room temperature and was added to 1 l of ice-water. The precipitate was filtered off with suction, washed with water and dried, with 60 g of the title compound being isolated (melting point: 192° C.).
  • the title compound was prepared by the method described in example 7 starting from n-propylamine and 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid (see example 6).
  • the desired piperidine derivative can be obtained starting from piperidine and 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (example 5, intermediate 3) in analogy to the method described in example 10.
  • reaction is carried out in analogy to the method described in example 10, starting from pyrrolidine and 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (example 5, intermediate 3).
  • the product obtained after purification by chromatography is taken up in the DMSO/acetonitrile mixture, whereupon a precipitate separates out. This is filtered off, dissolved in 2 N HCl and freeze dried, resulting in the title compound of a colorless solid.
  • Acetyl was eliminated from N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide (example 34) by the method described in example 17, intermediate 1, in the presence of sodium ethanolate.
  • the mixture was stirred into 1.5 l of ice-water, and the precipitated product was filtered off with suction, thoroughly washed with ice-water and dried in vacuo.
  • the crude product contained, according to HPLC and NMR, some precursor and dibrominated product, but was pure enough (about 85% strength) for further reaction.
  • the title compound was synthesized starting from the compound of example 35 and methyl isothiocyanate by the method described in example 78.
  • bromo ketone building blocks was synthesized by methods known from the literature, starting from commercial acetophenones by treatment with bromine in glacial acetic acid in analogy to example 1, intermediate 2.
  • the compounds of examples 100 to 111 were prepared starting from the amine and bromo ketone components shown in table 3 in analogy to the synthetic route shown in example 1 (alkylation of the amine component by the bromo ketone component, subsequent reduction with NaBH 4 and final H 2 SO 4 -mediated cyclization).
  • Example 1 The following examples were prepared analogously to example 151. But THF was used as solvent in a closed vial. For examples 159 and 166 a reaction temperature of 85° C. was required. Example 20 required preparative HPLC purification. TABLE 6 Example Structure 159 160 161 162 163 164 165 166 167
  • N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide 150 mg, example 27
  • tetrahydrofurane 2.5 ml
  • lithium aluminiumhydride in tetrahydrofurane 0.45 ml
  • tetrahydrofurane 2.5 ml
  • N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide (588 mg, example 194) dissolved in tetrahydrofurane (10 ml) was added to a 1 M solution of lithium aluminiumhydride in tetrahydrofurane (1.8 ml). After the addition the mixture was heated to reflux temperature for 1 h. After standing over night at room temperature the mixture was heated to 50° C. and further lithium aluminiumhydride solution (2 ml) added. The mixture was heated to reflux temperature and after 0.5 h the mixture was cooled and ice added.
  • the aqueous phase was 4 times extracted with ethyl acetate. The organic layers were combined, dried (magnesium sulphate) and concentrated. The crude material was purified by preparative HPLC. The product containing fractions were combined and the acetonitrile was removed in vaccuo. After addition of sodium bicarbonate the aqueous phase was extracted with ethyl acetate. The organic layer was separated, dried (magnesium sulphate), filtered and concentrated in vaccuo to yield 270 mg of the salt free base. 45 mg of the base was dissolved in water/2N hydrochloric acid and freeze dried to give 45 mg of the title compound.
  • the crude material was purified by preparative HPLC. The product containing fractions were combined and the acetonitrile was removed in vaccuo. After addition of sodium bicarbonate the aqueous phase was extracted with ethyl acetate. The organic layer was separated, dried (magnesium sulphate), filtered and concentrated in vaccuo. The residue was dissolved in water/2N hydrochloric acid and freeze dried to give 5 mg of the title compound.
  • Racemic N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide (96 mg, example 83) was resolved by chiral preparative HPLC.
  • Racemic 1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea (316 mg, example 80) were resolved by chiral preparative HPLC.
  • the enantiomers were separately further purified using preparative HPLC.
  • the product containing fractions were combined and the acetonitrile was removed in vaccuo. After addition of sodium bicarbonate the aqueous phase was extracted with ethyl acetate.
  • the recovery in the intracellular pH (pH i ) after an acidification is ascertained, which is initiated if the NHE is capable of functioning, even under bicarbonate-free conditions.
  • the pH i was determined using the pH-sensitive fluorescent dye BCECF (Calbiochem, the precursor BCECF-AM is employed).
  • the cells were initially loaded with BCECF.
  • the BCECF fluorescence was determined in a “Ratio Fluorescence Spectrometer” (Photon Technology International, South Brunswick, N.J., USA) at excitation wavelengths of 505 and 440 nm and an emission wavelength of 535 nm and converted into the pH i using calibration curves.
  • the cells were incubated in NH 4 Cl buffer (pH 7.4) (NH 4 Cl buffer: 115 mM NaCl, 20 mM NH 4 Cl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgSO 4 , 20 mM Hepes, 5 mM glucose, 1 mg/ml BSA; a pH of 7.4 is adjusted with 1 M NaOH) even during the BCECF loading.
  • the intracellular acidification was induced by adding 975 ⁇ l of an NH 4 Cl-free buffer (see below) to 25 ⁇ l aliquots of the cells incubated in NH 4 Cl buffer. The subsequent rate of pH recovery was recorded for two minutes with NHE1, five minutes with NHE2 and three minutes with NHE3.
  • the cells were initially investigated in buffers with which a complete or absolutely no pH recovery took place.
  • the cells were incubated in Na + -containing buffer (133.8 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl 2 , 1.25 mM MgCl 2 , 0.97 mM Na 2 HPO 4 , 0.23 mM NaH 2 PO 4 , 5 mM Hepes, 5 mM glucose, a pH of 7.0 is adjusted with 1 M NaOH).
  • the cells were incubated in an Na + -free buffer (133.8 mM choline chloride, 4.7 mM KCl, 1.25 mM CaCl 2 , 1.25 mM MgCl 2 , 0.97 mM K 2 HPO 4 , 0.23 mM KH 2 PO 4 , 5 mM Hepes, 5 mM glucose, a pH of 7.0 is adjusted with 1 M NaOH).
  • the substances to be tested were made up in the Na + -containing buffer. The recovery of the intracellular pH at each test concentration of a substance was expressed as a percentage of the maximum recovery.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds of the formula I
Figure US20050009864A1-20050113-C00001
 in which R1 to R9 are as defined herein. In one embodiment, these compounds may be used as antihypertensives, for reducing or preventing ischemia-induced damage, as medicaments for surgical intervention for the treatment of ischemias of the nervous system, of stroke and of cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxative, as agent against ectoparasites, to prevent the formation of gallstones, as antiatherosclerotics, agents against late complications of diabetes, cancers, fibrotic disorders, endothelial dysfunction, organ hypertrophies and hyperplasias. In one embodiment, the compounds may be inhibitors of the cellular sodium-proton antiporter and influence serum lipoproteins and thus be used for the prophylaxis and for the regression of atherosclerotic lesions.

Description

  • This application claims the benefit of foreign priority under 35 U.S.C. §119 of German patent application no. 10159714.2 , filed on Dec. 5, 2001 and the contents of which are incorporated by reference herein.
  • The invention relates to compounds of the formula I
    Figure US20050009864A1-20050113-C00002
    wherein:
      • R1, R2, R3 and R4 are independently of one another H, F, Cl, Br, I, CN, NO2, OH, NH2, CaH2a+1, CqqH2qq−1, OCbH2b+1, COOR10, OCOR10, COR10 or Ox-(CH2)y-phenyl; wherein
        • a and b are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CaH2a+1 and OCbH2b+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • qq is 3, 4, 5, 6, 7 or 8, wherein the group CqqH2qq−1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R10 is H or CcH2c+1;
          • c is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CcH2c+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • x is zero or 1;
        • y is zero, 1, 2, 3 or 4; where the phenyl ring in the group Ox—(CH2)y-phenyl is unsubstituted or substituted by 1-3 independently chosen from F, Cl, Br, CN, NO2, OH, NH2 and CdH2d+1,
          • d is 1, 2, 3 or 4, wherein the group CdH2d+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another chosen from a heteroaryl with at least one heteroatom chosen from 1, 2, 3 or 4 N atoms, 1 oxygen atom and 1 S atom, present as ring atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another CONR11R12 or NR11R12;
      • wherein
        • R11 and R12 are independently of one another H, CeH2e+1, CrrH2rr−1;
          • e is 1, 2, 3, 4, 5, 6, 7 or 8;
          • rr is 3, 4, 5, 6, 7, or 8, wherein the groups CeH2e+1 and CrrH2rr−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O or NR13;
            • R13 is H or CfH2f+1;
            •  f is 1, 2, 3 or 4, wherein the group CfH2f+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
            • or
            • R13 and a CH2 group of R11 or R12 together with the N atom to which they are bonded form a 5- or 6-membered ring;
        • or
        • R11 and R12 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
        • or
        • R11 and R12 are independently of one another COR14, CSR14 or SO2R14;
        • wherein
          • R14 is CgH2g+1;
            • g is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CgH2g+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms, and/or one or more CH2 groups are replaced by O or NR13;
      • or
      • R1, R2, R3 and R4 are independently of one another —Oh—SOj—R15, with
        • h is zero or 1;
        • j is zero, 1 or 2;
        • R15 is CkH2k+1, OH, OClH2l+1 or NR17R18;
          • k is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CkH2k+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
          • l is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group OClH2l+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
          • R17 and R18 are independently of one another H or CmH2m+1;
            • m is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CmH2m+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms and/or one or more CH2 groups are replaced by O, CO, CS or NR19;
            •  R19 is H or CnH2n+1;
            •  n is 1, 2, 3 or 4, wherein the group CnH2n+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
            •  or
            •  R19 and a CH2 group of R17 or R18 together with the N atom to which they are bonded form a 5- or 6-membered ring;
          • or
          • R17 and R18 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
      • but where R2 does not equal H in any of the foregoing definitions,
      • R5 is H, CpH2p+1, CssH2ss−1, COR20 or SO2R20; wherein
        • p is 1, 2, 3, 4, 5, 6, 7 or 8,
        • ss is 3, 4, 5, 6, 7 or 8,
        • R20 is CqH2q+1;
          • q is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CpH2p+1, CssH2ss−1 and CqH2q+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O or NR21;
          • R21 is H or CrH2r+1;
            • r is 1, 2, 3 or 4; wherein the group CrH2r+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • R6 is H, F, Cl, Br, I, CsH2s+1, CddH2dd−1, OH, OCtH2t+1 or OCOR22; wherein
        • s and t are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8;
        • dd is 3, 4, 5, 6, 7 or 8, wherein the groups CsH2s+1, CddH2dd−1 and OCtH2t+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R22 is CuH2u+1;
        • u 1, 2, 3 or 4, wherein the group CuH2u+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • R7, R8 and R9 are independently of one another —Ov—SOw—R23; wherein
        • v is zero or 1;
        • w is zero, 1 or 2;
        • R23 is CnnH2nn+1, CmmH2mm−1, OH, OCppH2pp+1 or NR25R26;
          • nn and pp are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8, mm is 3, 4, 5, 6, 7 or 8, wherein the groups CnnH2nn+1, CmmH2mm−1 and OCppH2pp+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
          • R25 and R26 are independently of one another H, CN, CzH2z+1, or CzzH2zz−1;
            • z is 1, 2, 3, 4, 5, 6, 7 or 8;
            • zz is 3, 4, 5, 6, 7 or 8, wherein the group CzH2z+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms and, wherein the group CzH2z+1, is unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O, CO, CS or NR27;
            • R27 is H or CaaH2aa+1;
            •  aa is 1, 2, 3 or 4, wherein the group CaaH2aa+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
            • or
            • R27 and a CH2 group of R25 or R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
            • or
            • R25 and R26 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
      • or
      • R7, R8 and R9 are independently of one another NR32COR30, NR32CSR30 or NR32SObbR30;
        • R30 is H, CccH2cc+1, CyyH2yy−1, pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl or piperidinyl is unsubstituted or substituted where a CH2 group is replaced by O or NR33;
        • R32 and R33 are independently of one another H or ChH2h+1;
        • bb is 2 or 3;
        • cc is 1, 2, 3, 4, 5, 6, 7 or 8;
        • yy is 3, 4, 5, 6, 7 or 8;
        • h is 1, 2, 3, 4, 5, 6, 7 or 8,
        • wherein the group ChH2h+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms, and
        • whrein the groups CccH2cc+1 and CyyH2yy−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by NR31 and/or one CH2 group are replaced by O;
        • R31 is H, CkkH2kk+1, COR65 or SO2 R65;
          • kk is 1, 2, 3, or 4; wherein the group CkkH2kk+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms,
          • R65 is H, or CxxH2xx+1;
            • xx is 1, 2, 3 or 4, wherein the group CxxH2xx+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R31 together with a CH2 group of R30 forms a 5-, 6- or 7-membered ring;
        • or
        • R30 is a 5- or 6-membered heteroaryl with at least one hetero atom chosen from 1, 2, 3 or 4 N atoms, zero, 1 S atom and 1 O atom,
          • which is unsubstituted or substituted by up to three substituents chosen from F, Cl, Br, I, CooH2oo+1, and
          • NR70R71;
          • R70 and R71 are independently of one another H, CuuH2uu+1 or COR72;
            • R72 is H, or CvvH2vv+1;
            • oo, uu and vv are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CooH2oo+1, CuuH2uu+1 and CvvH2vv+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R7, R8 and R9 are independently of one another H, F, Cl, Br, I, NO2, CN, OH, NH2, CeeH2ee+1, CwwH2ww−1, OCffH2ff+1, NR40R41, CONR40R41, COOR42, COR42 or OCOR42,
        • ee and ff are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8;
        • ww is 3, 4, 5, 6, 7 or 8, wherein the groups CeeH2ee+1, CwwH2ww−1 and OCffH2ff+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R40 and R41 are independently of one another H, CttH2tt+1 or C(NH)NH2;
          • tt is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CttH2tt+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or where one or more CH2 groups are replaced by O or NR44;
          • R44 is H or CggH2gg+1;
            • gg is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CggH2gg+1 is unnsubstituted or substituted where one or more H atoms are replaced by F atoms
          • or
          • R44 forms a 5- or 6-membered ring together with a (CH2) group of R40 or R41 and the N atom to which they are bound;
        • or
        • R40 and R41 with the N atom to which they are bonded form a 5- or 6-membered ring;
        • R42 is H or ChhH2hh+1;
          • hh is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group ChhH2hh+1 is unnsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • with the proviso that two substituents chosen from the group R7, R8 and R9 can not simultaneously be OH and OCH3,
      • and that at least one of the substituents R7, R8 and R9 is chosen from CONR4OR41, —Ov—SOw—R23, NR32COR30, NR32CSR30 and NR32SObbR30;
      • and the pharmaceutically acceptable salts and trifluoroacetates thereof.
  • In another embodiment, compounds of the formula I are chosen from:
      • R1, R2, R3 and R4 are independently of one another, H, F, Cl, Br, I, CN, NO2, OH, NH2, CaH2a+1, cycloalkyl with 3, 4, 5 or 6 C atoms, OCbH2b+1, or COOR10;
      • wherein
        • a and b are independently of one another 1, 2, 3 or 4, wherein the group CaH2a+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R10 is H or CcH2c+1;
        • c is 1, 2, 3 or 4, wherein the group CcH2c+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
      • R1, R2, R3 and R4 are independently of one another a 5- or 6-membered heteroaryl choawn from pyridyl, imidazolyl, pyrazolyl, pyrrolyl, triazolyl, tetrazolyl, thiazolyl and oxazolyl;
      • or
      • R1, R2, R3 and R4 are independently of one another CONR11 R12 or NR11 R12;
      • wherein
        • R11 and R12 are independently of one another H, CeH2e+1, CrrH2rr−1;
          • e is 1, 2, 3 or 4,
          • rr is 3, 4, 5 or 6, wherein the groups CeH2e+1 and CrrH2rr−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R11 and R12 independently of one another are hydroxyethyl, N,N-dimethylaminoethyl, N,N-diethylaminoethyl, pyrrolidinoethyl, N-methylpiperazinoethyl, piperazinoethyl, morpholinoethyl or piperidinoethyl;
        • or
        • R11 and R12 together with the N atom to which they are bonded form a pyrrolidine, piperidine, N-methylpiperazine, piperazine or morpholine ring;
        • or
        • R11 and R12 are independently of one another COR14, CSR14, CONHR14, CSNHR14 or SO2R14; wherein
          • R14 is CgH2g+1;
            • g is 1, 2, 3 or 4, wherein the group CgH2g+1 is unsbustituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another OSO3H, SO3H, SO2R15;
      • wherein
        • R15 is CkH2k+1, OClH2l+1 or NR17R18;
          • k is 1, 2, 3 or 4, wherein the group CkH2k+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
          • l is 1, 2, 3 or 4, wherein the group OClH2l+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
          • R17 and R18 are independently of one another H, or CmH2m+1, in which the first CH2 group bonded to the nitrogen of NR17R18 is replaced by CO and the second CH2 group is replaced by NR19;
            • m 1, 2, 3, 4 or 5, wherein the group CmH2m+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms;
            • R19 is H or CnH2n+1;
            •  n is 1, 2, 3 or 4, wherein the group CnH2n+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms;
          • or
          • R17 and R18 together with the N atom to which they are bonded form a 5- or 6-membered ring;
      • but where R2 does not equal H in any of the foregoing definitions,
      • R5 is H, or CpH2p+1;
        • p is 1, 2, 3 or 4, wherein the group CpH2p+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms;
      • R6 is H, CsH2s+1, OCtH2t+1 or OCOR22;
        • s and t are independently of one another 1, 2, 3 or 4, wherein the groups CsH2s+1 and OCtH2t+1 independently of another are unsubstituted or substituted where one or more H atoms is replaced by F atoms;
        • R22 is CuH2u+1;
          • u is 1, 2, 3 or 4; wherein the group CuH2u+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms;
      • R7, R8 and R9 are independently of one another OSO3H, SO3H or SO2R23;
      • wherein
        • R23 is CnnH2nn+1, CmmH2mm−1, OCppH2pp+1 or NR25R26;
          • nn and pp are independently of one another 1, 2, 3, 4 or 5,
        • mm is 3, 4, 5 or 6, wherein the groups CnnH2nn+1, CmmH2mm−1 and OCppH2pp+1 independently of another are unsubstituted or substituted where one or more H atoms is replaced by F atoms;
        • R25 and R26 are independently of one another H, CN, or CzH2z+1, in which a first CH2 group bonded to the nitrogen of NR25R26 is replaced by CO or CS and a second CH2 is replaced by NR27;
          • z is 1, 2, 3, 4, 5 or 6; wherein the group CzH2z+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
          • R27 is H or CaaH2aa+1;
            • aa is 1, 2, 3 or 4, wherein the group CaaH2aa+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
          • or
          • R27 and a CH2 group of R25 or R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
        • or
        • R25 and R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
      • or
      • R7, R8 and R9 are independently of one another NR32COR30, NR32CSR30 or NR32SO2R30; wherein
        • R30 is H, OH, CccH2cc+1, CyyH2yy−1, pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl or piperidinyl is unsubstituted or substituted where a CH2 group is replaced by O or NR33;
        • R32 and R33 are independently of one another H or ChH2h+1;
          • cc is 1, 2, 3, 4, 5, 6, 7 or 8;
          • yy is 3, 4, 5 or 6;
        • h is 1, 2, 3 or 4; wherein the group ChH2h+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms, and wherein the groups CccH2cc+1 and CyyH2yy−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups to be replaced by NR31 and/or one CH2 group to be replaced by O;
        • R31 is H, CkkH2kk+1, COR65 or SO2 R65;
          • kk is 1, 2, 3, or 4, wherein the group CkkH2kk+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms,
          • R65 is H, or CxxH2xx+1;
            • xx is 1, 2, 3 or 4, wherein the group CxxH2xx+1 is unsubstituted where one or more H atoms are replaced by F atoms;
        • or
        • R31 together with a CH2 group of R30 and the N atom to which they are jointly bonded form form a 5- or 6-membered ring;
        • or
        • R30 is a 5- or 6-membered heteroaryl chosen from pyridyl, imidazolyl, pyrazolyl, pyrrolyl, triazolyl, tetrazolyl, thienyl, thiazolyl and oxazolyl, which is unsubstituted or substituted by up to three substituents chosen from F, Cl, Br, I, CooH2oo+1, and NR7OR71,
          • R70 and R71 are independently of one another H, CuuH2uu+1 or COR72;
            • R72 is H, or CvvH2vv+1;
          • oo, uu and w are independently of one another 1, 2, 3 or 4, wherein the groups CooH2oo+1, CuuH2uu+1 and CvvH2vv+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R7, R8 and R9 are independently of one another H, F, Cl, Br, I, NO2, CN, OH, NH2, CeeH2ee+1, CwwH2ww−1, OCffH2ff+1, NR40R41, CONR40R41, COOR42, COR42 or OCOR42;
        • ee and ff are independently of one another 1, 2, 3 or 4;
        • ww is 3, 4, 5 or 6, wherein the groups CeeH2ee+1, CwwH2ww−1 and OCffH2ff+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R40 and R41 are independently of one another H, CttH2tt+1, or C(NH)NH2;
          • tt is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CttH2tt+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R40 and R41 are independently of one another chosen from hydroxyethyl, N,N-dimethylaminoethyl, N,N-diethylaminoethyl, pyrrolidinoethyl, N-methylpiperazinoethyl, piperazinoethyl, morpholinoethyl and piperidinoethyl;
        • or
        • R40 and R41 together with the N atom to which they are bonded form a ring chosen from pyrrolidine, piperidine, N-methylpiperazine, piperazine and morpholine;
        • R42 is H or ChhH2hh+1;
          • hh is 1, 2, 3 or 4, wherein the group ChhH2hh+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • with the proviso that two substituents chosen from the group R7, R8 and R9 can not simultaneously be OH and OCH3,
      • and that at least one of the substituents R7, R8 and R9 is chosen from CONR4OR41, —Ov—SOw—R23, NR32COR30, NR32CSR30 and NR32SObbR30;
      • and the pharmaceutically acceptable salts and trifluoroacetates thereof.
  • In another embodiment, compounds of the formula I are chosen from:
      • R1, R2, R3 and R4 are independently of one another H, F, Cl, Br, OH, NH2,
      • CaH2a+1, cycloalkyl with 3, 4, 5 or 6 C atoms, or OCbH2b+1; wherein
        • a and b are independently of one another 1, 2, 3 or 4, wherein the groups CaH2a+1 and OCbH2b+1 independenly of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another NR11 R12;
        • R11 and R12 are independently of one another H, CeH2e+1, or CrrH2rr−1;
          • e is 1, 2, 3 or 4,
          • rr is 3, 4, 5 or 6, wherein the groups CeH2e+1 and CrrH2rr−1 independenly of one another are unsubtituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R11 and R12 together with the N atom to which they are bonded form a ring chosen from pyrrolidine, piperidine, N-methylpiperazine, piperazine and morpholine;
        • or
        • R11 and R12 are independently of one another COR14, CSR14, CONHR14, CSNHR14 or SO2R14; wherein
          • R14 is CgH2g+1;
            • g is 1, 2, 3 or 4, wherein the group CgH2g+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another OSO3H, SO3H, or SO2R15;
        • R15 is CkH2k+1 or NR17R18;
          • k is 1, 2, 3 or 4, wherein the group CkH2k+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
          • R17 and R18 are independently of one another H or CmH2m+1;
            • m is 1, 2, 3, 4 or 5, wherein the group CmH2m+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
          • or
          • R17 and R18 together with the N atom to which they are bonded form a 5- or 6-membered ring;
      • but where R2 does not equal H in any of the foregoing definitions;
      • R5 is methyl or trifluoromethyl;
      • R6 is H;
      • R7, R8 and R9 are independently of one another OSO3H, SO3H or SO2R23;
      • wherein
        • R23 is CnnH2nn+1 or NR25R26;
        • nn is 1, 2, 3, 4 or 5, wherein the group CnnH2nn+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
        • R25 and R26 are independently of one another H, CN or CzH2z+1 in which a first CH2 group bonded to the nitrogen of NR25R26 is replaced by CO or CS and a second CH2 is replaced by NR27;
          • z is 1, 2, 3, 4, 5 or 6, wherein the group CzH2z+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
        • R27 is H or CaaH2aa+1;
          • aa is 1, 2, 3 or 4, wherein the group CaaH2aa+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
        • or
        • R27 and a CH2 group of R25 or R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
        • or
        • R25 and R26 together with the N atom to which they are bonded form a 5- or 6-membered ring,
      • or
      • R7, R8 and R9 are independently of one another NR32COR30, NR32CSR30 or NR32SO2R30;
        • R30 is H, OH, CccH2cc+1, CyyH2yy−1, pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl or piperidinyl is unsubstituted or substituted where a CH2 group is replaced by O or NR33;
          • R32 and R33 are H, methyl or CF3;
          • cc is 1, 2, 3, 4, 5, 6, 7 or 8;
          • yy is 3, 4, 5 or 6; wherein the groups CccH2cc+1 and CyyH2yy−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by NR31 and/or one CH2 group is replaced by O
            • R31 is H, methyl, ethyl, CF3, CH2CF3, acetyl or propionyl, methanesulfonyl or ethanesulfonyl;
            • or
            • R31 together with a CH2 group of R30 and the N atom to which they are jointly bonded form a 5- or 6-membered ring;
        • or
        • R30 is pyridyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl or oxazolyl, which are unsubstituted or substituted by up to 3 substituents chosen from F, Cl, methyl, ethyl, trifluoromethyl, NH2, and NHacetyl;
      • or
      • R7, R8 and R9 are independently of one another H, F, Cl, OH, NH2, CeeH2ee+1, CwwH2ww−1, OCffH2ff+1, NR4OR41, CONR4OR41, COOR42 or OCOR42,
        • ee and ff are independently of one another 1, 2, 3 or 4;
          • ww is 3, 4, 5 or 6, wherein the groups CeeH2ee+1, CwwH2ww−1 and OCffH2ff+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R40 and R41 are H, CttH2tt+1 or C(NH)NH2;
          • tt is 1, 2, 3 or 4, wherein the group CttH2tt+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R40 and R41 independently of one another are hydroxyethyl, N,N-dimethylaminoethyl, N,N-diethylaminoethyl, pyrrolidinoethyl, N-methylpiperazinoethyl, piperazinoethyl, morpholinoethyl or piperidinoethyl;
        • or
        • R40 and R41 together with the N atom to which they are bonded form a pyrrolidine, piperidine, N-methylpiperazine, piperazine or morpholine ring;
        • R42 is H or ChhH2hh+1;
          • hh is 1, 2, 3 or 4, wherein the ChhH2hh+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • with the proviso that two substituents chosen from the group R7, R8 and R9 can not simultaneously be OH and OCH3,
      • and that at least one of the substituents R7, R8 and R9 is chosen from CONR4OR41, —Ov—SOw—R23, NR32COR30, NR32CSR30 and NR32SObbR30;
      • and the pharmaceutically acceptable salts and trifluoroacetates thereof.
  • In another embodiment, compounds of the formula I are chosen from:
      • R1, R2, R3 and R4 are independently of one another H, F, Cl, Br, OH, NH2, CaH2a+1, cycloalkyl with 3, 4, 5 or 6 C atoms, or OCbH2b+1;
        • a and b are independently of one another 1, 2, 3 or 4, wherein the groups CaH2a+1 and OCbH2b+1 independently of one another are unsubstituted or substituted where one or more H atoms to be replaced by F atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another NR11 R12; wherein
        • R11 and R12 are independently of one another H, CeH2e+1, or CrrH2rr−1;
          • e is 1, 2, 3 or 4,
          • rr is 3, 4, 5 or 6, wherein the groups CeH2e+1 and CrrH2rr−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R11 and R12 together with the N atom to which they are bonded form a ring chosen from pyrrolidine, piperidine, N-methylpiperazine, piperazine and morpholine;
        • or
        • R11 and R12 are independently of one another COR14, CSR14, CONHR14, CSNHR14 or SO2R14;
          • R14 is CgH2g+1;
            • g is 1, 2, 3 or 4, wherein the group CgH2g+1 is unsubstituted or substituted where one or more H atoms to be replaced by F atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another OSO3H, SO3H, or SO2R15;
      • wherein
        • R15 is CkH2k+1 or NR17R18;
          • k is 1, 2, 3 or 4, wherein the group CkH2k+1 is unsubstituted or substituted where one or more H atoms to be replaced by F atoms;
          • R17 and R18 are independently of one another H or CmH2m+1;
            • m is 1, 2, 3, 4 or 5, wherein the group CmH2m+1 is unsubstituted or substituted where one or more H atoms to be replaced by F atoms;
          • or
          • R17 and R18 together with the N atom to which they are bonded form a 5- or 6-membered ring;
      • but where R2 does not equal H in any of the foregoing definitions,
      • R5 is methyl or trifluoromethyl;
      • R6 is H;
      • R7, R8 and R9 are independently of one another OSO3H, SO3H or SO2R23;
        • R23 is CnnH2nn+1 or NR25R26;
          • nn is 1, 2, 3, 4 or 5, wherein the group CnnH2nn+1 is unsubstituted or substituted where one or more H atoms to be replaced by F atoms;
        • R25 and R26 are independently of one another H, CN or CzH2z+1 in which a first CH2 group bonded to the nitrogen of NR25R26 is replaced by CO or CS and a second CH2 is replaced by NR27;
          • z is 1, 2, 3, 4, 5 or 6, wherein the group CzH2z+1 is unsubstituted or substituted where one or more H atoms to be replaced by F atoms;
        • R27 is H or CaaH2aa+1;
          • aa is 1, 2, 3 or 4, wherein the group CaaH2aa+1 is unsubstituted or substituted where one or more H atoms to be replaced by F atoms;
        • or
        • R27 and a CH2 group of R25 or R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
        • or
        • R25 and R26 together with the N atom to which they are bonded form a 5- or 6-membered ring,
      • or
      • R7, R8 and R9 are independently of one another NR32COR30, NR32CSR30 or NR32SO2R30;
        • R30 is H, OH, CccH2cc+1, CyyH2yy−1, pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl or piperidinyl is unsubstituted or substituted where a CH2 group is replaced by O or NR33;
        • R32 and R33 are independently of one another H, methyl or CF3;
        • cc is 1, 2, 3, 4, 5, 6, 7 or 8;
        • yy is 3, 4, 5 or 6; wherein wherein the groups CccH2cc+1 and CyyH2yy−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by NR31 and/or one CH2 group are replaced by O;
          • R31 is H, methyl, ethyl, CF3, CH2CF3, acetyl or propionyl, methanesulfonyl or ethanesulfonyl;
          • or
          • R31 together with a CH2 group of R30 and the N atom to which they are jointly bonded form a 5- or 6-membered ring;
        • or
        • R30 is pyridyl, imidazolyl, pyrazolyl, pyrrolyl, triazolyl, tetrazolyl, thiazolyl or oxazolyl, which are unsubstituted or substituted by up to 3 substituents chosen from F, Cl, methyl, ethyl, trifluoromethyl, NH2, and NHacetyl;
      • or
      • R7, R8 and R9 are independently of one another H, F, Cl, OH, NH2, CeeH2ee+1, CwwH2ww−1, OCffH2ff+1, NR4OR41, CONR4OR41, COOR42 or OCOR42,
        • ee and ff are independently of one another 1, 2, 3 or 4;
          • ww is 3, 4, 5 or 6, wherein the groups CeeH2ee+1, CwwH2ww−1 and OCffH2ff+1 independently of one another are unsubstituted or substituted where one or more H atoms to be replaced by F atoms;
        • R40 and R41 is H, CttH2tt+1 or C(NH)NH2;
          • tt is 1, 2, 3 or 4, wherein the group CttH2tt+1 is unsubstituted or substituted where one or more H atoms to be replaced by F atoms;
        • or
        • R40 and R41 are independently of one another hydroxyethyl, N,N-dimethylaminoethyl, N,N-diethylaminoethyl, pyrrolidinoethyl, N-methylpiperazinoethyl, piperazinoethyl, morpholinoethyl or piperidinoethyl;
        • or
        • R40 and R41 together with the N atom to which they are bonded form a pyrrolidine, piperidine, N-methylpiperazine, piperazine or morpholine ring;
        • R42 is H or ChhH2hh+1;
          • hh is 1, 2, 3 or 4, wherein the group ChhH2hh+1 is unsubstituted or substituted where one or more H atoms to be replaced by F atoms;
      • with the proviso that two substituents chosen from the group R7, R8 and R9 can not simultaneously be OH and OCH3,
      • and that at least one of the substituents R7, R8 and R9 is chosen from —Ov—SOw—R23, NR32COR30, NR32CSR30 and NR32SObbR30;
      • and the pharmaceutically acceptable salts and trifluoroacetates thereof.
  • In another embodiment, compounds of the invention are chosen from the following:
      • 1) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 2) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide;
      • 3) 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide;
      • 4) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N,N-dimethyl-benzenesulfonamide;
      • 5) 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline;
      • 6) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid;
      • 7) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-ethyl-benzamide;
      • 8) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-propyl-benzamide;
      • 9) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-(2-dimethylamino-ethyl)-benzamide;
      • 10) 6,8-dichloro-2-methyl-4-(4-morpholin-4-yl-phenyl)-1,2,3,4-tetrahydroisoquinoline;
      • 11) [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-phenyl]-diethyl-amine
      • 12) 6,8-dichloro-2-methyl-4-(4-piperidin-1-yl-phenyl)-1,2,3,4-tetrahydroisoquinoline;
      • 13) 6,8-dichloro-2-methyl-4-(4-pyrrolidin-1-yl-phenyl)-1,2,3,4-tetrahydroisoquinoline;
      • 14) 6,8-dichloro-2-methyl-4-[4-(4-methyl-piperazin-1-yl)-phenyl]-1,2,3,4-tetrahydro-isoquinoline;
      • 15) 6,8-dichloro-2-cyclopropyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;
      • 16) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine;
      • 17) 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-propylurea;
      • 18) 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 19) 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 20) N-[4-(6-methanesulfonyl-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 21) N-[4-(2,6,8-trimethyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 22) N-[4-(6-bromo-8-chloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 23) N-[4-(8-chloro-2-methyl-6-pyrrolidin-1-yl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 24) N-[4-(8-chloro-2-methyl-6-morpholin-4-yl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 25) N-{4-[8-chloro-2-methyl-6-(4-methyl-piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinolin-4-yl]-phenyl}-acetamide;
      • 26) N-{4-[8-chloro-6-(cyclopropylmethyl-amino)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl]-phenyl}-acetamide;
      • 27) 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoic acid;
      • 28) 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-N-methyl-benzamide;
      • 29) 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-ethyl-2-hydroxy-benzamide;
      • 30) 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-(2-dimethylamino-ethyl)-2-hydroxy-benzamide;
      • 31) N-[5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoyl]-guanidine;
      • 32) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 33) 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine;
      • 34) 2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine;
      • 35) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 36) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 37) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]pentanamide;
      • 38) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isobutyramide;
      • 39) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2-dimethyl-propionamide;
      • 40) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopropanecarboxamide;
      • 41) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclobutanecarboxamide;
      • 42) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopentanecarboxamide;
      • 43) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoro-acetamide;
      • 44) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetylpiperidine-4-carboxamide;
      • 45) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-nicotinamide;
      • 46) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methane-sulfonamide;
      • 47) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide;
      • 48) N′,N′-dimethylamino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-sulfamide;
      • 49) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 50) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 51) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-pentanamide;
      • 52) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isobutyramide;
      • 53) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2-dimethyl-propionamide;
      • 54) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopropanecarboxamide;
      • 55) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclobutanecarboxamide;
      • 56) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopentanecarboxamide;
      • 57) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoro-acetamide;
      • 58) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetylpiperidine-4-carboxamide;
      • 59) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-nicotinamide;
      • 60) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methane-sulfonamide;
      • 61) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide;
      • 62) N′,N′-dimethylamino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-sulfamide;
      • 63) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 64) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 65) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-pentanamide;
      • 66) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isobutyramide;
      • 67) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2-dimethyl-propionamide;
      • 68) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopropanecarboxamide;
      • 69) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclobutanecarboxamide;
      • 70) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopentanecarboxamide;
      • 71) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoro-acetamide;
      • 72) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetylpiperidine-4-carboxamide;
      • 73) N-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methane-sulfonamide;
      • 74) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide;
      • 75) N′,N′-dimethylamino-N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-sulfamide;
      • 76) 1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 77) 1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 78) 1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 79) 1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 80) N-{5-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylsulfamoyl]-4-methyl-thiazol-2-yl}-acetamide;
      • 81) N-{5-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylsulfamoyl]-4-methyl-thiazol-2-yl}-acetamide;
      • 82) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,2-dimethyl-1H-imidazole-4-sulfonamide;
      • 83) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,2-dimethyl-1H-imidazole-4-sulfonamide;
      • 84) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonamide;
      • 85) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonamide;
      • 86) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-5-bromo-thiophene-2-sulfonamide;
      • 87) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-5-bromo-thiophene-2-sulfonamide;
      • 88) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-C,C,C-trifluoro-methanesulfonamide;
      • 89) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-C,C,C-trifluoro-methanesulfonamide;
      • 90) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoroethanesulfonamide;
      • 91) 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoro-ethanesulfonamide;
      • 92) N-ethyl-N′-4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonylurea;
      • 93) 2-chloro-5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide;
      • 94) 2-methyl-4-phenyl-6,8-bis-trifluoromethyl-1,2,3,4-tetrahydro-isoquinoline;
      • 95) 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 96) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-methylamino-acetamide;
      • 97) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-dimethylamino-acetamide;
      • 98) 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 99) 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 100) 2,6-Diamino-hexanoic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 101) Pyrrolidine-2-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 102) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isonicotinamide;
      • 103) 1H-Pyrrole-3-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 104) 1H-Pyrrole-2-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 105) 1-Methyl-piperidine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 106) 1,4-Dimethyl-1H-pyrrole-2-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 107) 4-Nitro-1H-pyrrole-2-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 108) 2,5-Dimethyl-1H-pyrrole-3-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 109) 1H-Imidazole-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 110) 1-Methanesulfonyl-piperidine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 111) 3,5-Dimethyl-1H-pyrazole-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 112) 1H-Pyrazole-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 113) 3-Trifluoromethyl-1H-pyrazole-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 114) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-methylamino-acetamide;
      • 115) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-dimethylamino-acetamide;
      • 116) 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 117) 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 118) 2,6-Diamino-hexanoic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 119) Pyrrolidine-2-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 120) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isonicotinamide;
      • 121) 1H-Pyrrole-3-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 122) 1H-Pyrrole-2-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 123) 1-Methyl-piperidine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 124) 1,4-Dimethyl-1H-pyrrole-2-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 125) 4-Nitro-1H-pyrrole-2-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 126) 2,5-Dimethyl-1H-pyrrole-3-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 127) 1H-Imidazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 128)1-Methanesulfonyl-piperidine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 129) 3,5-Dimethyl-1H-pyrazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 130) 1H-Pyrazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 131) 3-Trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 132) 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-thiourea;
      • 133) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-thiourea;
      • 134) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-thiourea;
      • 135) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea;
      • 136) 4-Methyl-piperazine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 137) Piperidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 138) Morpholine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 139) Pyrrolidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 140) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-diethyl-urea;
      • 141) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 142) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 143) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(tetrahydro-furan-3-yl)-urea;
      • 144) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(tetrahydro-pyran-4-yl)-urea;
      • 145) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-methyl-1-(1-methyl-piperidin-4-yl)-urea;
      • 146) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-(3-dimethylamino-propyl)-1-methyl-urea;
      • 147) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-(2-dimethylamino-ethyl)-1-methyl-urea;
      • 148) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(3-dimethylamino-propyl)-urea;
      • 149) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-methoxy-ethyl)-urea;
      • 150) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-pyridin-3-yl-urea;
      • 151)1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-pyridin-4-yl-urea;
      • 152) 4-Methyl-piperazine-1-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 153) 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 154) 3-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea;
      • 155) 3-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-diethyl-urea;
      • 156) Piperidine-1-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 157) Morpholine-4-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 158) Pyrrolidine-1-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 159) 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 160) 4-Methyl-piperazine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 161) Pyrrolidine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 162)1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 163) 3-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea;
      • 164) 3-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-diethyl-urea;
      • 165) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 166) Piperidine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 167) Morpholine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 168) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide;
      • 169) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amine;
      • 170) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3-dimethyl-urea;
      • 171) 4-Methyl-piperazine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 172) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3,3-trimethyl-urea;
      • 173) Piperidine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 174) Morpholine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 175) Pyrrolidine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 176) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-1-methyl-urea;
      • 177) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3,3-diethyl-1-methyl-urea;
      • 178) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide;
      • 179) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amine;
      • 180) Pyrrolidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 181) Piperidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 182) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3,3-trimethyl-urea;
      • 183) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3-dimethyl-urea;
      • 184) Morpholine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 185) 4-Methyl-piperazine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 186) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-1-methyl-urea;
      • 187) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3,3-diethyl-1-methyl-urea;
      • 188) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 189) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 190) [2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 191) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid methyl ester;
      • 192) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid ethyl ester;
      • 193) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid isopropyl ester;
      • 194) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2,2-dimethyl-propyl ester;
      • 195) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid methyl ester;
      • 196) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid isopropyl ester;
      • 197) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2,2-dimethyl-propyl ester;
      • 198) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid ethyl ester;
      • 199) (+)-N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide;
      • 200) (−)-N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide;
      • 201) (+)-1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 202) (−)-1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 203) N-[3-(6,8-Difluoro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 204) 4-(3-Bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline;
      • 205) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-hydroxy-ethyl)-urea;
      • 206) 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid ethyl ester; and
      • 207) 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid
        and the pharmaceutically acceptable salts thereof.
  • In another embodiment, compounds of the invention are chosen from the following:
      • 1) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 2) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide;
      • 3) 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide;
      • 4) 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 5) 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 6) N-[4-(6-bromo-8-chloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 7) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 8) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 9) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetyl-piperidine-4-carboxamide;
      • 10) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methane-sulfonamide;
      • 11) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide;
      • 12) N′,N′-dimethylamino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-sulfamide;
      • 13) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 14) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 15) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isobutyramide;
      • 16) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopropanecarboxamide;
      • 17) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclobutanecarboxamide;
      • 18) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoro-acetamide;
      • 19) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetyl-piperidine-4-carboxamide;
      • 20) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-nicotinamide;
      • 21) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methane-sulfonamide;
      • 22) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide;
      • 23) N′,N′-dimethylamino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-sulfamide;
      • 24) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopropanecarboxamide;
      • 25) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetyl-piperidine-4-carboxamide;
      • 26) 1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 27) 1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 28) 1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 29) 1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 30) N-{5-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylsulfamoyl]-4-methyl-thiazol-2-yl}-acetamide;
      • 31) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,2-dimethyl-1H-imidazole-4-sulfonamide;
      • 32) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-C,C,C-trifluoro-methanesulfonamide;
      • 33) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-C,C,C-trifluoro-methanesulfonamide;
      • 34) N-ethyl-N′-4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonylurea;
      • 35) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-dimethylamino-acetamide;
      • 36) 2,6-Diamino-hexanoic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 37) 1H-Pyrrole-3-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 38) 1-Methyl-piperidine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 39) 1-Methanesulfonyl-piperidine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 40) 1H-Pyrazole-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 41) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-methylamino-acetamide;
      • 42) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-dimethylamino-acetamide;
      • 43) 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 44) 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 45) 2,6-Diamino-hexanoic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 46) 1-Methyl-piperidine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 47) 1H-Imidazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 48) 1-Methanesulfonyl-piperidine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 49) 3,5-Dimethyl-1H-pyrazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 50) 1H-Pyrazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 51) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea;
      • 52) 4-Methyl-piperazine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 53) Piperidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 54) Morpholine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 55) Pyrrolidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 56) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-diethyl-urea;
      • 57) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 58) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 59) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(tetrahydro-furan-3-yl)-urea;
      • 60) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(tetrahydro-pyran-4-yl)-urea;
      • 61) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-methyl-1-(1-methyl-piperidin-4-yl)-urea;
      • 62) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-(3-dimethylamino-propyl)-1-methyl-urea;
      • 63) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-(2-dimethylamino-ethyl)-1-methyl-urea;
      • 64) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(3-dimethylamino-propyl)-urea;
      • 65) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-methoxy-ethyl)-urea;
      • 66) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-pyridin-3-yl-urea;
      • 67) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-pyridin-4-yl-urea;
      • 68) 4-Methyl-piperazine-1-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 69) 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 70) 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 71) 4-Methyl-piperazine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 72) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 73) 3-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea;
      • 74) 3-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-diethyl-urea;
      • 75) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 76) Morpholine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 77) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide;
      • 78) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide;
      • 79) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3,3-trimethyl-urea;
      • 80) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3-dimethyl-urea;
      • 81) Morpholine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 82) 4-Methyl-piperazine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 83) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-1-methyl-urea;
      • 84) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 85) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 86) [2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 87) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid methyl ester;
      • 88) (R or S)—N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide;
      • 89) (R or S)-1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea; and
      • 90) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-hydroxy-ethyl)-urea;
        and the pharmaceutically acceptable salts thereof.
  • In one embodiment, the invention encompasses the use of the compounds of the formula I for the treatment of disorders which can be influenced by inhibition of the sodium-proton exchange of subtype III (NHE3), in which:
      • wherein:
      • R1, R2, R3 and R4 are independently of one another H, F, Cl, Br, I, CN, NO2, OH, NH2, CaH2a+1, CqqH2qq−1, OCbH2b+1, COOR10, OCOR10, COR10 or Ox—(CH2)y-phenyl; wherein
        • a and b are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CaH2a+1 and OCbH2b+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • qq is 3, 4, 5, 6, 7 or 8, wherein the group CqqH2qq−1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R10 is H or CcH2c+1;
          • c is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CcH2c+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • x is zero or 1;
        • y is zero, 1, 2, 3 or 4; where the phenyl ring in the group Ox—(CH2)y-phenyl is unsubstituted or substituted by 1-3 independently chosen from F, Cl, Br, CN, NO2, OH, NH2 and CdH2d+1,
          • d is 1, 2, 3 or 4, wherein the group CdH2d+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another chosen from a heteroaryl with at least one heteroatom chosen from 1, 2, 3 or 4 N atoms, 1 oxygen atom and 1 S atom, present as ring atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another CONR11R12 or NR11R12;
      • wherein
        • R11 and R12 are independently of one another H, CeH2e+1, CrrH2rr−1;
          • e is 1, 2, 3, 4, 5, 6, 7 or 8;
          • rr is 3, 4, 5, 6, 7, or 8, wherein the groups CeH2e+1 and CrrH2rr−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O or NR13;
            • R13 is H or CfH2f+1;
            •  f is 1, 2, 3 or 4, wherein the group CfH2f+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
            • or
            • R13 and a CH2 group of R11 or R12 together with the N atom to which they are bonded form a 5- or 6-membered ring;
        • or
        • R11 and R12 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
        • or
        • R11 and R12 are independently of one another COR14, CSR14 or SO2R14;
        • wherein
          • R14 is CgH2g+1;
            • g is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CgH2g+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms, and/or one or more CH2 groups are replaced by O or NR13;
      • or
      • R1, R2, R3 and R4 are independently of one another —Oh—SOj—R15, with
        • h is zero or 1;
        • j is zero, 1 or 2;
        • R15 is CkH2k+1, OH, OClH2l+1 or NR17R18;
          • k is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CkH2k+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
          • l is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group OClH2l+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
          • R17 and R18 are independently of one another H or CmH2m+1;
            • m is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CmH2m+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms and/or one or more CH2 groups are replaced by O, CO, CS or NR19;
            •  R19 is H or CnH2n+1;
            •  n is 1, 2, 3 or 4, wherein the group CnH2n+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
            •  or
            •  R19 and a CH2 group of R17 or R18 together with the N atom to which they are bonded form a 5- or 6-membered ring;
          • or
          • R17 and R18 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
      • R5 is H, CpH2p+1, CssH2ss−1, COR20 or SO2R20; wherein
        • p is 1, 2, 3, 4, 5, 6, 7 or 8,
        • ss is 3, 4, 5, 6, 7 or 8,
        • R20 is CqH2q+1;
          • q is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CpH2p+1, CssH2ss−1 and CqH2q+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O or NR21;
          • R21 is H or CrH2r+1;
            • r is 1, 2, 3 or 4; wherein the group CrH2r+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • R6 is H, F, Cl, Br, I, CsH2s+1, CddH2dd−1, OH, OCtH2t+1 or OCOR22; wherein
        • s and t are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8;
        • dd is 3, 4, 5, 6, 7 or 8, wherein the groups CsH2s+1, CddH2dd−1 and OCtH2t+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R22 is CuH2u+1;
          • u 1, 2, 3 or 4, wherein the group CuH2u+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • R7, R8 and R9 are independently of one another —Ov—SOw—R23; wherein
        • v is zero or 1;
        • w is zero, 1 or 2;
        • R23 is CnnH2nn+1, CmmH2mm−1, OH, OCppH2pp+1 or NR25R26;
          • nn and pp are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8,
          • mm is 3, 4, 5, 6, 7 or 8, wherein the groups CnnH2nn+1,
          • CmmH2mm−1 and OCppH2pp+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
          • R25 and R26 are independently of one another H, CN, CzH2z+1, or CzzH2zz−1;
            • z is 1, 2, 3, 4, 5, 6, 7 or 8;
            • zz is 3, 4, 5, 6, 7 or 8, wherein the group CzH2z+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms and, wherein the group CzH2z+1, is unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O, CO, CS or NR27;
            • R27 is H or CaaH2aa+1;
            •  aa is 1, 2, 3 or 4, wherein the group CaaH2aa+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
            • or
            • R27 and a CH2 group of R25 or R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
          • or
          • R25 and R26 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
      • or
      • R7, R8 and R9 are independently of one another NR32COR30, NR32CSR30 or NR32SObbR30;
        • R30 is H, CccH2cc+1, CyyH2yy−1, pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl or piperidinyl is unsubstituted or substituted where a CH2 group is replaced by O or NR33;
        • R32 and R33 are independently of one another H or ChH2h+1;
        • bb is 2 or 3;
        • cc is 1, 2, 3, 4, 5, 6, 7 or 8;
        • yy is 3, 4, 5, 6, 7 or 8;
        • h is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group ChH2h+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms, and whrein the groups CccH2cc+1 and CyyH2yy−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by NR31 and/or one CH2 group are replaced by O;
        • R31 is H, CkkH2kk+1, COR65 or SO2 R65;
          • kk is 1, 2, 3, or 4; wherein the group CkkH2kk+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms,
          • R65 is H, or CxxH2xx+1;
          • xx is 1, 2, 3 or 4, wherein the group CxxH2xx+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R31 together with a CH2 group of R30 forms a 5-, 6- or 7-membered ring;
        • or
        • R30 is a 5- or 6-membered heteroaryl with at least one hetero atom chosen from 1, 2, 3 or 4 N atoms, zero, 1 S atom and 1 O atom,
          • which is unsubstituted or substituted by up to three substituents chosen from F, Cl, Br, I, CooH2oo+1, and NR70R71;
          • R70 and R71 are independently of one another H, CuuH2uu+1 or COR72;
            • R72 is H, or CvvH2vv+1;
            • oo, uu and w are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CooH2oo+1, CuuH2uu+1 and CvvH2vv+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R7, R8 and R9 are independently of one another H, F, Cl, Br, I, NO2, CN, OH, NH2, CeeH2ee+1, CwwH2ww−1, OCffH2ff+1, NR40R41, CONR40R41, COOR42, COR42 or OCOR42,
        • ee and ff are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8;
        • ww is 3, 4, 5, 6, 7 or 8, wherein the groups CeeH2ee+1, CwwH2ww−1 and OCffH2ff+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R40 and R41 are independently of one another H, CttH2tt+1 or C(NH)NH2;
          • tt is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CttH2tt+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or where one or more CH2 groups are replaced by O or NR44;
          • R44 is H or CggH2gg+1;
            • gg is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CggH2gg+1 is unnsubstituted or substituted where one or more H atoms are replaced by F atoms
          • or
          • R44 forms a 5- or 6-membered ring together with a (CH2) group of R40 or R41 and the N atom to which they are bound;
        • or
        • R40 and R41 with the N atom to which they are bonded form a 5- or 6-membered ring;
        • R42 is H or ChhH2hh+1;
          • hh is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group ChhH2hh+1 is unnsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • and the pharmaceutically acceptable salts thereof.
  • In another embodiment, the use of the compounds of the formula I for the treatment of disorders which can be influenced by inhibition of the sodium-proton exchange of subtype III (NHE3), are chosen from:
      • R1, R2, R3 and R4 are independently of one another, H, F, Cl, Br, I, CN, NO2, OH,
      • NH2, CaH2a+1, cycloalkyl with 3, 4, 5 or 6 C atoms, OCbH2b+1, or COOR10;
      • wherein
        • a and b are independently of one another 1, 2, 3 or 4, wherein the group CaH2a+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R10 is H or CcH2c+1;
        • c is 1, 2, 3 or 4, wherein the group CcH2c+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
      • R1, R2, R3 and R4 are independently of one another a 5- or 6-membered heteroaryl choawn from pyridyl, imidazolyl, pyrazolyl, pyrrolyl, triazolyl, tetrazolyl, thiazolyl and oxazolyl;
      • or
      • R1, R2, R3 and R4 are independently of one another CONR11R12 or NR11R12;
      • wherein
        • R11 and R12 are independently of one another H, CeH2e+1, CrrH2rr−1;
          • e is 1, 2, 3 or 4,
          • rr is 3, 4, 5 or 6, wherein the groups CeH2e+1 and CrrH2rr−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R11 and R12 independently of one another are hydroxyethyl, N,N-dimethylaminoethyl, N,N-diethylaminoethyl, pyrrolidinoethyl, N-methylpiperazinoethyl, piperazinoethyl, morpholinoethyl or piperidinoethyl;
        • or
        • R11 and R12 together with the N atom to which they are bonded form a pyrrolidine, piperidine, N-methylpiperazine, piperazine or morpholine ring;
        • or
        • R11 and R12 are independently of one another COR14, CSR14, CONHR14, CSNHR14 or SO2R14; wherein
          • R14 is CgH2g+1;
            • g is 1, 2, 3 or 4, wherein the group CgH2g+1 is unsbustituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another OSO3H, SO3H, SO2R15;
      • wherein
        • R15 is CkH2k+1, OClH2l+1 or NR17R18;
          • k is 1, 2, 3 or 4, wherein the group CkH2k+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
          • l is 1, 2, 3 or 4, wherein the group OClH2l+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
          • R17 and R18 are independently of one another H, or CmH2m+1, in which the first CH2 group bonded to the nitrogen of NR17R18 is replaced by CO and the second CH2 group is replaced by NR19;
            • m 1, 2, 3, 4 or 5, wherein the group CmH2m+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms;
            • R19 is H or CnH2n+1;
            •  n is 1, 2, 3 or 4, wherein the group CnH2n+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms;
          • or
          • R17 and R18 together with the N atom to which they are bonded form a 5- or 6-membered ring;
      • R5 is H, CpH2p+1 or CssH2ss−1;
        • p is 1, 2, 3 or 4,
        • ss is 3, 4, 5 or 6, wherein the groups CpH2p+1 and CssH2ss−1 independently of one another are unsubstituted or substituted where one or more H atoms is replaced by F atoms;
      • R6 is H, CsH2s+1, OCtH2t+1 or OCOR22;
        • s and t are independently of one another 1, 2, 3 or 4, wherein the groups CsH2s+1 and OCtH2t+1 independently of another are unsubstituted or substituted where one or more H atoms is replaced by F atoms;
        • R22 is CuH2u+1;
          • u is 1, 2, 3 or 4; wherein the group CuH2u+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms;
      • R7, R8 and R9 are independently of one another OSO3H, SO3H or SO2R23;
      • wherein
        • R23 is CnnH2nn+1, CmmH2mm−1, OCppH2pp+1 or NR25R26;
          • nn and pp are independently of one another 1, 2, 3, 4 or 5,
          • mm is 3, 4, 5 or 6, wherein the groups CnnH2nn+1, CmmH2mm−1 and OCppH2pp+1 independently of another are unsubstituted or substituted where one or more H atoms is replaced by F atoms;
        • R25 and R26 are independently of one another H, CN, or CzH2z+1, in which a first CH2 group bonded to the nitrogen of NR25R26 is replaced by CO or CS and a second CH2 is replaced by NR27;
          • z is 1, 2, 3, 4, 5 or 6; wherein the group CzH2z+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
          • R27 is H or CaaH2aa+1;
            • aa is 1, 2, 3 or 4, wherein the group CaaH2aa+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
          • or
          • R27 and a CH2 group of R25 or R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
        • or
        • R25 and R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
      • or
      • R7, R8 and R9 are independently of one another NR32COR30, NR32CSR30 or NR32SO2R30; wherein
        • R30 is H, OH, CccH2cc+1, CyyH2yy−1, pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl or piperidinyl is unsubstituted or substituted where a CH2 group is replaced by O or NR33;
        • R32 and R33 are independently of one another H or ChH2h+1;
          • cc is 1, 2, 3, 4, 5, 6, 7 or 8;
          • yy is3,4,5or6;
          • h is 1, 2, 3 or 4; wherein the group ChH2h+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms, and
          • wherein the groups CccH2cc+1 and CyyH2yy−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups to be replaced by NR31 and/or one CH2 group to be replaced by O;
            • R31 is H, CkkH2kk+1, COR65 or SO2 R65;
            • kk is 1, 2, 3, or 4, wherein the group CkkH2kk+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms,
            • R65 is H, or CxxH2xx+1;
            • xx is 1, 2, 3 or 4, wherein the group CxxH2xx+1 is unsubstituted where one or more H atoms are replaced by F atoms;
        • or
          • R31 together with a CH2 group of R30 and the N atom to which they are jointly bonded form form a 5- or 6-membered ring;
        • or
        • R30 is a 5- or 6-membered heteroaryl chosen from pyridyl, imidazolyl, pyrazolyl, pyrrolyl, triazolyl, tetrazolyl, thienyl, thiazolyl and oxazolyl,
          • which is unsubstituted or substituted by up to three substituents chosen from F, Cl, Br, I, CooH2oo+1, and NR7OR71,
          • R70 and R71 are independently of one another H, CuuH2uu+1 or COR72;
            • R72 is H, or CvvH2vv+1;
          • oo, uu and w are independently of one another 1, 2, 3 or 4, wherein the groups CooH2oo+1, CuuH2uu+1 and CvvH2vv+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R7, R8 and R9 are independently of one another H, F, Cl, Br, I, NO2, CN, OH, NH2, CeeH2ee+1, CwwH2ww−1, OCffH2ff+1, NR40R41, CONR40R41, COOR42, COR42 or OCOR42;
        • ee and ff are independently of one another 1, 2, 3 or 4;
        • ww is 3, 4, 5 or 6, wherein the groups CeeH2ee+1, CwwH2ww−1 and OCffH2ff+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R40 and R41 are independently of one another H, CttH2tt+1, or C(NH)NH2;
          • tt is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CttH2tt+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R40 and R41 are independently of one another chosen from hydroxyethyl, N, N-dimethylaminoethyl, N, N-diethylaminoethyl, pyrrolidinoethyl, N-methylpiperazinoethyl, piperazinoethyl, morpholinoethyl and piperidinoethyl;
        • or
        • R40 and R41 together with the N atom to which they are bonded form a ring chosen from pyrrolidine, piperidine, N-methylpiperazine, piperazine and morpholine;
        • R42 is H or ChhH2hh+1;
          • hh is 1, 2, 3 or 4, wherein the group ChhH2hh+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • and the pharmaceutically acceptable salts thereof.
  • In one embodiment, the use of the compounds of the formula I for the treatment of disorders which can be influenced by inhibition of the sodium-proton exchange of subtype III (NHE3), are chosen from:
      • R1, R2, R3 and R4 are independently of one another H, F, Cl, Br, OH, NH2,
      • CaH2a+1, cycloalkyl with 3, 4, 5 or 6 C atoms, or OCbH2b+1; wherein
        • a and b are independently of one another 1, 2, 3 or 4, wherein the groups CaH2a+1 and OCbH2b+1 independenly of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another NR11R12;
        • R11 and R12 are independently of one another H, CeH2e+1, or CrrH2rr−1;
          • e is 1, 2, 3 or 4,
          • rr is 3, 4, 5 or 6, wherein the groups CeH2e+1 and CrrH2rr−1 independenly of one another are unsubtituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R11 and R12 together with the N atom to which they are bonded form a ring chosen from pyrrolidine, piperidine, N-methylpiperazine, piperazine and morpholine;
        • or
        • R11 and R12 are independently of one another COR14, CSR14, CONHR14, CSNHR14 or SO2R14; wherein
          • R14 is CgH2g+1;
            • g is 1, 2, 3 or 4, wherein the group CgH2g+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • or
      • R1, R2, R3 and R4 are independently of one another OSO3H, SO3H, or SO2R15;
        • R15 is CkH2k+1 or NR17R18;
          • k is 1, 2, 3 or 4, wherein the group CkH2k+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
          • R17 and R18 are independently of one another H or CmH2m+1;
            • m is 1, 2, 3, 4 or 5, wherein the group CmH2m+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
          • or
          • R17 and R18 together with the N atom to which they are bonded form a 5- or 6-membered ring;
      • but where R2 does not equal H in any of the foregoing definitions;
      • R5 is methyl or trifluoromethyl;
      • R6 is H;
      • R7, R8 and R9 are independently of one another OSO3H, SO3H Or SO2R23;
      • wherein
        • R23 is CnnH2nn+1 or NR25R26;
          • nn is 1, 2, 3, 4 or 5, wherein the group CnnH2nn+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
        • R25 and R26 are independently of one another H, CN or CzH2z+1 in which a first CH2 group bonded to the nitrogen of NR25R26 is replaced by CO or CS and a second CH2 is replaced by NR27;
          • z is 1, 2, 3, 4, 5 or 6, wherein the group CzH2z+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
        • R27 is H or CaaH2aa+1;
          • aa is 1, 2, 3 or 4, wherein the group CaaH2aa+1 is unsubstituted or substituted where one ore more H atoms are replaced by F atoms;
        • or
        • R27 and a CH2 group of R25 or R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
        • or
        • R25 and R26 together with the N atom to which they are bonded form a 5- or 6-membered ring,
      • or
      • R7, R8 and R9 are independently of one another NR32COR30, NR32CSR30 or NR32SO2R30;
        • R30 is H, OH, CccH2cc+1, CyyH2yy−1, pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl or piperidinyl is unsubstituted or substituted where a CH2 group is replaced by O or NR33;
          • R32 and R33 are H, methyl or CF3;
          • cc is 1, 2, 3, 4, 5, 6, 7 or 8;
          • yy is 3, 4, 5 or 6;
          • wherein the groups CccH2cc+1 and CyyH2yy−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by NR31 and/or one CH2 group is replaced by O
          • R31 is H, methyl, ethyl, CF3, CH2CF3, acetyl or propionyl, methanesulfonyl or ethanesulfonyl;
          • or
          • R31 together with a CH2 group of R30 and the N atom to which they are jointly bonded form a 5- or 6-membered ring;
        • or
        • R30 is pyridyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl or oxazolyl, which are unsubstituted or substituted by up to 3 substituents chosen from F, Cl, methyl, ethyl, trifluoromethyl, NH2, and NHacetyl;
      • or
      • R7, R8 and R9 are independently of one another H, F, Cl, OH, NH2, CeeH2ee+1, CwwH2ww−1, OCffH2ff+1, NR40R41, CONR40R41, COOR42 or OCOR42,
        • ee and ff are independently of one another 1, 2, 3 or 4;
          • ww is 3, 4, 5 or 6, wherein the groups CeeH2ee+1 CwwH2ww−1 and OCffH2ff+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • R40 and R41 are H, CttH2tt+1 or C(NH)NH2;
          • tt is 1, 2, 3 or 4, wherein the group CttH2tt+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
        • or
        • R40 and R41 independently of one another are hydroxyethyl, N,N-dimethylaminoethyl, N,N-diethylaminoethyl, pyrrolidinoethyl, N-methylpiperazinoethyl, piperazinoethyl, morpholinoethyl or piperidinoethyl;
        • or
        • R40 and R41 together with the N atom to which they are bonded form a pyrrolidine, piperidine, N-methylpiperazine, piperazine or morpholine ring;
        • R42 is H or ChhH2hh+1;
          • hh is 1, 2, 3 or 4, wherein the ChhH2hh+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
      • and the pharmaceutically acceptable salts thereof.
  • In another embodiment, the invention encompasses the use of the compounds of the formula I for the treatment of disorders which can be influenced by inhibition of the sodium-proton exchange of subtype III (NHE3), chosen from:
      • 1) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 2) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide;
      • 3) 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide;
      • 4) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N, N-dimethyl-benzenesulfonamide;
      • 5) 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline;
      • 6) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid;
      • 7) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-ethyl-benzamide;
      • 8) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-propyl-benzamide;
      • 9) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-(2-dimethylamino-ethyl)-benzamide;
      • 10) 6,8-dichloro-2-methyl-4-(4-morpholin-4-yl-phenyl)-1,2,3,4-tetrahydroisoquinoline;
      • 11) [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-phenyl]-diethyl-amine
      • 12) 6,8-dichloro-2-methyl-4-(4-piperidin-1-yl-phenyl)-1,2,3,4-tetrahydroisoquinoline;
      • 13) 6,8-dichloro-2-methyl-4-(4-pyrrolidin-1-yl-phenyl)-1,2,3,4-tetrahydroisoquinoline;
      • 14) 6,8-dichloro-2-methyl-4-[4-(4-methyl-piperazin-1-yl)-phenyl]-1,2,3,4-tetrahydro-isoquinoline;
      • 15) 6,8-dichloro-2-cyclopropyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;
      • 16) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine;
      • 17) 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-propylurea;
      • 18) 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 19) 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 20) N-[4-(6-methanesulfonyl-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 21) N-[4-(2,6,8-trimethyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 22) N-[4-(6-bromo-8-chloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 23) N-[4-(8-chloro-2-methyl-6-pyrrolidin-1-yl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 24) N-[4-(8-chloro-2-methyl-6-morpholin-4-yl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 25) N-{4-[8-chloro-2-methyl-6-(4-methyl-piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinolin-4-yl]-phenyl}-acetamide;
      • 26) N-{4-[8-chloro-6-(cyclopropylmethyl-amino)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl]-phenyl}-acetamide;
      • 27) 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoic acid;
      • 28) 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-N-methyl-benzamide;
      • 29) 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-ethyl-2-hydroxy-benzamide;
      • 30) 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-(2-dimethylamino-ethyl)-2-hydroxy-benzamide;
      • 31) N-[5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoyl]-guanidine;
      • 32) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 33) 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine;
      • 34) 2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine;
      • 35) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 36) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 37) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]pentanamide;
      • 38) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isobutyramide;
      • 39) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2-dimethyl-propionamide;
      • 40) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopropanecarboxamide;
      • 41) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclobutanecarboxamide;
      • 42) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopentanecarboxamide;
      • 43) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoro-acetamide;
      • 44) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetylpiperidine-4-carboxamide;
      • 45) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-nicotinamide;
      • 46) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methane-sulfonamide;
      • 47) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide;
      • 48) N′,N′-dimethylamino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-sulfamide;
      • 49) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 50) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 51) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-pentanamide;
      • 52) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isobutyramide;
      • 53) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2-dimethyl-propionamide;
      • 54) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopropanecarboxamide;
      • 55) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclobutanecarboxamide;
      • 56) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopentanecarboxamide;
      • 57) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoro-acetamide;
      • 58) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetylpiperidine-4-carboxamide;
      • 59) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-nicotinamide;
      • 60) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methane-sulfonamide;
      • 61) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide;
      • 62) N′,N′-dimethylamino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-sulfamide;
      • 63) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 64) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 65) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-pentanamide;
      • 66) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isobutyramide;
      • 67) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2-dimethyl-propionamide;
      • 68) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopropanecarboxamide;
      • 69) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclobutanecarboxamide;
      • 70) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopentanecarboxamide;
      • 71) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoro-acetamide;
      • 72) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetylpiperidine-4-carboxamide;
      • 73) N-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methane-sulfonamide;
      • 74) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide;
      • 75) N′,N′-dimethylamino-N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-sulfamide;
      • 76) 1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 77) 1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 78) 1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 79) 1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 80) N-{5-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylsulfamoyl]-4-methyl-thiazol-2-yl}-acetamide;
      • 81) N-{5-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylsulfamoyl]-4-methyl-thiazol-2-yl}-acetamide;
      • 82) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,2-dimethyl-1H-imidazole-4-sulfonamide;
      • 83) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,2-dimethyl-1H-imidazole-4-sulfonamide;
      • 84) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonamide;
      • 85) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonamide;
      • 86) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-5-bromo-thiophene-2-sulfonamide;
      • 87) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-5-bromo-thiophene-2-sulfonamide;
      • 88) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-C,C,C-trifluoro-methanesulfonamide;
      • 89) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-C,C,C-trifluoro-methanesulfonamide;
      • 90) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoroethanesulfonamide;
      • 91) 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoro-ethanesulfonamide;
      • 92) N-ethyl-N′-4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonylurea;
      • 93) 2-chloro-5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide;
      • 94) 2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine;
      • 95) 6,8-dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 96) 4-(8-amino-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenol;
      • 97) 8-methoxy-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 98) 2-(8-amino-2-ethyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenol;
      • 99) 2-(8-amino-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenol;
      • 100) 5-(8-amino-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-methoxy-phenol;
      • 101) 2-methyl-8-nitro-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 102) 4-(8-amino-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzene-1,2-diol;
      • 103) 2,8-dimethyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 104) 4-(3,4-dichloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-isoquinoline;
      • 105) 4-(3,4-dichloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine;
      • 106) 4-(2,4-dichloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine;
      • 107) 4-(3-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine;
      • 108) 2,4-dimethyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 109) 2-butyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine;
      • 110) N-(2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-yl)-acetamide;
      • 111) 7-chloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 112) 8-chloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 113) 2,6-dimethyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 114) 6-chloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 115) 6-methoxy-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 116) 2-ethyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 117) 2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 118) 6,8-dichloro-2-ethyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 119) 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline;
      • 120) 2-methyl-4-phenyl-6,8-bis-trifluoromethyl-1,2,3,4-tetrahydro-isoquinoline;
      • 121) 6,8-dichloro-2-isopropyl-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 122) 5,8-dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 123) 6,8-dichloro-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-isoquinoline;
      • 124) 6,8-Dichloro-2-methyl-4-p-tolyl-1,2,3,4-tetrahydro-isoquinoline;
      • 125) 5,6-dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 126) 6,7-dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 127) 8-bromo-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 128) 6,8-dichloro-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-isoquinoline;
      • 129) 6,8-dichloro-2-cyclopropyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline;
      • 130) 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 131) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-methylamino-acetamide;
      • 132) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-dimethylamino-acetamide;
      • 133) 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 134) 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 135) 2,6-Diamino-hexanoic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 136) Pyrrolidine-2-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 137) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isonicotinamide;
      • 138) 1H-Pyrrole-3-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 139) 1H-Pyrrole-2-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 140) 1-Methyl-piperidine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 141) 1,4-Dimethyl-1H-pyrrole-2-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 142) 4-Nitro-1H-pyrrole-2-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 143) 2,5-Dimethyl-1H-pyrrole-3-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 144) 1H-Imidazole-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 145) 1-Methanesulfonyl-piperidine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 146) 3,5-Dimethyl-1H-pyrazole-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 147) 1H-Pyrazole-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 148) 3-Trifluoromethyl-1H-pyrazole-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 149) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-methylamino-acetamide;
      • 150) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-dimethylamino-acetamide;
      • 151) 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 152) 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 153) 2,6-Diamino-hexanoic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 154) Pyrrolidine-2-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 155) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isonicotinamide;
      • 156) 1H-Pyrrole-3-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 157) 1H-Pyrrole-2-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 158) 1-Methyl-piperidine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 159) 1,4-Dimethyl-1H-pyrrole-2-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 160) 4-Nitro-1H-pyrrole-2-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 161) 2,5-Dimethyl-1H-pyrrole-3-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 162) 1H-Imidazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 163) 1-Methanesulfonyl-piperidine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 164) 3,5-Dimethyl-1H-pyrazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 165) 1H-Pyrazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 166) 3-Trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 167) 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-thiourea;
      • 168) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-thiourea;
      • 169) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-thiourea;
      • 170) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea;
      • 171) 4-Methyl-piperazine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 172) Piperidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 173) Morpholine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 174) Pyrrolidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 175) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-diethyl-urea;
      • 176) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 177) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 178) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(tetrahydro-furan-3-yl)-urea;
      • 179) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(tetrahydro-pyran-4-yl)-urea;
      • 180) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-methyl-1-(1-methyl-piperidin-4-yl)-urea;
      • 181) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-(3-dimethylamino-propyl)-1-methyl-urea;
      • 182) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-(2-dimethylamino-ethyl)-1-methyl-urea;
      • 183) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(3-dimethylamino-propyl)-urea;
      • 184) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-methoxy-ethyl)-urea;
      • 185) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-pyridin-3-yl-urea;
      • 186) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-pyridin-4-yl-urea;
      • 187) 4-Methyl-piperazine-1-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 188) 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 189) 3-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea;
      • 190) 3-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-diethyl-urea;
      • 191) Piperidine-1-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 192) Morpholine-4-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 193) Pyrrolidine-1-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 194) 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 195) 4-Methyl-piperazine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 196) Pyrrolidine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 197) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 198) 3-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea;
      • 199) 3-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-diethyl-urea;
      • 200) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 201) Piperidine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 202) Morpholine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 203) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide;
      • 204) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amine;
      • 205) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3-dimethyl-urea;
      • 206) 4-Methyl-piperazine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 207) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3,3-trimethyl-urea;
      • 208) Piperidine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 209) Morpholine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 210) Pyrrolidine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 211) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-1-methyl-urea;
      • 212)1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3,3-diethyl-1-methyl-urea;
      • 213) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide;
      • 214) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amine;
      • 215) Pyrrolidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 216) Piperidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 217) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3,3-trimethyl-urea;
      • 218) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3-dimethyl-urea;
      • 219) Morpholine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 220) 4-Methyl-piperazine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 221) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-1-methyl-urea;
      • 222) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3,3-diethyl-1-methyl-urea;
      • 223) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 224) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 225) [2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 226) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid methyl ester;
      • 227) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid ethyl ester;
      • 228) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid isopropyl ester;
      • 229) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2,2-dimethyl-propyl ester;
      • 230) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid methyl ester;
      • 231) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid isopropyl ester;
      • 232) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2,2-dimethyl-propyl ester;
      • 233) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid ethyl ester;
      • 234) (+)-N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide;
      • 235) (−)-N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide;
      • 236) (+)-1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 237) (−)-1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 238) N-[3-(6,8-Difluoro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 239) 4-(3-Bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline;
      • 240) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-hydroxy-ethyl)-urea;
      • 241) 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid ethyl ester; and
      • 242) 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid;
        and the pharmaceutically acceptable salts thereof.
  • In one embodiment, the invention encompasses the use of the compounds of the formula I for the treatment of disorders which can be influenced by inhibition of the sodium-proton exchange of subtype III (NHE3), chosen from:
      • 1) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 2) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide;
      • 3) 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide;
      • 4) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid;
      • 5) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-ethyl-benzamide;
      • 6) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-propyl-benzamide;
      • 7) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-(2-dimethylamino-ethyl)-benzamide;
      • 8) 6,8-dichloro-2-methyl-4-(4-morpholin-4-yl-phenyl)-1,2,3,4-tetrahydroisoquinoline;
      • 9) 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine;
      • 10) 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 11) 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 12) N-[4-(6-bromo-8-chloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 13) 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoic acid;
      • 14) 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-(2-dimethylamino-ethyl)-2-hydroxy-benzamide;
      • 15) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
      • 16) 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine;
      • 17) 2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine;
      • 18) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 19) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetyl-piperidine-4-carboxamide;
      • 20) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methane-sulfonamide;
      • 21) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide;
      • 22) N′,N′-dimethylamino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-sulfamide;
      • 23) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 24) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 25) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-isobutyramide;
      • 26) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopropanecarboxamide;
      • 27) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclobutanecarboxamide;
      • 28) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2,2,2-trifluoro-acetamide;
      • 29) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetyl-piperidine-4-carboxamide;
      • 30) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-nicotinamide;
      • 31) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methane-sulfonamide;
      • 32) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide;
      • 33) N′,N′-dimethylamino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-sulfamide;
      • 34) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-cyclopropanecarboxamide;
      • 35) N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-acetyl-piperidine-4-carboxamide;
      • 36) 1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 37) 1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 38) 1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 39) 1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea;
      • 40) N-{5-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylsulfamoyl]-4-methyl-thiazol-2-yl}-acetamide;
      • 41) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,2-dimethyl-1H-imidazole-4-sulfonamide;
      • 42) N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-C,C,C-trifluoro-methanesulfonamide;
      • 43) N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-C,C,C-trifluoro-methanesulfonamide;
      • 44) N-ethyl-N′-4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonylurea;
      • 45) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-dimethylamino-acetamide;
      • 46) 2,6-Diamino-hexanoic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 47) 1H-Pyrrole-3-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 48) 1-Methyl-piperidine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 49) 1-Methanesulfonyl-piperidine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 50) 1H-Pyrazole-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 51) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-methylamino-acetamide;
      • 52) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-2-dimethylamino-acetamide;
      • 53) 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-propionamide;
      • 54) 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-butyramide;
      • 55) 2,6-Diamino-hexanoic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 56) 1-Methyl-piperidine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 57) 1H-Imidazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 58) 1-Methanesulfonyl-piperidine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 59) 3,5-Dimethyl-1H-pyrazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 60) 1H-Pyrazole-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 61) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea;
      • 62) 4-Methyl-piperazine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 63) Piperidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 64) Morpholine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 65) Pyrrolidine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 66) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-diethyl-urea;
      • 67) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 68) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 69) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(tetrahydro-furan-3-yl)-urea;
      • 70) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(tetrahydro-pyran-4-yl)-urea;
      • 71) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-methyl-1-(1-methyl-piperidin-4-yl)-urea;
      • 72) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-(3-dimethylamino-propyl)-1-methyl-urea;
      • 73) 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1-(2-dimethylamino-ethyl)-1-methyl-urea;
      • 74) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(3-dimethylamino-propyl)-urea;
      • 75) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-methoxy-ethyl)-urea;
      • 76) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-pyridin-3-yl-urea;
      • 77) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-pyridin-4-yl-urea;
      • 78) 4-Methyl-piperazine-1-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 79) 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 80) 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 81) 4-Methyl-piperazine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 82) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-urea;
      • 83) 3-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea;
      • 84) 3-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-diethyl-urea;
      • 85) 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-urea;
      • 86) Morpholine-4-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide;
      • 87) N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide;
      • 88) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amine;
      • 89) N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide;
      • 90) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amine;
      • 91) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3,3-trimethyl-urea;
      • 92) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3-dimethyl-urea;
      • 93) Morpholine-4-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 94) 4-Methyl-piperazine-1-carboxylic acid [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amide;
      • 95) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-dimethylamino-ethyl)-1-methyl-urea;
      • 96) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 97) [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 98) [2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester;
      • 99) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid methyl ester;
      • 100) (R or S)—N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide;
      • 101) (R or S)-1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea;
      • 102) 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-(2-hydroxy-ethyl)-urea;
      • 103) 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid ethyl-ester; and
      • 104) 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid
        and the pharmaceutically acceptable salts thereof.
  • If the compounds of the formula I contain one or more centers of asymmetry, these may have both the S and the R configuration. The compounds may be in the form of optical isomers, of diastereomers, of racemates or of mixtures thereof.
  • The defined alkyl radicals and partly or completely fluorinated alkyl radicals may be both straight-chain and branched. Groups CaH2a-1 and their analogs as far as CyyH2yy-1 mean either the corresponding alkenyls, cycloalkyls, cycloalkylalkyls or alkylcycloalkyls.
  • Appropriate heteroaryls are, for example, 2- or 3-thienyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 1,2,3-triazol-1-, -4- or 5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 1,2,3-oxadiazol-4- or 5-yl, 1,2,4-oxadiazol-3-or 5-yl, 1,3,4-oxadiazol-2-yl or -5-yl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or 5-yl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-indazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 3-, 5-, 6-, 7- or 8-quinoxalinyl, 1-, 4-, 5-, 6-, 7- or 8-phthalazinyl. The corresponding N-oxides of these compounds are additionally encompassed, that is to say, for example, 1-oxy-2-, 3- or 4-pyridyl.
  • In one embodiment, the 5- or 6-membered heterocycles are chosen. In a further embodiment, imidazolyl, pyrazolyl, pyrrolyl, triazolyl, tetrazolyl, thiazolyl and oxazolyl are chosen.
  • The terminal CH3 groups in an alkyl chain are also regarded as CH2 units and are in this connection viewed as CH2 groups.
  • Methods for preparing the compounds of the invention are also described.
  • The substances described herein can be prepared, for example, starting from the benzylamine precursors IV. These in turn can, if not obtainable commercially, be synthesized by standard processes from the corresponding benzyl chlorides or bromides III.
    Figure US20050009864A1-20050113-C00003
  • The benzylamines IV obtained in this way may be alkylated in a manner known to the skilled worker with the appropriately substituted alpha-bromoacetophenone compounds V.
    Figure US20050009864A1-20050113-C00004
  • The alpha-bromacetophenone compounds V may be obtained from the corresponding acetophenone precursors by bromination in processes known from the literature. The desired tetrahydroisoquinolines I may be obtained by known processes by reduction of the carbonyl group in VI and subsequent acid-catalyzed cyclization of the corresponding alcohols VII (cf. Tetrahedron Lett.; 1989, 30, 5837; Org. Prep. Proced. Int.; 1995, 27, 513).
    Figure US20050009864A1-20050113-C00005
  • When R6 is not equal to H, the desired compounds of the formula I may be prepared for example from the iodides VIII by halogen/metal exchange and subsequent nucleophilic attack of the intermediate organolithium species on the carbonyl group (cf. Chem. Pharm. Bull.; 1995, 43,1543).
    Figure US20050009864A1-20050113-C00006
  • The tertiary alcohols synthesized in this way may be converted by known methods into other derivatives.
  • Alkyl-branched analogs (i) may be prepared by alkylating the corresponding diphenylacetic esters X in the alpha position by known methods. The desired product XI may be converted by standard processes into the corresponding amides XII, which may be converted into the desired tetrahydroisoquinolines I in a Pictet-Spengler-analogous reaction (cf. Tetrahedron; 1987, 43, 439; Chem. Pharm. Bull.; 1985, 33, 340).
    Figure US20050009864A1-20050113-C00007
  • As used herein, treating or treatment includes the treating of, for example, a patient inflicted with a disease or condition, as well as the prevention, prophylaxis, or protective treatment of a patient. Treatment also includes treating a subject susceptible to or predisposed to developing a disease or condition, which could include patients in whom a disease or condition has not yet presented as well as patients in whom the disease has been successfully treated but could redevelop or reoccur.
  • In one embodiment, the compounds of the formula I may be excellent inhibitors of the sodium-hydrogen exchanger (NHE)—especially of the sodium of the sodium-hydrogen exchanger of subtype 3 (NHE3).
  • On the basis of these properties, the compounds may be suitable for the treatment of disorders caused by oxygen deficiency. The compounds may be, as a result of their pharmacological properties, suitable as antiarrhythmic medicaments with a cardioprotective component for prophylaxis of infarction and for treatment of infarction, and for the treatment of angina pectoris, in which connection they may also inhibit or reduce in a preventive manner the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the induction of ischemia-induced cardiac arrhythmias. Because of their possible protective effects against pathological hypoxic and ischemic situations, the compounds of the formula I which are used according to the invention may, as a result of inhibition of the cellular Na+/H+ exchange mechanism, be used as medicaments for the treatment of all acute or chronic damage induced by ischemia or disorders induced primarily or secondarily thereby. This relates to the possible use thereof as medicaments for surgical interventions, e.g. in organ transplantations, in which cases the compounds may be used, for exmple, both to protect the organs in the donor before and during removal, to protect removed organs for example on treatment with or storage thereof in physiological bath fluids, as well as during the transfer into the recipient organism. The compounds may in some embodiments likewise be valuable medicaments with a protective action during the performance of angioplastic surgical interventions, for example on the heart as well as peripheral vessels. In accordance with their possible protective action against ischemia-induced damage, the compounds may also be suitable as medicaments for the treatment of ischemias of the nervous system, especially of the CNS, in which connection they may be suitable for example for the treatment of stroke or of cerebral edema. In addition, the compounds of the formula I which are used according to the invention may likewise be suitable for the treatment of types of shock, such as, for example, of allergic, cardiogenic, hypovolemic and bacterial shock.
  • In addition, the compounds may induce an improvement in the respiratory drive and may therefore be used to treat respiratory conditions associated with the following clinical conditions and diseases: disturbance of central respiratory drive (e.g. central sleep apnea, sudden infant death, postoperative hypoxia), muscle-related breathing disorders, breathing disorders after long-term ventilation, breathing disorders associated with altitude adaptation, obstructive and mixed type of sleep apnea, acute and chronic pulmonary disorders with hypoxia and hypercapnia.
  • The compounds additionally may in some embodiments increase the tone of the muscles of the upper airways, so that snoring is suppressed.
  • A combination of an NHE inhibitor with a carbonic anhydrase inhibitor (e.g. acetazolamide), the latter inducing metabolic acidosis and thus itself increasing respiratory activity, may in some embodiments prove to be advantageous due to an enhanced effect and reduced use of active ingredient.
  • In one embodiment, the compounds used according to the invention have a mild laxative effect and accordingly may be used advantageously as laxatives or if there is a risk of constipation, in which case the compounds may prevent the ischemic damage associated with constipation in the intestinal region.
  • In another embodiment, it is possible to prevent the formation of gall stones.
  • In one embodiment, the compounds of the formula I used according to the invention may demonstrate a strong inhibitory effect on the proliferation of cells, for example of fibroblast cell proliferation and the proliferation of smooth muscular muscle cells. The compounds of the formula I may therefore is some embodiments be suitable as valuable therapeutic agents for diseases in which cell proliferation represents a primary or secondary cause, and may therefore be used as antiatherosclerotic agents, agents to prevent late complications of diabetes, cancers, fibrotic disorders such as pulmonary fibrosis, hepatic fibrosis or renal fibrosis, organ hypertrophies and hyperplasias, in particular for prostate hyperplasia or prostate hypertrophy.
  • In another embodiment, the compounds used according to the invention may be effective inhibitors of the cellular sodium-proton antiporter (Na/H exchanger) which is elevated in numerous disorders (essential hypertension, atherosclerosis, diabetes, etc.), also in those cells which are readily amenable to measurements, such as, for example, in erythrocytes, platelets or leukocytes. The compounds used according to the invention in some embodiments therefore may be suitable as excellent and simple scientific tools, for example in their use as diagnostic agents for determining and distinguishing different types of hypertension, but also of atherosclerosis, of diabetes, proliferative disorders etc. The compounds of the formula I may also be suitable for preventive therapy to prevent the development of high blood pressure, for example of essential hypertension.
  • In one embodiment, it has additionally been found that NHE inhibitors may show a beneficial effect on serum lipoproteins. It is generally acknowledged that blood lipid levels which are too high, so-called hyperlipoproteinemias, represent a considerable risk factor for the development of arteriosclerotic vascular lesions, especially coronary heart disease. The reduction of elevated serum lipoproteins therefore may have exceptional importance for the prophylaxis and regression of atherosclerotic lesions. The compounds used according to the invention may therefore in some embodiments be used for the prophylaxis and regression of atherosclerotic lesions by eliminating a causal risk factor. With this protection of the vessels against the syndrome of endothelial dysfunction, compounds of the formula I may be valuable medicaments for the prevention and treatment of coronary vasospasms, of atherogenesis and of atherosclerosis, of left-ventricular hypertrophy and of dilated cardiomyopathy, and thrombotic disorders.
  • In certain embodiment the compounds of the invention may therefore be used for producing a medicament for the prevention and treatment of sleep apneas and muscle-related respiratory disorders; for producing a medicament for the prevention and treatment of snoring; for producing a medicament for lowering blood pressure; for producing a medicament for the prevention and treatment of disorders induced by ischemia and reperfusion of central and peripheral organs, such as acute renal failure, stroke, endogenous states of shock, intestinal disorders etc.; for producing a medicament for the treatment of late damage from diabetes and chronic renal disorders, in particular of all inflammations of the kidneys (nephritides) which are associated with increased protein/albumin excretion; for producing a medicament for the treatment of infection by ectoparasites in human and veterinary medicine; for producing a medicament for the treatment of said disorders in combinations with hypotensive substances, preferably with angiotensin converting enzyme (ACE) inhibitors, with diuretics and saluretics such as furosemide, hydrochlorothiazide, pseudoaldosterone antagonists and aldosterone antagonists; with adenosine receptor modulators, in particular with adenosine receptor activators (A2 agonists); and with angiotensin receptor antagonists.
  • In another embodiment, at least one sodium-proton exchange inhibitors of the formula I is administered as a medicament for lowering elevated blood lipid levels, including as the combination of sodium-proton exchange inhibitors with hypotensive medicaments and/or medicaments with hypolipidemic activity.
  • Medicaments which comprise a compound of the invention can in this connection may be administered orally, parenterally, intravenously, rectally, transdermally or by inhalation, the preferred administration being dependent on the particular characteristics of the disorder. The compounds of the invention may moreover may be used alone or together with pharmaceutical excipients, both in veterinary medicine and in human medicine.
  • The excipients suitable for the desired pharmaceutical formulation are familiar to the skilled worker on the basis of his expert knowledge. Besides solvents, gel formers, suppository bases, tablet excipients, and other active ingredient carriers, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavorings, preservatives, solubilizers or colors.
  • For a form for oral administration, the active compounds may be mixed with additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into suitable dosage forms such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily solutions. Examples of inert carriers which can be used include, for example, gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. It is moreover possible for the preparation to take place both as dry granules and as wet granules. Examples of suitable oily carriers or solvents are vegetable or animal oils such as sunflower oil or fish liver oil.
  • For subcutaneous or intravenous administration, the active compounds used may be converted, if desired with the substances customary for this purpose, such as solubilizers, emulsifiers or other excipients, into a solution, suspension or emulsion. Examples of suitable solvents are: water, physiological saline or alcohols, e.g. ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else a mixture of the various solvents mentioned.
  • Compounds of the invention are also suitable as a pharmaceutical formulation for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active ingredient of the formula I in a pharmaceutically acceptable solvent such as, in particular, ethanol or water, or a mixture of such solvents.
  • The formulation may, if required, also contain other pharmaceutical excipients such as surfactants, emulsifiers and stabilizers, and a propellant gas. Such a preparation normally contains the active ingredient in a concentration of about 0.1 to 10, in particular of about 0.3 to 3, % by weight.
  • The dosage of the active ingredient of the coumpounds of the invention to be administered, and the frequency of administration, depend on the potency and duration of action of the compounds used; additionally also on the nature and severity of the disorder to be treated and on the sex, age, weight and individual responsiveness of the mammal to be treated.
  • On average, the daily dose of a compound of the formula I for a patient weighing about 75 kg is at least 0.001 mg/kg, preferably 0.001 mg/kg, to a maximum of 10 mg/kg, preferably 1 mg/kg, of body weight. For acute episodes of the disorder, for example immediately after suffering a myocardial infarction, higher and, in particular, more frequent dosages may also be necessary, e.g. up to 4 single doses a day. Up to 200 mg a day may be necessary, in particular on i.v. administration, for example for a patient with infarction in the intensive care unit.
    • DESCRIPTIONS OF EXPERIMENTS AND EXAMPLES
  • List of Abbreviations Used:
    Rt retention time
    TFA trifluoroacetic acid
    HPLC high performance liquid chromatography
    eq equivalent
    LCMS liquid chromatography mass spectroscopy
    MS mass spectroscopy
    CI chemical ionization
    RT room temperature
    THF tetrahydrofuran
    TOTU O-[(ethoxycarbonyl)-cyanomethyleneamino]-N,N,N′,N′-
    tetramethyluronium tetrafluoroborate
    DMSO dimethyl sulfoxide
    abs. absolute
    decomp. decomposition
    DMF dimethylformamid

    General:
  • The retention times (Rt) indicated below relate to LCMS measurements with the following parameters:
    Method A:
    stationary phase: Merck Purospher 3μ 2 × 55 mm
    mobile phase: 95% H2O (0.05% TFA) → 95% acetonitrile; 4 min;
    95% acetonitrile; 1.5 min → 5% acetonitrile; 1 min;
    0.5 ml/min, 30° C.
    Method B:
    stationary phase: Merck Purospher 3μ 2 × 55 mm
    mobile Phase: 0 min 90% H2O (0.05% TFA) 2.5 min-95% acetoni-
    trile; 95% acetonitrile to 3.3 min; 10% acetonitrile
    3.4 min; 1 ml/min.
    Method B1:
    stationary phase: YMC, J'sphere ODS H80 4μ 2 × 20 mm
    mobile phase: 0 min 90% H2O (0.05% TFA) 1,9 min-95% acetoni-
    trile; 95% acetonitrile bis 2,4 min; 10% acetonitrile
    2,45 min; 1 ml/min.
    Method C:
    stationary phase: Merck LiChroCart 55-2 Purospher STAR RP 18e
    solvent: solvent A: acetonitrile/water 90:10 + 0.5% HCOOH
    solvent B: acetonitrile/water 10:90 + 0.5% HCOOH
    flow rate: 0.75 ml/min
    time[min] solvent B[%]
    0.00 95.0
    0.50 95.0
    1.75 5.0
    4.25 5.0
    4.50 95.0
    5.00 95.0
    stop time: 6.20 min
    temperature: 40° C.
    Method D:
    stationary phase: Merck RP18 Purospher Star, 55 × 2 mm,
    3μ KorngröBe
    solvent: Solvent A: acetonitrile + 0.08% HCOOH
    Solvent B: water + 0.1% HCOOH
    Flow rate 0.45 ml/min
    time [min] solvent B[%]
    0 95
    5 5
    7 5
    8 95
    9 5
    temperature: room temperature
    • Example 1 N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide
  • Figure US20050009864A1-20050113-C00008
  • Intermediate 1: 2,4-Dichlorobenzyl-(methyl)-amine was prepared by methods known from the literature (J. Med. Chem.; 1984, 27, 1111).
  • Intermediate 2: N-[4-(2-Bromo-acetyl)-phenyl]-acetamide wais synthesized in a manner known to the skilled worker by bromination of N-(4-acetyl-phenyl)-acetamide.
  • The starting compound (0.256 mol) was introduced into 300 ml of acetic acid and, at 60° C, a solution of 39.9 g of bromine (1.0 eq) in 60 ml of acetic acid was added dropwise. After 1.5 h, the reaction mixture was allowed to cool to room temperature and was added to 1 l of ice-water. The precipitate was filtered off with suction, washed with water and dried, with 60 g of the title compound being isolated (melting point: 192° C.).
  • Intermediate 3: N-{4-[2-(2,4-Dichloro-benzylamino)-acetyl]-phenyl}-acetamide; 37.1 g (0.195 mol) of intermediate 1 was introduced into 400 ml of dioxane, and a solution of 60 g (0.234 mol) of intermediate 2 in 600 ml of dioxane was added. 134 ml of triethylamine were added, and the mixture was stirred at room temperature for 4 h. After standing overnight, the precipitate was filtered off and the filtrate was concentrated in vacuo. The residue was taken up in ethyl acetate, washed with NaHCO3 and H2O, dried with MgSO4 and concentrated. The oily residue resulting thereby was triturated with an ethyl acetate/ether mixture, resulting in 36 g of intermediate 3 in the form of a crystalline solid (melting point: 115-117° C.).
  • Intermediate 4:
  • N-{4-[2-(2,4-Dichloro-benzylamino)-1-hydroxy-ethyl]-phenyl}-acetamide; 36 g (0.099 mol) of intermediate 3 was dissolved in 500 ml of methanol and, at 0° C., 7.8 g (2 eq) of sodium borohydride was added. The mixture was then stirred at 0° C. for 30 min and at room temperature for a further hour. For workup, the reaction mixture was concentrated and the residue was partitioned between 1 N HCl and ethyl acetate. The aqueous phase was separated off, adjusted to pH 9 and extracted twice with ethyl acetate. The combined organic phases were dried with MgSO4 and concentrated. The crude product obtained in this way was reacted further without further purification.
  • N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide; 20 g (0.054 mol) of intermediate 4 was dissolved in 250 ml of dichloromethane and, at 0° C., 250 ml of conc. H2SO4 was added dropwise. The mixture was stirred at 0° C. for 2 h and at room temperature for 1 h. For workup, the reaction mixture was added to ice-water, and the precipitate was filtered off with suction. The precipitate was taken up in 300 ml of 1 N NaOH and extracted three times with ethyl acetate. Drying of the organic phases and concentration affords a crude product which was triturated with diisopropyl ether, whereupon 11.7 g of the compound of the example were isolated as a crystalline solid (melting point: 205-206° C.)
  • 1a: N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide-hydrochloride;
    Figure US20050009864A1-20050113-C00009
  • An analytical sample (100 mg) of the title compound from example 1 was suspended in 10 ml of 2 N HCl, and THF was added until a clear solution was produced. It was concentrated in vacuo, and the residue was triturated with ether and filtered off with suction, whereupon the title compound was obtained as a crystalline solid (Rt=3.807 min (method A); melting point.: 125° C. with decomposition).
    • Example 2
  • 2a: (+)-4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzene-sulfonamide hydrochloride;
  • 2b: (+)-3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzene-sulfonamide hydrochloride;
  • 2c: (−)-4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzene-sulfonamide acetate;
  • 2d: (−)-3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzene-sulfonamide acetate;
    Figure US20050009864A1-20050113-C00010
  • Intermediate 1: 2,4-Dichlorobenzyl-(methyl)-amine was prepared by methods known from the literature (J. Med. Chem.; 1984, 27,1111).
  • Intermediate 2: 2-[(2,4-Dichloro-benzyl)-methyl-amino]-1-phenyl-ethanone; Intermediate 1 was reacted with 2-bromo-1-phenyl-ethanone in the manner described in example 1, intermediate 3. Workup in an analogous manner and purification on silica gel affords the desired alkylation product in good yield as a yellowish oil (Rt=4.188 min (method A); MS(Cl+)=308.2/310.2).
  • Intermediate 3: 2-[(2,4-Dichloro-benzyl)-methyl-amino]-1-phenyl-ethanol; Intermediate 2 was reduced with sodium borohydride in the manner described in example 1, intermediate 4. Once monitoring of the reaction indicates complete conversion, the mixture was concentrated and the residue was taken up in ethyl acetate. It was washed twice with H2O, dried with MgSO4 and freed of solvent. The crude product, which was obtained in quantitative yield, was reacted further without further purification (Rt=4.149 min (method A); MS(Cl+)=310.2/312.2).
  • Intermediate 4: 6,8-Dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline; 20 g (64.5 mmol) of intermediate 3 were dissolved in 55 ml of dichloromethane and cooled to 0° C. This solution was added dropwise to 55 ml of precooled conc. H2SO4 and then stirred at room temperature for two hours. For workup, the mixture was poured onto ice and made strongly alkaline with 6 N NaOH. Three extractions with dichloromethane were carried out. The combined organic phases were dried with MgSO4 and concentrated. The oily crude product was purified on silica gel, resulting in intermediate 4 in a yield of 53% (Rt=4.444 min (method A); MS(Cl+)=292.2/294.2).
  • 4a: (−)-6,8-Dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline trifluoroacetate;
  • 4b: (+)-6,8-Dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline trifluoroacetate;
  • Intermediate 4 was separated into the two enantiomers by HPLC on a chiral phase.
      • chiral column: Chiralpak OD 250×4.6 cm;
      • solvent: n-heptane/isopropanol 7:3+0.1% TFA;
      • flow rate: 1 ml/min;
      • Rt((−)-enantiomer/4a)=9.340 min;
      • Rt((+)-enantiomer/4b)=20.327 min.
  • 2a: (+)-4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzene-sulfonamide hydrochloride;
  • 2b: (+)-3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzene-sulfonamide hydrochloride;
  • A suspension of 500 mg (1.7 mmol) of intermediate 4a in 10 ml of dichloromethane was introduced at 0° C. into 1.2 ml of chlorosulfonic acid. The mixture was stirred at 0° C. for one hour and at room temperature for a further hour. A further 5 ml of chlorosulfonic acid was added and the mixture was stirred at room temperature for one hour. For workup, it was poured onto ice and adjusted to pH 8 with NaHCO3. Three extractions with ethyl acetate were carried out. The combined organic phases were dried with Na2SO4 and freed of solvent. The crude product obtained in this way was heated in 20 ml of conc. NH3 solution at 90° C. for three hours. After the conversion was complete, the reaction solution was concentrated and the residue was partitioned between H2O and ethyl acetate. The organic phase was separated off and the aqueous phase was extracted once more with ethyl acetate. The combined organic phases were dried with Na2SO4 and the solvent was removed in vacuo. Subsequent chromatography on silica gel affords 335 mg of a mixture of example 2a and 2b in the form of a yellow amorphous solid. Further purification on a preparative HPLC affords 212 mg of the para-substituted title compound 2a, plus 58 mg of the meta isomer 2b.
  • Conditions for the preparative HPLC.
      • chiral column: Chiralpak AS 250×4.6 mm;
      • solvents: n-heptane/ethanol/methanol/acetonitrile 20:1.5:0.5:0.5
      • flow rate: 1 ml/min;
      • Rt(main fraction)=14.145 min (→2a);
      • Rt(subsidiary fraction)=11.623 min (→2b).
  • Both fractions were dissolved in methanol/2 N HCl mixture and freeze dried, and it was possible to obtain the title compounds 2a and 2b in the form of crystalline solids. (Rt(2a)=3.630 min (method A); MS(2a),(ES+)=371.3/373.3 (M++H)/412.3/414.3 (M++CH3CN); Rt(2b)=3.668 min (method A); MS(2b),(ES+)=371.3/373.3 (M++H)/412.3/414.3 (M++CH3CN).
  • 2c: (−)-4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzene-sulfonamide acetate;
  • 2d: (−)-3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzene-sulfonamide acetate;
  • The title compound was synthesized by the method described under 2a/2b, using intermediate 4b as starting compound. The purification and separation from the meta isomer which was to be expected and takes place under the following conditions: chiral column: Chiralpak AS 250×4.6/12 mm;
      • solvent: acetonitrile
      • flow rate: 1 ml/min;
      • Rt(main fraction)=4.394 min (→2c);
      • Rt(subsidiary fraction)=4.130 min (→2d).
  • The purified products were each taken up in a 10% acetic acid solution and freeze dried, resulting in the desired acetates as slightly yellowish solids (Rt(2c)=3.656 min (method A); MS(ES+)=371.1/373.1 (M++H)/412.1/414.1 (M++CH3CN)); (Rt(2d)=1.562 min (method B); MS(ES+)=371.1/373.1 (M++H)/412.1/414.1 (M++CH3CN)).
    • Example 3 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N,N-dimethyl-benzenesulfonamide, hydrochloride
  • Figure US20050009864A1-20050113-C00011
  • 6,8-Dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline (intermediate 4, example 2) was introduced in portions into chlorosulfonic acid (6.6 ml). The mixture was subsequently stirred at 40° C. for one hour. The reaction mixture was then cooled to room temperature and an ice/water mixture was added. The precipitate which separated out during this was filtered off with suction and taken up in ethyl acetate which, after washing with saturated brine was dried over magnesium sulfate. Subsequent concentration afforded 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonyl chloride as a solid crude product, a portion of which (150 mg) was directly introduced in portions into dimethylamine solution (5 ml, approx. 40% in water) cooled to 10° C. The resulting suspension was subsequently stirred at this temperature for 1.5 h. Then ice-water was added and, after extraction three times with ethyl acetate, the combined ethyl acetate phases were washed with saturated brine and dried over magnesium sulfate. The residue was taken up with water and, after addition of 2 N HCl, freeze dried. The crude product obtained in this way was then purified by preparative HPLC.
  • Conditions:
  • stationary phase: Merck Purospher RP18 (10 μM) 250×25 mm
  • mobile phase: 90% H2O (0.05% TFA)→90% acetonitrile; 40 min; flow rate: 25 m/min
  • The fractions containing the product were combined, the acetonitrile was stripped off in a rotary evaporator, and the aqueous phase was washed with saturated potassium carbonate solution and then extracted three times with ethyl acetate. The combined ethyl acetate phases were washed with saturated brine, dried over magnesium sulfate and concentrated. The residue was taken up in water and, after addition of 2 N HCl, freeze dried. 80 mg of a pale solid were obtained. This consisted of ˜80% of the desired compound, in addition to ˜20% of a regioisomer (Rt=4.000 min (method A); MS(Cl+)=399.1).
    • Example 4
  • 4a: 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide, hydrochloride;
    Figure US20050009864A1-20050113-C00012
  • Intermediate 1: 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-benzenesulfonyl chloride
  • At 0° C., 1 mmol of 6,8-dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline (intermediate 4, example 2) was introduced into 1 ml of chlorosulfonic acid and stirred at room temperature for 3 hours. For workup, the reaction mixture was poured onto ice, adjusted to pH 7 to 8 with 1 N NaOH and extracted twice with ethyl acetate. The combined ethyl acetate phases were dried with Na2SO4 and concentrated in a rotary evaporator. The crude product obtained in this way was reacted further without further purification.
  • Intermediate 2: 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide
  • 319 mg of intermediate 1 were suspended in 6 ml of 25% strength ammonia and heated to 90° C. After 3 h, the mixture was diluted with H2O and extracted with ethyl acetate. The organic phase was separated off and dried with Na2SO4, resulting in 165 mg of the title compound.
  • 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide, hydrochloride;
  • 145 mg of intermediate 2 were suspended in 15 ml of diethyl ether, and 1 ml of ethereal HCl was added. After stirring at room temperature for 30 minutes, the precipitate was filtered off with suction and dried, resulting in 136 mg of the hydrochloride in the form of a yellowish solid.
  • 4b: 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonamide, acetate;
    Figure US20050009864A1-20050113-C00013
  • 255 mg of intermediate 2, example 8, was mixed with 5 ml of glacial acetic acid, and 50 ml of H2O was added. Filtration of sparingly soluble constituents was followed by freeze drying, resulting in 250 mg of the title compound.
    • Example 5 4-(4-Bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline, hydrochloride
  • Figure US20050009864A1-20050113-C00014
  • Intermediate 1: 1-(4-Bromo-phenyl)-2-[(2,4-dichloro-benzyl)-methyl-amino]-ethanone; (2,4-Dichloro-benzyl)-methyl-amine (see example 1, intermediate 1) and 2-bromo-1-(4-bromo-phenyl)-ethanone was reacted in analogy to the method described in example 1, intermediate 3. After analogous workup and chromatography on silica gel, the alkylation product was isolated in a yield of 69%.
  • Intermediate 2: 1-(4-Bromo-phenyl)-2-[(2,4-dichloro-benzyl)-methyl-amino]-ethanol; Intermediate 1 was reduced to the corresponding alcohol with 2 equivalents of NaBH4 in analogy to the manner described for intermediate 4, example 1, and the alcohol was isolated in a yield of 86%.
  • Intermediate 3: 4-(4-Bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline;
  • 5.45 g (14.0 mmol) of 1-(4-bromo-phenyl)-2-[(2,4-dichloro-benzyl)-methyl-amino]-ethanol was introduced into 15 ml of dichloromethane and, at 0° C., 15 ml of conc. H2SO4 are added. After stirring at room temperature for 2 hours, the reaction mixture was poured onto ice and made alkaline with 6 N NaOH. Three extractions with dichloromethane were carried out. The combined organic phases were dried with MgSO4 and concentrated. For further purification, the residue was chromatographed on silica gel, resulting in 2.6 g of the title compound as a yellowish oil.
  • 4-(4-Bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline, hydrochloride;
    Figure US20050009864A1-20050113-C00015
  • 300 mg of 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline was stirred in 2 N HCl at room temperature. The resulting precipitate was filtered off with suction and dried.
    • Example 6 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid
  • Figure US20050009864A1-20050113-C00016
  • 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid; 5.57 g (15 mmol) of 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (example 5, intermediate 3) was dissolved in 150 ml of abs. DMF/benzene (1:1). After the solution was degassed, under argon 1.18 g (4.5 mmol) of triphenylphosphine and 1.17 g (9 mmol) of Ca(HCO2)2 were added. After renewed flushing with argon, 867 mg (0.75 mmol) of Pd(PPh3)4 was added and carbon monoxide was passed into the solution. The mixture was stirred at 120° C. After six hours at 120° C. and standing overnight under argon, a further 867 mg (0.75 mmol) of Pd(PPh3)4 was added and stirring at 120° C. and passing carbon monoxide into the solution was continued for eight hours. After again standing overnight, 135 mg of PdCl2 was added and reaction was allowed to take place under the same conditions. For workup, the solvent was removed in vacuo and the residue was taken up in ethyl acetate. Three extractions with 2 N NaOH were carried out. The combined aqueous phases were adjusted to pH 6 with 6 N HCl and extracted three times with ethyl acetate. The organic phases were dried with MgSO4 and freed of solvent. The residue was purified on silica gel using a dichloromethane/methanol mixture, resulting in 420 mg of the title compound (Rt=4.025 min (method A); MS(Cl+)=336.1/338.1).
    • Example 7 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-ethyl-benzamide, trifluoroacetate
  • Figure US20050009864A1-20050113-C00017
  • 146 mg (0.43 mmol) of 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid (see example 6) was dissolved in 5 ml of DMF, and 1.0 equivalent of triethylamine was added. At 0° C., a solution of 141 mg (0.43 mmol) TOTU in 3 ml of DMF was added. The mixture was stirred at 0° C. for 30 min and at room temperature for 30 min. This solution was then added at 0° C. to a solution of 0.28 ml of 2 M ethylamine solution and 0.06 ml (0.043 mmol) of triethylamine in 5 ml of DMF, and the reaction mixture was stirred at room temperature for three hours. For workup, the solvent was distilled off in vacuo, and the residue was taken up in ethyl acetate and washed twice with 1 N KOH and once with H2O. The organic phase was dried with Na2SO4 and concentrated. Chromatography on silica gel (dichloromethane/methanol 95:5) was used for further purification. Further purification on a preparative HPLC (acetonitrile/H2O/trifluoroacetic acid) afforded the desired carboxamide as trifluoroacetate (Rt=4.169 min (method A); MS(Cl+)=363.3/365.3).
    • Example 8 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-propyl-benzamide, trifluoroacetate
  • Figure US20050009864A1-20050113-C00018
  • The title compound was prepared by the method described in example 7 starting from n-propylamine and 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzoic acid (see example 6).
  • (Rt=1.881 min (method B); MS(Cl+)=377.3/379.3).
    • Example 9 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-(2-dimethylamino-ethyl)-benzamide, trifluoroacetate
  • Figure US20050009864A1-20050113-C00019
  • was prepared in analogy to example 7 starting from example 6 and N1,N1-dimethylethane-1,2-diamine by a TOTU-mediated coupling reaction (Rt=1.449 min (method B); MS(Cl+)=406.3/408.3).
    • Example 10 6,8-Dichloro-2-methyl-4-(4-morpholin-4-yl-phenyl)-1,2,3,4-tetrahydroisoquinoline, trifluoroacetate
  • Figure US20050009864A1-20050113-C00020
  • 456 mg (1.4 mmol) of Cs2CO3, 6.75 mg (0.03 mmol) of palladium acetate and 28 mg (0.045 mmol) of 2,2-bis-(diphenylphosphino)-1,1-binaphthyl was introduced into 5 ml of abs. toluene. Under argon, a solution of 0.104 ml (1.2 mmol) of morpholine in 2.5 ml of abs. DMF, and a solution of 371 mg (1.0 mmol) of 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline in 2.5 ml of abs. toluene was added, and the mixture was stirred at 100° C. for a total of 9 hours. For workup, the solvent was removed, the residue was taken up in dichloromethane, and insoluble constituents were filtered off. After concentration of the filtrate, the residue was chromatographed on silica gel (CH2Cl2/methanol 95:5), resulting in 350 mg of the desired morpholine derivative. After a further purification on a preparative HPLC it was possible to isolate 160 mg of the corresponding trifluoroacetate in the form of a colorless solid.
    • Example 11 [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-phenyl]-diethyl-amine, trifluoroacetate
  • Figure US20050009864A1-20050113-C00021
  • The procedure was analogous to the method described in example 10 starting from diethylamine and 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline (example 5, intermediate 3). Reaction time: 2 days at 100° C.; three times the amount of Pd catalyst and phosphine ligand. The desired trifluoroacetate can be isolated as a colorless solid after preparative HPLC.
    • Example 12 6,8-Dichloro-2-methyl-4-(4-piperidin-1-yl-phenyl)-1,2,3,4-tetrahydro-isoquinoline, trifluoroacetate
  • Figure US20050009864A1-20050113-C00022
  • The desired piperidine derivative can be obtained starting from piperidine and 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (example 5, intermediate 3) in analogy to the method described in example 10.
    • Example 13 6,8-Dichloro-2-methyl-4-(4-pyrrolidin-1-yl-phenyl)-1,2,3,4-tetrahydroisoquinoline, hydrochloride
  • Figure US20050009864A1-20050113-C00023
  • The reaction is carried out in analogy to the method described in example 10, starting from pyrrolidine and 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (example 5, intermediate 3). The product obtained after purification by chromatography is taken up in the DMSO/acetonitrile mixture, whereupon a precipitate separates out. This is filtered off, dissolved in 2 N HCl and freeze dried, resulting in the title compound of a colorless solid.
    • Example 14 6,8-Dichloro-2-methyl-4-[4-(4-methyl-piperazin-1-yl)-phenyl]-1,2,3,4-tetrahydro-isoquinoline, trifluoroacetate
  • Figure US20050009864A1-20050113-C00024
  • Reaction of N-methyl-piperazine and 4-(4-bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline (example 5, intermediate 3) by the method described in example 10 affords the title compound in the form of a colorless solid.
    • Example 15 6,8-Dichloro-2-cyclopropyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline, trifluoroacetate
  • Figure US20050009864A1-20050113-C00025
  • Intermediate 1: Cyclopropyl-(2,4-dichloro-benzyl)-amine;
  • 5.25 g (30 mmol) of 2,4-dichlorobenzaldehyde was introduced into 140 ml of methanol and, at room temperature, a solution of 1.71 g (30 mmol) of cyclopropylamine was added. The mixture as stirred at room temperature for 40 min and then 1.42 g (37.5 mmol) of NaBH4 was added in portions. After standing overnight, the solvent was removed and the residue was taken up in 2 N HCl. Two extractions with ethyl acetate were carried out. The aqueous phase was made alkaline with NaOH and again extracted twice with ethyl acetate. The organic phases were dried with MgSO4 and concentrated. The crude product obtained in this way, in the form of a slightly yellowish oil, was reacted further without further purification.
  • Intermediate 2: 2-[Cyclopropyl-(2,4-dichloro-benzyl)-amino]-1-phenyl-ethanone; Intermediate 1 was reacted with alpha-bromoacetophenone in the presence of triethylamine in dioxane by the method described in example 1, intermediate 3. For workup, the solvent was distilled off, and the residue was taken up in ethyl acetate. It was washed twice with H2O and twice with 2 N HCl, dried with MgSO4 and concentrated. The crude product obtained in this way was reacted further without further purification.
  • Intermediate 3: 2-[Cyclopropyl-(2,4-dichloro-benzyl)-amino]-1-phenyl-ethanol; Intermediate 2 was reduced with NaBH4 in analogy to the method described in example 1, intermediate 4. For workup, the mixture was concentrated, and the residue was partitioned between 1 N HCl and ethyl acetate. The aqueous phase was separated off and extracted once more with ethyl acetate. The combined organic phases were dried with MgSO4 and the solvent was removed in vacuo.
  • 6,8-Dichloro-2-cyclopropyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline, trifluoroacetate; Intermediate 3 (1.9 g) was dissolved without further purification in 10 ml of dichloromethane and cyclized with conc. H2SO4 by the method described in example 1. For workup, the reaction mixture was poured onto ice. The organic phase was separated off, and the aqueous phase was extracted once more with dichloromethane. The combined organic phases were dried with MgSO4 and freed of solvent.
  • Chromatography on silica gel (n-heptane/ethyl acetate 5:1→3:1) affords 200 mg of a yellowish oil, which was subjected to further purification on a preparative HPLC. This resulted in 184 mg of the title compound as trifluoroacetate.
    • Example 16 16a: (−)-N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide
  • 16b: (+)-N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
    Figure US20050009864A1-20050113-C00026
  • 500 mg of the title compound from example 1 was separated on a chiral phase, resulting in about 250 mg of the two enantiomeric acetamides 16a and 16b.
      • chiral column: Chiralpak OD 250×4.6 mm;
      • solvent: acetonitrile;
      • flow rate: 1 ml/min;
      • Rt((−)-enantiomer/16a)=5.856 min;
      • Rt((+)-enantiomer/16b)=8.613 min.
    Example 17 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine, hydrochloride
  • Figure US20050009864A1-20050113-C00027
  • Intermediate 1: 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine; 3.0 g (8.6 mmol) of N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide (example 1) was dissolved in 100 ml of 20% strength sodium ethanolate solution and heated under reflux for four hours. A further 2.0 g (29.4 mmol) of solid sodium ethanolate was added, and the mixture was heated under reflux for three more hours. For workup, the solvent was removed in vacuo, and the residue was taken up in 200 ml of H2O and extracted twice with dichloromethane. The combined organic phases were dried with MgSO4 and concentrated. Further purification by chromatography on silica gel (ethyl acetate/heptane 1:1) resulted in the aniline as a yellowish oil quantitative yield.
  • 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine, hydrochloride;
  • 200 mg (0.65 mmol) of 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine are dissolved in 30 ml of ethanolic HCl. The clear solution was concentrated in vacuo. The residue was triturated in ether, filtered off with suction and dried, whereupon it was possible to isolate 208 mg of the desired hydrochloride.
    • Example 18 N-Ethyl-N′-4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzenesulfonylurea, hydrochloride
  • Figure US20050009864A1-20050113-C00028
  • 1.0 mmol of 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-benzene-sulfonamide (example 4, intermediate 2) as mixed with 350 mg (2.5 eq) of K2CO3 in 15 ml of dry acetone and stirred at room temperature for 1.5 hours. A solution of 2.5 eq of ethyl isocyanate in acetone was added dropwise at room temperature, and the solution was heated to reflux. For workup, the mixture was concentrated in vacuo, and the residue was taken up in H2O and extracted twice with ethyl acetate. The aqueous phase was acidified with 6 N HCl, and the resulting precipitate was filtered off with suction. Washing with ethyl acetate and drying in vacuo afforded the title compound in good yield.
    • Example 19 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-propylurea
  • Figure US20050009864A1-20050113-C00029
  • A solution of 0.17 g (2.0 mmol) of n-propyl isocyanate in toluene was added dropwise to a stirred solution of 500 mg (1.63 mmol) of 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (see example 17) in 15 ml of toluene. After one hour at 40° C., a further 0.17 g of n-propyl isocyanate was added, and the mixture was stirred at 80° C. for one hour. For workup, the solvent was removed and the residue was triturated with H2O and ether. Drying affords 503 mg of the desired n-propylurea.
  • 19a: 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-propyl-urea, hydrochloride;
    Figure US20050009864A1-20050113-C00030
  • 450 mg of 1-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-propyl-urea were dissolved in a mixture of 2 N HCl and THF. The clear solution was concentrated in vacuo, and the residue was triturated with ether and filtered off with suction. Drying affords 473 mg of the desired hydrochloride.
    • Example 20 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea
  • Figure US20050009864A1-20050113-C00031
  • Proceeding in analogy to the method described in example 19 and starting from 500 mg (1.63 mmol) of 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (see example 17) and 220 mg (3.0 mmol) of methyl isothiocyanate allowed 245 mg of the desired thiourea to be isolated.
    • Example 21 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethylurea
  • Figure US20050009864A1-20050113-C00032
  • Preparation takes place in analogy to a method described in example 19, starting from 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (500 mg; 1.63 mmol) and ethyl isocyanate (284 mg/4 mmol).
  • 21 a: 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea, hydrochloride;
    Figure US20050009864A1-20050113-C00033
  • Conversion into the corresponding hydrochloride takes place in analogy to the method described in example 19a.
    • Example 22 N-[4-(6-Methanesulfonyl-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide
  • Figure US20050009864A1-20050113-C00034
  • Intermediate 1: (4-Methanesulfonyl-benzyl)-methyl-amine was synthesized starting from 1-bromomethyl-4-methanesulfonylbenzene and methylamine in a manner known to the skilled worker.
  • The title compound was prepared in analogy to the synthetic route indicated in example 1, starting from (4-methanesulfonyl-benzyl)-methyl-amine (intermediate 1) and N-[4-(2-bromo-acetyl)-phenyl]-acetamide (example 1, intermediate 2).
    • Example 23 N-[4-(2,6,8-Trimethyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide
  • Figure US20050009864A1-20050113-C00035
  • The synthetic route detailed in example 1 was followed, starting from (2,4-dimethyl-benzyl)-methyl-amine, which can be prepared from 1-bromomethyl-2,4-dimethyl-benzene and methylamine in a manner known to the skilled worker, and N-[4-(2-bromo-acetyl)-phenyl]-acetamide (example 1, intermediate 2).
    • Example 24 N-[4-(6-Bromo-8-chloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide
  • Figure US20050009864A1-20050113-C00036
  • The synthetic route detailed in example 1 was followed, starting from (4-bromo-2-chloro-benzyl)-methyl-amine, which can be prepared from 4-bromo-1-bromomethyl-2-chloro-benzene and methylamine in a manner known to the skilled worker, and N-[4-(2-bromo-acetyl)-phenyl]-acetamide (example 1, intermediate 2).
    • Example 25 N-[4-(8-Chloro-2-methyl-6-pyrrolidin-1-yl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide
  • Figure US20050009864A1-20050113-C00037
  • 1.02 g (3.12 mmol) of Cs2CO3, 8.8 mg (0.04 mmol) of palladium acetate and 36.1 mg (0.06 mmol) of 2,2-bis-diphenylphosphino-1,1-binaphthyl was introduced into 6.5 ml of abs. toluene under argon. At room temperature, a solution of 512 mg (1.3 mmol) of N-[4-(6-bromo-8-chloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide (example 24) in 4 ml of abs. DMF, and a solution of 111 mg (1.56 mmol) of pyrrolidine in 4 ml of DMF were added, and the mixture was heated at 100° C. for 7 hours. For workup, the solvent was removed in vacuo, and the residue was taken up in dichloromethane. Insoluble constituents were filtered off, and the filtrate was concentrated. The residue was chromatographed on silica gel with a dichloromethane/methanol mixture, and it is possible to isolate 360 mg of the compound of the example.
  • 25a: N-[4-(8-Chloro-2-methyl-6-pyrrolidin-1-yl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide, hydrochloride;
    Figure US20050009864A1-20050113-C00038
  • 320 mg of N-[4-(8-chloro-2-methyl-6-pyrrolidin-1-yl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide was dissolved in 20 ml of ethanolic HCl, stirred at room temperature for 30 min and concentrated. The residue was taken up in H2O and freeze dried.
    • Example 26 N-[4-(8-Chloro-2-methyl-6-morpholin-4-yl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide, trifluoroacetate
  • Figure US20050009864A1-20050113-C00039
  • Preparation takes place in analogy to the method described in example 25, starting from N-[4-(6-bromo-8-chloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide (example 24) and morpholine. The chromatography on silica gel was followed by a further purification on a preparative HPLC.
    • Example 27 N-{4-[8-Chloro-2-methyl-6-(4-methyl-piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinolin-4-yl]-phenyl}-acetamide
  • Figure US20050009864A1-20050113-C00040
  • Preparation takes place in analogy to the method described in example 25, starting from N-[4-(6-Bromo-8-chloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide (example 24) and N-methyl-piperazine.
  • 27a: N-{4-[8-Chloro-2-methyl-6-(4-methyl-piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinolin-4yl]-phenyl}-acetamide, hydrochloride;
    Figure US20050009864A1-20050113-C00041
  • 220 mg of N-{4-[8-Chloro-2-methyl-6-(4-methyl-piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinolin-4-yl]-phenyl}-acetamide was dissolved in a little methanol, diluted with 2 N HCl and freeze dried, resulting in 226 mg of the desired hydrochloride.
    • Example 28 N-{4-[8-Chloro-6-(cyclopropylmethyl-amino)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl]-phenyl}-acetamide, hydrochloride
  • Figure US20050009864A1-20050113-C00042
  • Preparation takes place in analogy to the method described in example 25, starting from N-[4-(6-bromo-8-chloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide (example 24) and C-cyclopropyl-methylamine. The chromatography on silica gel was followed by a further purification on a preparative HPLC. The purified compound was dissolved in 1 N HCl, diluted with H2O and freeze dried.
    • Example 29 5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoic acid
  • Figure US20050009864A1-20050113-C00043
  • Intermediate 1: Ethyl 5-acetyl-2-hydroxy-benzoate was prepared from 5-acetyl-2-hydroxy-benzoic acid by acid-catalyzed esterification in a manner known to the skilled worker.
  • Intermediate 2: Ethyl 5-(2-bromo-acetyl)-2-hydroxy-benzoate was prepared from ethyl 5-acetyl-2-hydroxy-benzoate by a known method in analogy to the process described in example 1, intermediate 2.
  • Intermediate 3: Ethyl 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoate
  • The title compound was synthesized by the synthetic route described in example 1, starting from ethyl 5-(2-bromo-acetyl)-2-hydroxy-benzoate and 2,4-dichlorobenzyl-(methyl)-amine (see example 1, intermediate 1).
  • 5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoic acid; 6.8 g (18 mmol) of ethyl 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoate was hydrolyzed in an ethanol/2 N KOH mixture in a manner known to the skilled worker, resulting in 5.4 g of the free acid.
  • 29a: 5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoic acid, sodium salt;
    Figure US20050009864A1-20050113-C00044
  • 352 mg (1 mmol) of the free acid 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoic acid was dissolved in 10 ml of 0.1 M NaOH, diluted with H2O and freeze dried, resulting in 375 mg of the title compound.
    • Example 30 5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-N-methyl-benzamide, trifluoroacetate
  • Figure US20050009864A1-20050113-C00045
  • The title compound was prepared starting from 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoic acid in a TOTU-mediated reaction with methylamine in analogy to the method described in example 7.
    • Example 31 5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-ethyl-2-hydroxy-benzamide, trifluoroacetate
  • Figure US20050009864A1-20050113-C00046
  • The title compound was prepared starting from 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoic acid in a TOTU-mediated reaction with ethylamine in analogy to the method described in example 7.
    • Example 32 5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-N-(2-dimethylamino-ethyl)-2-hydroxy-benzamide, trifluoroacetate
  • Figure US20050009864A1-20050113-C00047
  • The title compound was prepared starting from 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoic acid in a TOTU-mediated reaction with N1,N1-dimethyl-ethane-1,2-diamine in analogy to the method described in example 7.
    • Example 33 N-[5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoyl]-guanidine
  • Figure US20050009864A1-20050113-C00048
  • 2.52 g of potassium tert-butoxide was added to a solution of 2.39 g (25 mmol) of guanidine hydrochloride in 15 ml of abs. DMF and stirred at room temperature for 45 min. A solution of 950 mg (2.5 mmol) of ethyl 5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-2-hydroxy-benzoate (example 29, intermediate 3) in 10 ml of abs. DMF was added, and the mixture was stirred at room temperature for four hours. After no further increase in conversion was detectable, the precipitate was removed by filtration with suction and the solvent was removed in vacuo. The residue was taken up in 2 N HCl and extracted twice with dichloromethane. The aqueous phase was adjusted to a pH of about 10 with KOH, whereupon the desired acylguanidine separates out as a colorless precipitate. Filtration with suction and drying affords 793 mg of the title compound.
    • Example 34 N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide
  • Figure US20050009864A1-20050113-C00049
  • N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide; The desired meta-substituted acetanilide was prepared in analogy to the synthetic route indicated for example 1, starting from N-(3-acetyl-phenyl)-acetamide and 2,4-dichlorobenzyl-(methyl)-amine (example 1, intermediate 1) in four analogous stages.
    • Example 35 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine
  • Figure US20050009864A1-20050113-C00050
  • Acetyl was eliminated from N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide (example 34) by the method described in example 17, intermediate 1, in the presence of sodium ethanolate.
    • Example 36 2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine
  • Figure US20050009864A1-20050113-C00051
  • Intermediate 1: N-[2-(2-Bromo-acetyl)-phenyl]-acetamide; 31 g (0.175 mol) of N-(2-Acetylphenyl)-acetamide (prepared by acylation of 2-aminoacetophenone with acetyl chloride as described by Fuerstner, Alois; Jumbam, Denis N.; Tetrahedron; 48; 29; 5991-6010, (1992)) was dissolved in 200 ml of glacial acetic acid. 127 ml of 33% strength HBr in glacial acetic acid was added and then, at room temperature, 8.75 ml (0.175 mol) of bromine was slowly run in. The mixture was stirred at room temperature overnight. The mixture was stirred into 1.5 l of ice-water, and the precipitated product was filtered off with suction, thoroughly washed with ice-water and dried in vacuo. The crude product contained, according to HPLC and NMR, some precursor and dibrominated product, but was pure enough (about 85% strength) for further reaction.
  • Yield: 43 g
  • Intermediate 2: N-(2-{2-[(2,4-Dichloro-benzyl)-methyl-amino]-acetyl}-phenyl)-acetamide;
  • 12.4 g (65.24 mmol) of 2,4-dichloro-N-methylbenzylamine (example 1, intermediate 1) was dissolved in 200 ml of dioxane. To this was added 19.96 g of the crude product from the preceding bromination, likewise dissolved in 200 ml of dioxane, and 45 ml of triethylamine. The mixture was stirred at room temperature overnight and then filtered. The filtrate was evaporated, and the residue was taken up in ethyl acetate and washed with saturated sodium bicarbonate solution and brine, dried over sodium sulfate and concentrated in a rotary evaporator. The crude product (20.4 g) was pure enough according to NMR for further reaction.
  • Intermediate 3: N-(2-{2-[(2,4-Dichloro-benzyl)-methyl-amino]-1-hydroxy-ethyl}-phenyl)-acetamide;
  • 20 g of the crude product from the preceding stage (about 50 mmol) was dissolved in 200 ml of methanol and cooled to <5° C. in an icebath. To this were added, while stirring vigorously, 4.3 g (109 mmol) of sodium borohydride in portions so that the internal temperature does not exceed 10° C. The mixture as then stirred in the icebath for 30 min and at RT for 1 h. After standing overnight, the mixture was evaporated, and the residue was taken up in ethyl acetate, washed 3× with water and 1× with brine, dried over sodium sulfate and concentrated in a rotary evaporator. The crude product (19.4 g) was reacted further without purification.
  • Intermediate 4:1-(2-Amino-phenyl)-2-[(2,4-dichloro-benzyl)-methyl-amino]-ethanol; 10 g of the crude product from the preceding stage ere dissolved in 300 ml of methanol. 200 ml of conc. hydrochloric acid were added, and the mixture was stirred at 50° C. for 10 h. The mixture was allowed to cool and was poured into water, and the pH was adjusted to 10-12 with 20% strength NaOH. The product was extracted with ethyl acetate, and the combined extracts were washed with brine, dried over sodium sulfate and evaporated. The crude product (9.9 g) contained some sodium chloride, but this does not interfere with further reaction.
  • 2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine;
  • 9.9 g of the crude product from the preceding stage was dissolved in 350 ml of chloroform. While cooling in an icebath, 123 ml of conc. sulfuric acid were added dropwise. The mixture was stirred in the icebath for 2 h and was then allowed slowly to reach RT and was finally heated at 50° C. overnight. The cooled mixture was poured onto ice and made alkaline (pH>10) with sodium hydroxide solution. The organic phase was separated off, the aqueous phase was back-extracted 2× with methylene chloride, and the combined organic phases were washed with water and NaCl, dried over sodium sulfate and evaporated.
    • General Method for Preparing the Compounds of Examples 37 to 77
  • 154 mg (0.5 mmol) of the title compounds from example 35, example 36 or example 17, intermediate 1, were introduced into 5 ml of dichloromethane, and 0.076 ml (0.55 mmol) of triethylamine was added. At 0° C., a solution of 1.1 equivalents (0.55 mmol,) of an acid chloride in 5 ml of dichloromethane was added, and the mixture was stirred overnight while warming up. For workup, it was filtered and freed of solvent. The residue was dissolved in 20 ml of ethyl acetate and washed once each with 5% strength NaHCO3 solution and 5% strength NaCl solution, and dried. Evaporation of the solvent was followed by final purification on a preparative HPLC.
    TABLE 1
    Precursor 1/ Precursor 2/
    Example aniline acid chloride Product
    34
    Figure US20050009864A1-20050113-C00052
    Figure US20050009864A1-20050113-C00053
    Figure US20050009864A1-20050113-C00054
    Ex. 17, Int. 1
    38
    Figure US20050009864A1-20050113-C00055
    Figure US20050009864A1-20050113-C00056
    Figure US20050009864A1-20050113-C00057
    Ex. 17, Int. 1
    39
    Figure US20050009864A1-20050113-C00058
    Figure US20050009864A1-20050113-C00059
    Figure US20050009864A1-20050113-C00060
    Ex. 17, Int. 1
    40
    Figure US20050009864A1-20050113-C00061
    Figure US20050009864A1-20050113-C00062
    Figure US20050009864A1-20050113-C00063
    Ex. 17, Int. 1
    41
    Figure US20050009864A1-20050113-C00064
    Figure US20050009864A1-20050113-C00065
    Figure US20050009864A1-20050113-C00066
    Ex. 17, Int. 1
    42
    Figure US20050009864A1-20050113-C00067
    Figure US20050009864A1-20050113-C00068
    Figure US20050009864A1-20050113-C00069
    Ex. 17, Int. 1
    43
    Figure US20050009864A1-20050113-C00070
    Figure US20050009864A1-20050113-C00071
    Figure US20050009864A1-20050113-C00072
    Ex. 17, Int. 1
    44
    Figure US20050009864A1-20050113-C00073
    Figure US20050009864A1-20050113-C00074
    Figure US20050009864A1-20050113-C00075
    Ex. 17, Int. 1
    45
    Figure US20050009864A1-20050113-C00076
    Figure US20050009864A1-20050113-C00077
    Figure US20050009864A1-20050113-C00078
    Ex. 17, Int. 1
     46*
    Figure US20050009864A1-20050113-C00079
    Figure US20050009864A1-20050113-C00080
    Figure US20050009864A1-20050113-C00081
    Ex. 17, Int. 1
    47
    Figure US20050009864A1-20050113-C00082
    Figure US20050009864A1-20050113-C00083
    Figure US20050009864A1-20050113-C00084
    Ex. 17, Int. 1
    48
    Figure US20050009864A1-20050113-C00085
    Figure US20050009864A1-20050113-C00086
    Figure US20050009864A1-20050113-C00087
    Ex. 17, Int. 1
    49
    Figure US20050009864A1-20050113-C00088
    Figure US20050009864A1-20050113-C00089
    Figure US20050009864A1-20050113-C00090
    Ex. 17, Int. 1
    50
    Figure US20050009864A1-20050113-C00091
    Figure US20050009864A1-20050113-C00092
    Figure US20050009864A1-20050113-C00093
    Ex. 17, Int. 1
    51
    Figure US20050009864A1-20050113-C00094
    Figure US20050009864A1-20050113-C00095
    Figure US20050009864A1-20050113-C00096
    Ex. 35
    52
    Figure US20050009864A1-20050113-C00097
    Figure US20050009864A1-20050113-C00098
    Figure US20050009864A1-20050113-C00099
    Ex. 35
    53
    Figure US20050009864A1-20050113-C00100
    Figure US20050009864A1-20050113-C00101
    Figure US20050009864A1-20050113-C00102
    Ex. 35
    54
    Figure US20050009864A1-20050113-C00103
    Figure US20050009864A1-20050113-C00104
    Figure US20050009864A1-20050113-C00105
    Ex. 35
    55
    Figure US20050009864A1-20050113-C00106
    Figure US20050009864A1-20050113-C00107
    Figure US20050009864A1-20050113-C00108
    Ex. 35
    56
    Figure US20050009864A1-20050113-C00109
    Figure US20050009864A1-20050113-C00110
    Figure US20050009864A1-20050113-C00111
    Ex. 35
    57
    Figure US20050009864A1-20050113-C00112
    Figure US20050009864A1-20050113-C00113
    Figure US20050009864A1-20050113-C00114
    Ex. 35
    58
    Figure US20050009864A1-20050113-C00115
    Figure US20050009864A1-20050113-C00116
    Figure US20050009864A1-20050113-C00117
    Ex. 35
    59
    Figure US20050009864A1-20050113-C00118
    Figure US20050009864A1-20050113-C00119
    Figure US20050009864A1-20050113-C00120
    Ex. 35
    60
    Figure US20050009864A1-20050113-C00121
    Figure US20050009864A1-20050113-C00122
    Figure US20050009864A1-20050113-C00123
    Ex. 35
    61
    Figure US20050009864A1-20050113-C00124
    Figure US20050009864A1-20050113-C00125
    Figure US20050009864A1-20050113-C00126
    Ex. 35
    62
    Figure US20050009864A1-20050113-C00127
    Figure US20050009864A1-20050113-C00128
    Figure US20050009864A1-20050113-C00129
    Ex. 35
    63
    Figure US20050009864A1-20050113-C00130
    Figure US20050009864A1-20050113-C00131
    Figure US20050009864A1-20050113-C00132
    Ex. 35
    64
    Figure US20050009864A1-20050113-C00133
    Figure US20050009864A1-20050113-C00134
    Figure US20050009864A1-20050113-C00135
    Ex. 35
    65
    Figure US20050009864A1-20050113-C00136
    Figure US20050009864A1-20050113-C00137
    Figure US20050009864A1-20050113-C00138
    Ex. 36
    66
    Figure US20050009864A1-20050113-C00139
    Figure US20050009864A1-20050113-C00140
    Figure US20050009864A1-20050113-C00141
    Ex. 36
    67
    Figure US20050009864A1-20050113-C00142
    Figure US20050009864A1-20050113-C00143
    Figure US20050009864A1-20050113-C00144
    Ex. 36
    68
    Figure US20050009864A1-20050113-C00145
    Figure US20050009864A1-20050113-C00146
    Figure US20050009864A1-20050113-C00147
    Ex. 36
    69
    Figure US20050009864A1-20050113-C00148
    Figure US20050009864A1-20050113-C00149
    Figure US20050009864A1-20050113-C00150
    Ex. 36
    70
    Figure US20050009864A1-20050113-C00151
    Figure US20050009864A1-20050113-C00152
    Figure US20050009864A1-20050113-C00153
    Ex. 36
    71
    Figure US20050009864A1-20050113-C00154
    Figure US20050009864A1-20050113-C00155
    Figure US20050009864A1-20050113-C00156
    Ex. 36
    72
    Figure US20050009864A1-20050113-C00157
    Figure US20050009864A1-20050113-C00158
    Figure US20050009864A1-20050113-C00159
    Ex. 36
    73
    Figure US20050009864A1-20050113-C00160
    Figure US20050009864A1-20050113-C00161
    Figure US20050009864A1-20050113-C00162
    Ex. 36
    74
    Figure US20050009864A1-20050113-C00163
    Figure US20050009864A1-20050113-C00164
    Figure US20050009864A1-20050113-C00165
    Ex. 36
    75
    Figure US20050009864A1-20050113-C00166
    Figure US20050009864A1-20050113-C00167
    Figure US20050009864A1-20050113-C00168
    Ex. 36
    76
    Figure US20050009864A1-20050113-C00169
    Figure US20050009864A1-20050113-C00170
    Figure US20050009864A1-20050113-C00171
    Ex. 36
    77
    Figure US20050009864A1-20050113-C00172
    Figure US20050009864A1-20050113-C00173
    Figure US20050009864A1-20050113-C00174
    Ex. 36

    *Product precipitates from the reaction solution and requires no further purification
    • Example 78 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea, trifluoroacetate
  • Figure US20050009864A1-20050113-C00175
  • 0.355 mmol of the compound of example 35 was dissolved in 5 ml of dry acetonitrile, and 0.39 mmol of ethyl isocyanate was added. After standing overnight with exclusion of moisture, the solvent was removed and the crude product was purified on a preparative HPLC, resulting in the title compound as a colorless solid.
    • Example 79 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea, trifluoroacetate
  • Figure US20050009864A1-20050113-C00176
  • The title compound was synthesized starting from the compound of example 35 and methyl isothiocyanate by the method described in example 78.
    • Example 80 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea
  • Figure US20050009864A1-20050113-C00177
  • The process is analogous to example 78, starting from the compound of example 36 and ethyl isocyanate. For workup, the resulting precipitate was filtered off with suction and washed with acetonitrile, resulting in the desired ethylurea as a colorless solid.
    • Example 81 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-methyl-thiourea, trifluoroacetate
  • Figure US20050009864A1-20050113-C00178
  • The compound of example 36 and methyl isothiocyanate are reacted in analogy to the method described in example 78.
    • Example 82 N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide, hydrochloride
  • Figure US20050009864A1-20050113-C00179
  • 307.1 mg (1 mmol) of the compound of example 35 was dissolved in 10 ml of pyridine and at 0° C., 0.19 g (1.5 mmol) of ethanesulfonyl chloride, and a catalytic amount of DMAP are added. The mixture was stirred at room temperature.
  • For workup, the solvent was removed in vacuo, the residue was taken up in ethyl acetate and washed with H2O. The organic phase was dried with MgSO4 and concentrated. The crude product was chromatographed on silica gel. The sulfonamide obtained in this way was dissolved in a THF/2 N HCl mixture and again concentrated in vacuo, resulting in 208 mg of the desired hydrochloride.
    • Example 83 N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide, hydrochloride
  • Figure US20050009864A1-20050113-C00180
  • The process is analogous to the method described in example 82, starting from the compound of example 35 and methanesulfonyl chloride.
    • Example 84 N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-ethanesulfonamide, hydrochloride
  • Figure US20050009864A1-20050113-C00181
  • The process is analogous to the method described in example 82, starting from the compound of example 17, intermediate 1, and ethanesulfonyl chloride.
    • Example 85 N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide, hydrochloride
  • Figure US20050009864A1-20050113-C00182
  • The process is analogous to the method described in example 82, starting from the compound of example 17, intermediate 1, and methanesulfonyl chloride.
    • Example 86 86a: (−)-N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide
  • 86b: (+)-N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide;
    Figure US20050009864A1-20050113-C00183
  • 2.0 g of the title compound from example 34 were separated on a chiral phase, resulting in about 1.0 g of the two enantiomeric acetamides 86a and 86b.
      • chiral column: Chiralpak ADH/31 250×4.6 mm;
      • solvent: acetonitrile;
      • flow rate: 1 ml/min;
      • Rt((−)-enantiomer/86a)=5.541 min;
      • Rt((+)-enantiomer/86b)=7.033 min.
    General Method for Preparing the Compound of Examples 87 to 98
  • 1.0 mmol of 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (example 17, intermediate 1) or 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (example 35) was introduced into 10 ml of pyridine and, at 0° C., a solution of 1.2 equivalents of the appropriate sulfonyl chloride (see table 2) in 5 ml of dichloromethane was added dropwise. The mixture as stirred at room temperature. A catalytic amount of DMAP was added depending on the progress of the reaction and, where appropriate, the reaction temperature was increased to 50° C. until no further increase in conversion can be detected. For workup, the mixture was concentrated and the residue was partitioned between ethyl acetate and saturated NaHCO3 solution. The organic phase was separated off and washed once more with saturated NaHCO3 solution and H2O, dried with Na2SO4 and concentrated. For further purification, the crude product obtained in this way was chromatographed on silica gel. The products obtained in this way were converted into the corresponding hydrochlorides by dissolving the substances in 2 N HCl or ethanolic HCl and freeing off solvent, resulting in the desired HCl salts.
  • Purification in a preparative HPLC system results in the corresponding products as trifluoroacetates.
    TABLE 2
    Precursor 1/ Precursor 2/
    Example aniline acid chloride Product
    87
    Figure US20050009864A1-20050113-C00184
    Figure US20050009864A1-20050113-C00185
    Figure US20050009864A1-20050113-C00186
    Ex. 17, Int. 1
    88
    Figure US20050009864A1-20050113-C00187
    Figure US20050009864A1-20050113-C00188
    Figure US20050009864A1-20050113-C00189
    Ex. 17, Int. 1
     88a
    Figure US20050009864A1-20050113-C00190
    Figure US20050009864A1-20050113-C00191
    Figure US20050009864A1-20050113-C00192
    Ex. 17, Int. 1
    89
    Figure US20050009864A1-20050113-C00193
    Figure US20050009864A1-20050113-C00194
    Figure US20050009864A1-20050113-C00195
    Ex. 17, Int. 1
     89a
    Figure US20050009864A1-20050113-C00196
    Figure US20050009864A1-20050113-C00197
    Figure US20050009864A1-20050113-C00198
    Ex. 17, Int. 1
    90
    Figure US20050009864A1-20050113-C00199
    Figure US20050009864A1-20050113-C00200
    Figure US20050009864A1-20050113-C00201
    Ex. 17, Int. 1
     90a
    Figure US20050009864A1-20050113-C00202
    Figure US20050009864A1-20050113-C00203
    Figure US20050009864A1-20050113-C00204
    Ex. 17, Int. 1
    91
    Figure US20050009864A1-20050113-C00205
    Figure US20050009864A1-20050113-C00206
    Figure US20050009864A1-20050113-C00207
    Ex. 17, Int. 1
     91a
    Figure US20050009864A1-20050113-C00208
    Figure US20050009864A1-20050113-C00209
    Figure US20050009864A1-20050113-C00210
    Ex. 17, Int. 1
    92
    Figure US20050009864A1-20050113-C00211
    Figure US20050009864A1-20050113-C00212
    Figure US20050009864A1-20050113-C00213
    Ex. 17, Int. 1
     92a
    Figure US20050009864A1-20050113-C00214
    Figure US20050009864A1-20050113-C00215
    Figure US20050009864A1-20050113-C00216
    Ex. 17, Int. 1
    93
    Figure US20050009864A1-20050113-C00217
    Figure US20050009864A1-20050113-C00218
    Figure US20050009864A1-20050113-C00219
    Ex. 35
    94
    Figure US20050009864A1-20050113-C00220
    Figure US20050009864A1-20050113-C00221
    Figure US20050009864A1-20050113-C00222
    Ex. 35
     94a
    Figure US20050009864A1-20050113-C00223
    Figure US20050009864A1-20050113-C00224
    Figure US20050009864A1-20050113-C00225
    Ex. 35
    95
    Figure US20050009864A1-20050113-C00226
    Figure US20050009864A1-20050113-C00227
    Figure US20050009864A1-20050113-C00228
    Ex. 35
    96
    Figure US20050009864A1-20050113-C00229
    Figure US20050009864A1-20050113-C00230
    Figure US20050009864A1-20050113-C00231
    Ex. 35
     96a
    Figure US20050009864A1-20050113-C00232
    Figure US20050009864A1-20050113-C00233
    Figure US20050009864A1-20050113-C00234
    Ex. 35
    97
    Figure US20050009864A1-20050113-C00235
    Figure US20050009864A1-20050113-C00236
    Figure US20050009864A1-20050113-C00237
    Ex. 35
     97a
    Figure US20050009864A1-20050113-C00238
    Figure US20050009864A1-20050113-C00239
    Figure US20050009864A1-20050113-C00240
    Ex. 35
    98
    Figure US20050009864A1-20050113-C00241
    Figure US20050009864A1-20050113-C00242
    Figure US20050009864A1-20050113-C00243
    Ex. 35
    • General Method for Synthesizing the Compounds of Examples 99 to 110
  • Preparation of the Amine Component
  • 4.0 mmol of the aromatic amine (see table 3) was stirred with 8.0 mmol of the aliphatic aldehyde (see table 3) in methanol at room temperature for 2 hours and then, depending on the progress of the reaction, 0.67 to 2.0 eq of NaBH4 was added in portions. After standing at room temperature overnight, the solvent was removed and the residue was taken up in 1 N HCl. It was extracted with dichloromethane. The aqueous phase was adjusted to a pH of 11 to 12 with NaOH and again extracted with dichloromethane. The organic phases were dried with MgSO4 and concentrated in a rotary evaporator. Further purification takes place by chromatography on silica gel or on a preparative HPLC.
  • Preparation of the Bromo Ketone Component
  • The bromo ketone building blocks was synthesized by methods known from the literature, starting from commercial acetophenones by treatment with bromine in glacial acetic acid in analogy to example 1, intermediate 2.
  • The compounds of examples 100 to 111 were prepared starting from the amine and bromo ketone components shown in table 3 in analogy to the synthetic route shown in example 1 (alkylation of the amine component by the bromo ketone component, subsequent reduction with NaBH4 and final H2SO4-mediated cyclization).
  • The resulting tetrahydroisoquinolines was converted into the corresponding salts in a manner known to the skilled worker.
    TABLE 3
    Example Aromatic Aliphatic Bromo ketone
    No. aldehyde amine Amine component component Compound of example
    99
    Figure US20050009864A1-20050113-C00244
         		—NH2
    Figure US20050009864A1-20050113-C00245
    Figure US20050009864A1-20050113-C00246
     *)
    Figure US20050009864A1-20050113-C00247
    100
    Figure US20050009864A1-20050113-C00248
         		—NH2
    Figure US20050009864A1-20050113-C00249
    Figure US20050009864A1-20050113-C00250
    Figure US20050009864A1-20050113-C00251
    101
    Figure US20050009864A1-20050113-C00252
         		—NH2
    Figure US20050009864A1-20050113-C00253
    Figure US20050009864A1-20050113-C00254
    Figure US20050009864A1-20050113-C00255
    102
    Figure US20050009864A1-20050113-C00256
    Figure US20050009864A1-20050113-C00257
    Figure US20050009864A1-20050113-C00258
    Figure US20050009864A1-20050113-C00259
    Figure US20050009864A1-20050113-C00260
    103
    Figure US20050009864A1-20050113-C00261
         		—NH2
    Figure US20050009864A1-20050113-C00262
    Figure US20050009864A1-20050113-C00263
    Figure US20050009864A1-20050113-C00264
    104
    Figure US20050009864A1-20050113-C00265
    Figure US20050009864A1-20050113-C00266
    Figure US20050009864A1-20050113-C00267
    Figure US20050009864A1-20050113-C00268
    Figure US20050009864A1-20050113-C00269
    105
    Figure US20050009864A1-20050113-C00270
         		—NH2
    Figure US20050009864A1-20050113-C00271
    Figure US20050009864A1-20050113-C00272
    Figure US20050009864A1-20050113-C00273
    106
    Figure US20050009864A1-20050113-C00274
         		—NH2
    Figure US20050009864A1-20050113-C00275
    Figure US20050009864A1-20050113-C00276
    Figure US20050009864A1-20050113-C00277
    107
    Figure US20050009864A1-20050113-C00278
         		—NH2
    Figure US20050009864A1-20050113-C00279
    Figure US20050009864A1-20050113-C00280
    Figure US20050009864A1-20050113-C00281
    108
    Figure US20050009864A1-20050113-C00282
         		—NH2
    Figure US20050009864A1-20050113-C00283
    Figure US20050009864A1-20050113-C00284
    Figure US20050009864A1-20050113-C00285
    109
    Figure US20050009864A1-20050113-C00286
         		—NH2
    Figure US20050009864A1-20050113-C00287
    Figure US20050009864A1-20050113-C00288
    Figure US20050009864A1-20050113-C00289
    110
    Figure US20050009864A1-20050113-C00290
         		—NH2
    Figure US20050009864A1-20050113-C00291
    Figure US20050009864A1-20050113-C00292
    Figure US20050009864A1-20050113-C00293

    *)Synthesis described in: Lang et al., DE-A 24 36 263
    • Standard Procedure for the Preparation of the Example Compounds 111 to 124
  • 0.358 mmol of the acid component, which are listed in table 4, were dissolved in 1 ml DMF and 0.221 ml (1.30 mmol) of Diisopropylethylamine were added. At 0° C. a solution of 128 mg (0.390 mmol) TOTU was added followed by a solution of the amine component, listed in table 4. After the resulting solution was kept at room temperature overnight, the reaction mixture was filtered and the filter was washed with 20 ml of ethyl acetate. The filtrate was washed twice with sat. NaHCO3-sol., followed by 5% NaCl-sol. The organic layers were dried using MgSO4 and the solvent evaporated i. vac. The obtained crude products, which still contained Boc-protecting groups, were deprotected following the procedure given below, without further purification. The above obtained crude products, which were not Boc-protected were purified on a HPLC, by which the example compounds were obtained as the corresponding Trifluoroacetates.
    • Standard Procedure for the Preparation of the Example Compounds 125 to 147
  • 0.358 mmol of the acid component, which were listed in table 4, were dissolved in 1 ml DMF and 0.221 ml (1.30 mmol) of Diisopropylethylamine were added. At 0° C., 151 mg (0.975 mmol) Diethylcarbodiimide, a solution of 132 mg (0.975 mmol) HOBt in 1 ml DMF and 20 mg (0.162 mmol) DMAP were added, followed by a solution of the amine component, listed in table 4, in 2 ml DMF. The solution was kept at room temperature overnight. For the working up, the reaction mixture was filtered and the filter was washed with 20 ml of ethyl acetate. The filtrate was washed twice with sat. NaHCO3-sol., followed by 5% NaCl-sol. The organic layers were dried using MgSO4 and the solvent evaporated i. vac. The obtained crude products, which still contained Boc-protecting groups, were deprotected following the procedure given below, without further purification. The above obtained crude products, which were not Boc-protected were purified on a HPLC, by which the example compounds were obtained as the corresponding Trifluoroacetates.
  • Standard Procedure for the Deprotection of the Boc-Groups:
  • The obtained crude products were dissolved in 5 ml of a 10% solution of Trifluoro-acetic acid in Dichloromethane for 1 h at room temperature. The reaction mixture was evaporated i. vac. and the resulting residues were purified by HPLC. The example compounds were obtained as Trifluoro acetates.
    TABLE 4
    Example-No. Acid component Amine component Example compound
    111
    Figure US20050009864A1-20050113-C00294
    Figure US20050009864A1-20050113-C00295
    Figure US20050009864A1-20050113-C00296
    112
    Figure US20050009864A1-20050113-C00297
    Figure US20050009864A1-20050113-C00298
    Figure US20050009864A1-20050113-C00299
    113
    Figure US20050009864A1-20050113-C00300
    Figure US20050009864A1-20050113-C00301
    Figure US20050009864A1-20050113-C00302
    114
    Figure US20050009864A1-20050113-C00303
    Figure US20050009864A1-20050113-C00304
    Figure US20050009864A1-20050113-C00305
    115
    Figure US20050009864A1-20050113-C00306
    Figure US20050009864A1-20050113-C00307
    Figure US20050009864A1-20050113-C00308
    116
    Figure US20050009864A1-20050113-C00309
    Figure US20050009864A1-20050113-C00310
    Figure US20050009864A1-20050113-C00311
    117
    Figure US20050009864A1-20050113-C00312
    Figure US20050009864A1-20050113-C00313
    Figure US20050009864A1-20050113-C00314
    118
    Figure US20050009864A1-20050113-C00315
    Figure US20050009864A1-20050113-C00316
    Figure US20050009864A1-20050113-C00317
    119
    Figure US20050009864A1-20050113-C00318
    Figure US20050009864A1-20050113-C00319
    Figure US20050009864A1-20050113-C00320
    120
    Figure US20050009864A1-20050113-C00321
    Figure US20050009864A1-20050113-C00322
    Figure US20050009864A1-20050113-C00323
    121
    Figure US20050009864A1-20050113-C00324
    Figure US20050009864A1-20050113-C00325
    Figure US20050009864A1-20050113-C00326
    122
    Figure US20050009864A1-20050113-C00327
    Figure US20050009864A1-20050113-C00328
    Figure US20050009864A1-20050113-C00329
    123
    Figure US20050009864A1-20050113-C00330
    Figure US20050009864A1-20050113-C00331
    Figure US20050009864A1-20050113-C00332
    124
    Figure US20050009864A1-20050113-C00333
    Figure US20050009864A1-20050113-C00334
    Figure US20050009864A1-20050113-C00335
    125
    Figure US20050009864A1-20050113-C00336
    Figure US20050009864A1-20050113-C00337
    Figure US20050009864A1-20050113-C00338
    126
    Figure US20050009864A1-20050113-C00339
    Figure US20050009864A1-20050113-C00340
    Figure US20050009864A1-20050113-C00341
    127
    Figure US20050009864A1-20050113-C00342
    Figure US20050009864A1-20050113-C00343
    Figure US20050009864A1-20050113-C00344
    128
    Figure US20050009864A1-20050113-C00345
    Figure US20050009864A1-20050113-C00346
    Figure US20050009864A1-20050113-C00347
    129
    Figure US20050009864A1-20050113-C00348
    Figure US20050009864A1-20050113-C00349
    Figure US20050009864A1-20050113-C00350
    130
    Figure US20050009864A1-20050113-C00351
    Figure US20050009864A1-20050113-C00352
    Figure US20050009864A1-20050113-C00353
    131
    Figure US20050009864A1-20050113-C00354
    Figure US20050009864A1-20050113-C00355
    Figure US20050009864A1-20050113-C00356
    132
    Figure US20050009864A1-20050113-C00357
    Figure US20050009864A1-20050113-C00358
    Figure US20050009864A1-20050113-C00359
    133
    Figure US20050009864A1-20050113-C00360
    Figure US20050009864A1-20050113-C00361
    Figure US20050009864A1-20050113-C00362
    134
    Figure US20050009864A1-20050113-C00363
    Figure US20050009864A1-20050113-C00364
    Figure US20050009864A1-20050113-C00365
    135
    Figure US20050009864A1-20050113-C00366
    Figure US20050009864A1-20050113-C00367
    Figure US20050009864A1-20050113-C00368
    136
    Figure US20050009864A1-20050113-C00369
    Figure US20050009864A1-20050113-C00370
    Figure US20050009864A1-20050113-C00371
    137
    Figure US20050009864A1-20050113-C00372
    Figure US20050009864A1-20050113-C00373
    Figure US20050009864A1-20050113-C00374
    138
    Figure US20050009864A1-20050113-C00375
    Figure US20050009864A1-20050113-C00376
    Figure US20050009864A1-20050113-C00377
    139
    Figure US20050009864A1-20050113-C00378
    Figure US20050009864A1-20050113-C00379
    Figure US20050009864A1-20050113-C00380
    140
    Figure US20050009864A1-20050113-C00381
    Figure US20050009864A1-20050113-C00382
    Figure US20050009864A1-20050113-C00383
    141
    Figure US20050009864A1-20050113-C00384
    Figure US20050009864A1-20050113-C00385
    Figure US20050009864A1-20050113-C00386
    142
    Figure US20050009864A1-20050113-C00387
    Figure US20050009864A1-20050113-C00388
    Figure US20050009864A1-20050113-C00389
    143
    Figure US20050009864A1-20050113-C00390
    Figure US20050009864A1-20050113-C00391
    Figure US20050009864A1-20050113-C00392
    144
    Figure US20050009864A1-20050113-C00393
    Figure US20050009864A1-20050113-C00394
    Figure US20050009864A1-20050113-C00395
    145
    Figure US20050009864A1-20050113-C00396
    Figure US20050009864A1-20050113-C00397
    Figure US20050009864A1-20050113-C00398
    146
    Figure US20050009864A1-20050113-C00399
    Figure US20050009864A1-20050113-C00400
    Figure US20050009864A1-20050113-C00401
    147
    Figure US20050009864A1-20050113-C00402
    Figure US20050009864A1-20050113-C00403
    Figure US20050009864A1-20050113-C00404
    • Example 148 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-thiourea-Hydrochloride Salt
  • Figure US20050009864A1-20050113-C00405
  • 2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (95 mg, example 36) was dissolved in acetonitrile (4 ml) and isothiocyanato-ethane (27 mg) was added to the stirred solution. After standing for 15 h at room temperature the solvent was removed and the residue purified by preparative HPLC. The product containing fractions were combined and the acetonitrile was removed in vaccuo. After addition of potassium carbonate the aqueous phase was extracted with ethyl acetate. The organic layer was separated, dried (magnesium sulphate), filtered and concentrated in vaccuo. The residue was dissolved in water/2N hydrochloric acid and freeze dried to give 36 mg of the title compound.
    • Example 149 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-thiourea—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00406
  • 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (50 mg, example 17, intermediate 1) was dissolved in tetrahydrofurane (4 ml) and isothiocyanato-ethane (14 mg) was added to the stirred solution. After 2 h at reflux temperature the solution was concentrated and the residue kept for 2 h at 85° C. The crude product was purified by preparative HPLC. The product containing fractions were combined and the acetonitrile was removed in vaccuo. After addition of potassium carbonate the aqueous phase was extracted with ethyl acetate. The organic layer was separated, dried (magnesium sulphate), filtered and concentrated in vaccuo. The residue was dissolved in water/2N hydrochloric acid and freeze dried to give 33 mg of the title compound.
    • Example 150 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-thiourea—Trifluoroacetic acid salt
  • Figure US20050009864A1-20050113-C00407
  • 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (50 mg, example 35) was dissolved in tetrahydrofurane (3 ml) and isothiocyanato-ethane (14 mg) was added to the stirred solution. After 2 h at reflux temperature the solution was concentrated and the residue kept for 2 h at 85° C. The crude product was purified by preparative HPLC. The product containing fractions were combined and the solvent was removed in vaccuo to give 66 mg of the title compound.
    • Example 151 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1-dimethyl-urea—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00408
  • Intermediate 1: [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 4-nitro-phenyl ester—Hydrochloride salt
  • 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (350 mg, example 35) was dissolved in dichloromethane (17.5 ml) and 4-nitrophenyl-chloroformate (230 mg) was added to the stirred solution. After 4.5 h an additional 0.1 equivalents of 4-nitrophenyl-chloroformate (23 mg) was added and the mixture stirred over night. The precipitate was removed by suction, washed with dichloromethane and dried under vacuum. The product (545 mg) was used in the next step without further purification.
    • 3-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,1 -dimethyl-urea—Hydrochloride salt
  • [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 4-nitro-phenyl ester—Hydrochloride salt (35 mg) was suspended in dichloromethane (3.5 ml). Under stirring dimethylamine (3.7 mg) dissolved in dichloromethane (1 ml) was added. After 1 h dichloromethane, water and saturated potassium carbonate solution were added. The organic layer was separated, washed two times with saturated potassium carbonate solution, dried over magnesium sulphate, filtered and concentrated in vacuo. The residue was dissolved in water/2N hydrochloric acid and freeze dried to give 29 mg of the title compound.
  • The following examples were synthesised analogously to example 4 using the respective amine. Sometimes preparative HPLC purification was required.
    TABLE 5
    Example Structure
    152
    Figure US20050009864A1-20050113-C00409
    153
    Figure US20050009864A1-20050113-C00410
    154
    Figure US20050009864A1-20050113-C00411
    155
    Figure US20050009864A1-20050113-C00412
    156
    Figure US20050009864A1-20050113-C00413
    157
    Figure US20050009864A1-20050113-C00414
    158
    Figure US20050009864A1-20050113-C00415
  • The following examples were prepared analogously to example 151. But THF was used as solvent in a closed vial. For examples 159 and 166 a reaction temperature of 85° C. was required. Example 20 required preparative HPLC purification.
    TABLE 6
    Example Structure
    159
    Figure US20050009864A1-20050113-C00416
    160
    Figure US20050009864A1-20050113-C00417
    161
    Figure US20050009864A1-20050113-C00418
    162
    Figure US20050009864A1-20050113-C00419
    163
    Figure US20050009864A1-20050113-C00420
    164
    Figure US20050009864A1-20050113-C00421
    165
    Figure US20050009864A1-20050113-C00422
    166
    Figure US20050009864A1-20050113-C00423
    167
    Figure US20050009864A1-20050113-C00424
    • Example 168 4-Methyl-piperazine-1-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00425
  • Intermediate 1:[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 4-nitro-phenyl ester—Hydrochloride salt
  • 2(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (200 mg, example 36) was dissolved in dichloromethane (10 ml) and 4-nitrophenyl-chloroformate (131 mg) was added to the stirred solution. After 3.5 h the precipitate was removed by suction, washed with dichloromethane and dried. The crude material was re-crystalized from dichloromethane to give 159 mg of the title compound.
    • 4-Methyl-piperazine-1-carboxylic acid [2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide—Hydrochloride salt
  • [2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 4-nitro-phenyl ester—Hydrochloride salt (15 mg) was suspended in dichloromethane (2 ml). Under stirring 1-methyl-piperazine (3.2 mg) dissolved in dichloromethane (1 ml) was added. After 1 h dichloromethane, water and saturated potassium carbonate solution were added. The organic layer was separated, washed two times with saturated potassium carbonate solution, dried over magnesium sulphate, filtered and concentrated in vacuo. The residue was dissolved in water/2N hydrochloric acid and freeze dried to give 13 mg of the title compound.
  • The following examples were synthesised analogously to example 168:
    TABLE 7
    Example Structure
    169
    Figure US20050009864A1-20050113-C00426
    170
    Figure US20050009864A1-20050113-C00427
    171
    Figure US20050009864A1-20050113-C00428
    172
    Figure US20050009864A1-20050113-C00429
    173
    Figure US20050009864A1-20050113-C00430
    174
    Figure US20050009864A1-20050113-C00431
    175
    Figure US20050009864A1-20050113-C00432
    • Example 176 4-Methyl-piperazine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00433
  • Intermediate 1: [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 4-nitro-phenyl ester—Hydrochloride salt
  • 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (200 mg, example 17, intermediate 1) was dissolved in dichloromethane (10 ml) and 4-nitrophenyl-chloroformate (131 mg) was added to the stirred solution. After 4.5 h the precipitate was removed by suction, washed with dichloromethane and dried. The crude material was re-crystalized twice from dichloromethane to give 254 mg of the title compound.
    • 4-Methyl-piperazine-1-carboxylic acid [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-amide—Hydrochloride salt
  • [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 4-nitro-phenyl ester—Hydrochloride salt (15 mg) was suspended in dichloromethane (2 ml). Under stirring 1-methyl-piperazine (3.2 mg) dissolved in dichloromethane (1 ml) was added. After 5 h of stirring and standing over night dichloromethane, water and saturated potassium carbonate solution were added. The organic layer was separated, washed two times with saturated potassium carbonate solution, dried over magnesium sulphate, filtered and concentrated in vacuo. The residue was dissolved in water/2N hydrochloric acid and freeze dried to give 13 mg of the title compound.
  • The following examples were synthesised analogously to example 176:
    TABLE 8
    Example Structure
    177
    Figure US20050009864A1-20050113-C00434
    178
    Figure US20050009864A1-20050113-C00435
    179
    Figure US20050009864A1-20050113-C00436
    180
    Figure US20050009864A1-20050113-C00437
    181
    Figure US20050009864A1-20050113-C00438
    182
    Figure US20050009864A1-20050113-C00439
    183
    Figure US20050009864A1-20050113-C00440
    • Example 184 N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phen{circumflex over ( )}-yl]-formamide—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00441
  • 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (200 mg, example 17, intermediate 1) was dissolved in formic acid (1 ml) and kept for 15 min at reflux temperature. After standing over night an ice/water mixture was added followed by ethyl acetate. After separating the organic layer the aqueous phase was again extracted with ethyl acetate. The combined organic layers were dried (magnesium sulphate), filtered and concentrated in vacuo. The residue was dissolved in a mixture of dichloromethane and saturated sodium bicarbonate solution. The organic layer was separated and the aqueous phase was extracted 3 times with dichloromethane. The organic layers were combined, dried (magnesium sulphate), filtered and concentrated in vacuo to yield 167 mg crude material. 10 mg of this material was dissolved in water/2N hydrochloric acid and freeze dried to give 11 mg of the title compound.
    • Example 185 [4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amine—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00442
  • At 50° C. under stirring and argon atmosphere N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide (150 mg, example 27) dissolved in tetrahydrofurane (2.5 ml) was added to a 1 M solution of lithium aluminiumhydride in tetrahydrofurane (0.45 ml) diluted with tetrahydrofurane (2.5 ml). After the addition the mixture was heated to reflux temperature for 1 h. After standing over night at room temperature the mixture was heated to 50° C. and further lithium aluminiumhydride solution (0.22 ml) was added. The mixture was heated to reflux temperature and after 1 h the mixture was cooled, ice added and the tetrahydrofurane removed in vaccuo. The residue was dissolved in dichloromethane and hydrochloric acid. The aqueous layer was extracted three times with dichloromethane, the organic layers were combined, dried (magnesium sulphate) and concentrated. The crude material was purified by preparative HPLC. The product containing fractions were combined and the acetonitrile was removed in vaccuo. After addition of sodium bicarbonate the aqueous phase was extracted with dichloromethane. The organic layer was separated, dried (magnesium sulphate), filtered and concentrated in vaccuo to yield 80 mg of the salt free base. 10 mg of the base was dissolved in water/2N hydrochloric acid and freeze dried to give 10 mg of the title compound.
    • Example 186 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-1,3-dimethyl-urea—Hydrochloride salt
  • A002955438A
    Figure US20050009864A1-20050113-C00443
  • Following the procedure described in example 151 using [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amine, 4-nitrophenyl-chloroformate and methylamine (20 μl, 2 molar in THF) 9 mg of the title compound was obtained.
  • The following examples were synthesised analogously to example 186:
    TABLE 9
    Example Structure
    187
    Figure US20050009864A1-20050113-C00444
    188
    Figure US20050009864A1-20050113-C00445
    189
    Figure US20050009864A1-20050113-C00446
    190
    Figure US20050009864A1-20050113-C00447
    191
    Figure US20050009864A1-20050113-C00448
    192
    Figure US20050009864A1-20050113-C00449
    193
    Figure US20050009864A1-20050113-C00450
    • Example 194 N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl)-formamide
  • Figure US20050009864A1-20050113-C00451
  • 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (600 mg, example 35) was dissolved in formic acid (2.4 ml) and kept for 15 min at reflux temperature. After standing over night an ice/water mixture was added followed by ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated and the aqueous phase was extracted 3 times with dichloromethane. The organic layers were combined, dried (magnesium sulphate), filtered and concentrated in vacuo to yield 588 mg of the title compound.
    • Example 195 [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amine—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00452
  • At 50° C. under stirring and argon atmosphere N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-formamide (588 mg, example 194) dissolved in tetrahydrofurane (10 ml) was added to a 1 M solution of lithium aluminiumhydride in tetrahydrofurane (1.8 ml). After the addition the mixture was heated to reflux temperature for 1 h. After standing over night at room temperature the mixture was heated to 50° C. and further lithium aluminiumhydride solution (2 ml) added. The mixture was heated to reflux temperature and after 0.5 h the mixture was cooled and ice added. The aqueous phase was 4 times extracted with ethyl acetate. The organic layers were combined, dried (magnesium sulphate) and concentrated. The crude material was purified by preparative HPLC. The product containing fractions were combined and the acetonitrile was removed in vaccuo. After addition of sodium bicarbonate the aqueous phase was extracted with ethyl acetate. The organic layer was separated, dried (magnesium sulphate), filtered and concentrated in vaccuo to yield 270 mg of the salt free base. 45 mg of the base was dissolved in water/2N hydrochloric acid and freeze dried to give 45 mg of the title compound.
  • Following the procedure described in example 151 using [3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methyl-amine, 4-nitrophenyl-chloroformate and the respective amine the following urea derivatives were prepared:
    TABLE 10
    Example Structure
    196
    Figure US20050009864A1-20050113-C00453
    197
    Figure US20050009864A1-20050113-C00454
    198
    Figure US20050009864A1-20050113-C00455
    199
    Figure US20050009864A1-20050113-C00456
    200
    Figure US20050009864A1-20050113-C00457
    201
    Figure US20050009864A1-20050113-C00458
    202
    Figure US20050009864A1-20050113-C00459
    203
    Figure US20050009864A1-20050113-C00460
    • Example 204 [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-dimethylamino-ethyl ester—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00461
  • Under stirring and argon atmosphere [3-(6,8-dichloro-2-methyl--1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 4-nitro-phenyl ester—hydrochloride salt (15 mg, example 151, intermediate 1) was suspended in dichloromethane (1.5 ml) and 2-dimethylamino-ethanol (3 mg) dissolved in dichloromethane (0.5 ml) was added. After stirring for 6 h and standing over night dichloromethane, water and saturated potassium carbonate solution were added. The organic layer was separated, washed three times with saturated potassium carbonate solution, dried over magnesium sulphate, filtered and concentrated in vacuo. The crude material was purified by preparative HPLC. The product containing fractions were combined and the acetonitrile was removed in vaccuo. After addition of sodium bicarbonate the aqueous phase was extracted with ethyl acetate. The organic layer was separated, dried (magnesium sulphate), filtered and concentrated in vaccuo. The residue was dissolved in water/2N hydrochloric acid and freeze dried to give 5 mg of the title compound.
  • Following the procedure described in the example above the following carbamates were prepared starting from 2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine and 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine, respectively.
    TABLE 11
    Example Structure
    205
    Figure US20050009864A1-20050113-C00462
    206
    Figure US20050009864A1-20050113-C00463
    • Example 207 [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid methyl ester—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00464
  • Under stirring and argon 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine (15 mg, example 35) was dissolved in dichloromethane (1.5 ml) and methyl chloroformate (4.6 mg) dissolved in dichloromethane (0.5 ml) was added. After stirring for 6 h and standing over night additional chloro formate (2.3 mg) was added. Stirring was continued for 5 h, then the solvent was removed and the residue was dissolved in water/2N hydrochloric acid and freeze dried to give 20 mg of the title compound.
  • Following the procedure described in the example above the following carbamates were prepared starting from 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine and 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine, respectively.
    TABLE 12
    Example Structure
    208
    Figure US20050009864A1-20050113-C00465
    209
    Figure US20050009864A1-20050113-C00466
    210
    Figure US20050009864A1-20050113-C00467
    211
    Figure US20050009864A1-20050113-C00468
    212
    Figure US20050009864A1-20050113-C00469
    213
    Figure US20050009864A1-20050113-C00470
    214
    Figure US20050009864A1-20050113-C00471
    • Example
  • 215a: (+)-N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide—Hydrochloride salt
  • 215b: (−)-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide—Hydrochloride salt
    Figure US20050009864A1-20050113-C00472
  • Racemic N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-methanesulfonamide (96 mg, example 83) was resolved by chiral preparative HPLC.
      • Chiral phase: Chiralpak AD 250×50 mm; 20μ;
      • Solvent: Heptane:Ethanol:Methanol: 10:1:1;
      • Flow rate: 50 ml/min
  • The residue was dissolved in water/2N hydrochloric acid and freeze dried to give 37 mg of the first eluting and 37 mg of the second eluting enantiomer.
  • The enantiomeric purity was determined by analytical HPLC.
      • column: Chiralpak AD-H/31 250×4.6 mm
      • mobile Phase: heptane:ethanol:methanol 10:1:1, flow: 1 m/min.
      • First eluting enantiomer: 6.84 min, 100% ee, MS (ES+, M+H+): 385.2
      • Second eluting enantiomer: 8.02 min, 100% ee, MS (ES+, M+H+): 385.2
    Example
  • 216a: (+)-1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea—Hydrochloride salt
  • 216b: (−)-1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea—Hydrochloride salt
    Figure US20050009864A1-20050113-C00473
  • Racemic 1-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-3-ethyl-urea (316 mg, example 80) were resolved by chiral preparative HPLC.
      • Chiral phase: Chiralpak OD 250×50 mm; 20μ;
      • Solvent: Heptane:Ethanol:iso-Propanol: 10:1:1; 0.3% Diethylamine;
      • Flow rate: 50 m/min
  • The enantiomers were separately further purified using preparative HPLC. The product containing fractions were combined and the acetonitrile was removed in vaccuo. After addition of sodium bicarbonate the aqueous phase was extracted with ethyl acetate.
  • The organic layer was separated, dried (magnesium sulphate), filtered and concentrated in vaccuo. The residue was dissolved in water/2N hydrochloric acid and freeze dried to give 37 mg of the first eluting and 58 mg of the second eluting enantiomer.
  • The enantiomeric purity was determined by analytical HPLC.
      • column: Chiralpak OD-20 250×4.6 mm
      • mobile Phase: heptane:ethanol:iso-propanol 50:2:1 (+0.3% diethylamine), flow: 1 ml/min.
      • First eluting enantiomer: 9.22 min, 100% ee, MS (ES+, M+H+): 378.1
      • Second eluting enantiomer: 9.96 min, 98% ee, MS (ES+, M+H+): 378.1
    Example 217 N-[3-(6,8-Difluoro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00474
  • Intermediate 1: 2,4-Difluorobenzyl-methyl-amine was prepared starting from 2,4-Difluoro-benzaldehyd by standart procedures.
    • N-[3-(6,8-Difluoro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-acetamide—Hydrochloride salt
  • Starting from N-(3-Acetyl-phenyl)-acetamide and 2,4-Difluorobenzyl-methyl-amine (intermediate 1) the title compound was prepared following the procedure described in example 1.
    • Example 218 4-(3-Bromo-phenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline—Hydrochloride salt
  • Figure US20050009864A1-20050113-C00475
  • Following the procedure described in example 1 starting from 2,4-dichloro-benzaldehyde and using 2-bromo-1-(3-bromo-phenyl)-ethanone as alkylating reagent 780 mg of the title compound was obtained.
    • Example 219 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline-4-yl)-phen-yl]-3-(2-hydroxy-ethyl)-urea
  • Figure US20050009864A1-20050113-C00476
  • 509 mg (1,0 mmol) [3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic-acid 4-nitro-phenyl-ester-Hydrochloride (example 151, intermediate 1) were dissolved in 15 ml DMF and at 0° C. a solution of 67,2 mg (1,1 mmol) of 2-Aminoethanol in 10 ml DMF was added. After stirring for 3 h at room temperature the solvent was removed i. vac. The residue was dissolved in ethylacetate and washed with sat. NaHCO3-solution. The organic layer was separated and the aqueous layer was extracted twice with ethylacetate. The combined organic layers were washed with sat. NaCl-solution, dried (MgSO4) and concentrated. Purification by silica gel chromatography (dichloromethane/methanol) yielded 265 mg of the title compound.
    • Example 220 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline-4-yl)-benzoic-acid-ethyl-ester
  • Figure US20050009864A1-20050113-C00477
  • Intermediate 1: 3-Acetyl-benzoic-acid can be prepared by literature procedures.
  • Intermediate 2: 3-Acetyl-benzoic-acid-ethyl-ester can be synthesized starting from Intermediate 1 by standart procedures.
  • Intermediate 3: 3-(2-Bromo-acetyl)-benzoic-acid-ethyl-ester was prepared analoguosly to Example 1, Intermediate 2, starting from 3-Acetyl-benzoic-acid-ethyl-ester (Intermediate 2).
  • 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline-4-yl)-benzoic-acid-ethyl-ester Starting from 3-(2-Bromo-acetyl)-benzoic-acid-ethyl-ester (Intermediate 3) and Dichloro-benzyl-methyl-amine (Example 1, Intermediate 1), the title compound can be prepared by the methode described in example 1.
    • Example 221 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline-4-yl)-benzoic-acid
  • Figure US20050009864A1-20050113-C00478
  • 500 mg 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinoline-4-yl)-benzoic-acid-ethyl-ester (Example 220) were dissolved in 15 ml methanol and treated with 10 ml of a 2 N KOH-solution. After 1 h at 50° C. the solvent was removed i. vac. The residue was taken up in water and was washed with ether. The aqueous phase was seperated and 2 N HCl was added until a pH-value of about 6 was reached. The precipitate was filtered off by suction and dried to give 304 mg of the title compound.
  • Analytical data for the compounds of examples 1 to 221:
    TABLE 13
    Rt MS
    Ex. Structure [min] Method MS [M + H+] Method
     1
    Figure US20050009864A1-20050113-C00479
         		1,60 B 349,1/350,1/ 351,0 ESI m.p.: 205-206° C.
      1a
    Figure US20050009864A1-20050113-C00480
         		1,60 B 349,2/351,2 ESI m.p.: 125° C. (decomp.)
      2a
    Figure US20050009864A1-20050113-C00481
         		3,63 A 371,3/373,3 412,3/414,3 ESI (+)-enantiomer
      2b
    Figure US20050009864A1-20050113-C00482
         		3,67 A 371,3/373,3 412,3/414,3 ESI (+)-enantiomer
      2c
    Figure US20050009864A1-20050113-C00483
         		3,66 A 371,1/373,1 412,1/414,1 ESI (−)-enantiomer
      2d
    Figure US20050009864A1-20050113-C00484
         		1,56 B 371,1/373,1 412,1/414,1 ESI (−)-enantiomer
     3
    Figure US20050009864A1-20050113-C00485
         		4,00 A 399,1/401,1 CI
      4a
    Figure US20050009864A1-20050113-C00486
         		3,59 A 371,2/373,2 412,2/414,2 ESI
      4b
    Figure US20050009864A1-20050113-C00487
         		1,58 B 371,0/372,0/ 373,0/373,9 ESI
     5
    Figure US20050009864A1-20050113-C00488
         		4,57 A 369,9/371,9/ 373,9 CI
     6
    Figure US20050009864A1-20050113-C00489
         		4,03 A 336,1/338,1 CI
     7
    Figure US20050009864A1-20050113-C00490
         		4,17 A 363,3/365,3 CI
     8
    Figure US20050009864A1-20050113-C00491
         		1,88 B 377,3/379,3 CI
     9
    Figure US20050009864A1-20050113-C00492
         		1,45 B 406,3/408,3 CI
     10
    Figure US20050009864A1-20050113-C00493
         		4,37 A 377.1/379,1 CI
     11
    Figure US20050009864A1-20050113-C00494
         		4,05 A 363,2/365,2 ESI
     12
    Figure US20050009864A1-20050113-C00495
         		3,79 A 375,2/377,2 ESI
     13
    Figure US20050009864A1-20050113-C00496
         		4,92 A 361,2/363,2 ESI
     14
    Figure US20050009864A1-20050113-C00497
         		4,08 A 390,2/392,2 ESI
     15
    Figure US20050009864A1-20050113-C00498
         		4,80 A 318,2/320,2 CI
     16a
    Figure US20050009864A1-20050113-C00499
         		1,61 B 349,1/350,1/ 351,1 ESI (−)-enantiomer
     16b
    Figure US20050009864A1-20050113-C00500
         		1,61 B 349,1/350,1/ 351,1 ESI (+)-enantiomer
     17
    Figure US20050009864A1-20050113-C00501
         		0,91 B 307,1/309,0 ESI
     18
    Figure US20050009864A1-20050113-C00502
         		1,63 B 442,0/444,0 ESI
     19
    Figure US20050009864A1-20050113-C00503
         		4,00 A 392,2/394,2 ESI
     19a
    Figure US20050009864A1-20050113-C00504
         		1,80 B 392,1/394,1 ESI
     20
    Figure US20050009864A1-20050113-C00505
         		1,67 B 380,1/382,2 ESI
     21
    Figure US20050009864A1-20050113-C00506
         		1,68 B 378,3/380,2 ESI m.p.: 218-220°°C.
     21a
    Figure US20050009864A1-20050113-C00507
         		1,68 B 378,1/379,1/ 380,1 ESI
     22
    Figure US20050009864A1-20050113-C00508
         		0,32 B 359,1 717,3/718,3/ 719,3 ESI
     23
    Figure US20050009864A1-20050113-C00509
         		1,60 B 309,2/310,1 ESI
     24
    Figure US20050009864A1-20050113-C00510
         		1,67 B 393,0/394,0/ 396,0/397,0 ESI
     25
    Figure US20050009864A1-20050113-C00511
         		1,85 B 384,1/386,1 ESI
     25a
    Figure US20050009864A1-20050113-C00512
         		1,78 B 384,1/385,1/ 386,2 ESI
     26
    Figure US20050009864A1-20050113-C00513
         		1,46 B 400,1/401,2/ 401,2 ESI
     27
    Figure US20050009864A1-20050113-C00514
         		0.27 B 413,2/414,2/ 415,2 ESI
     27a
    Figure US20050009864A1-20050113-C00515
         		0,25 B 413,2/414,2/ 415,2 ESI
     28
    Figure US20050009864A1-20050113-C00516
         		1,65 B 384,2/385,2 386,2 ESI
     29
    Figure US20050009864A1-20050113-C00517
         		1,67 B 352,0/353,0/ 354,0 ESI
     29a
    Figure US20050009864A1-20050113-C00518
         		1,68 B 352,0/353,0/ 354,0 ESI
     30
    Figure US20050009864A1-20050113-C00519
         		1,68 B 365,1/366,1/ 367,0/368,0 ESI
     31
    Figure US20050009864A1-20050113-C00520
         		1,79 B 379,1/380,1/ 381,1 ESI
     32
    Figure US20050009864A1-20050113-C00521
         		1,47 B 422,1/423,1/ 424,1/425,1 ESI
     33
    Figure US20050009864A1-20050113-C00522
         		1,46 B 393,1/394,1/ 395,1 ESI
     34
    Figure US20050009864A1-20050113-C00523
         		1,63 B 349,0/350,1/ 351,0 ESI
     35
    Figure US20050009864A1-20050113-C00524
         		1,17 B 307,0/308,1/ 309,1 ESI
     36
    Figure US20050009864A1-20050113-C00525
         		1,66 B 307,0/308,0/ 309,1 ESI
     37
    Figure US20050009864A1-20050113-C00526
         		2,35 C 363,3/365,3 ESI
     38
    Figure US20050009864A1-20050113-C00527
         		2,43 C 377,3/379,3 ESI
     39
    Figure US20050009864A1-20050113-C00528
         		2,49 C 391,3/393,3 ESI
     40
    Figure US20050009864A1-20050113-C00529
         		2,43 C 377,3/379,3 ESI
     41
    Figure US20050009864A1-20050113-C00530
         		2,48 C 391,3/393,3 ESI
     42
    Figure US20050009864A1-20050113-C00531
         		2,40 C 375,3/377,3 ESI
     43
    Figure US20050009864A1-20050113-C00532
         		2,45 C 389,3/391,3 ESI
     44
    Figure US20050009864A1-20050113-C00533
         		2,52 C 403,4/405,4 ESI
     45
    Figure US20050009864A1-20050113-C00534
         		2,49 C 403,2/404,2 ESI
     46
    Figure US20050009864A1-20050113-C00535
         		2,36 C 460,4/462,4 ESI
     47
    Figure US20050009864A1-20050113-C00536
         		2,35 C 412,2/414,3 ESI
     48
    Figure US20050009864A1-20050113-C00537
         		2,29 C 385,3/387,3 ESI
     49
    Figure US20050009864A1-20050113-C00538
         		2,37 C 399,3/401,3 ESI
     50
    Figure US20050009864A1-20050113-C00539
         		2,42 C 414,4/416,4 ESI
     51
    Figure US20050009864A1-20050113-C00540
         		2,37 C 363,3/365,3 ESI
     52
    Figure US20050009864A1-20050113-C00541
         		2,44 C 377,3/379,3 ESI
     53
    Figure US20050009864A1-20050113-C00542
         		2,51 C 391,3/393,3 ESI
     54
    Figure US20050009864A1-20050113-C00543
         		2,44 C 377,3/379,3 ESI
     55
    Figure US20050009864A1-20050113-C00544
         		2,49 C 391,3/393,3 ESI
     56
    Figure US20050009864A1-20050113-C00545
         		2,41 C 375,3/377,3 ESI
     57
    Figure US20050009864A1-20050113-C00546
         		2,47 C 389,3/391,3 ESI
     58
    Figure US20050009864A1-20050113-C00547
         		2,52 C 403,4/405,4 ESI
     59
    Figure US20050009864A1-20050113-C00548
         		2,48 C 403,2/404,2 ESI
     60
    Figure US20050009864A1-20050113-C00549
         		2,34 C 460,4/462,4 ESI
     61
    Figure US20050009864A1-20050113-C00550
         		2,36 C 412,2/414,3 ESI
     62
    Figure US20050009864A1-20050113-C00551
         		2,32 C 385,3/387,3 ESI
     63
    Figure US20050009864A1-20050113-C00552
         		2,38 C 399,3/401,3 ESI
     64
    Figure US20050009864A1-20050113-C00553
         		2,41 C 414,4/416,4 ESI
     65
    Figure US20050009864A1-20050113-C00554
         		2,30 C 363,3/365,3 ESI
     66
    Figure US20050009864A1-20050113-C00555
         		2,41 C 377,3/379,3 ESI
     67
    Figure US20050009864A1-20050113-C00556
         		2,52 C 391,3/393,3 ESI
     68
    Figure US20050009864A1-20050113-C00557
         		2,41 C 377,3/379,3 ESI
     69
    Figure US20050009864A1-20050113-C00558
         		2,45 C 391,3/393,3 ESI
     70
    Figure US20050009864A1-20050113-C00559
         		2,36 C 375,3/377,3 ESI
     71
    Figure US20050009864A1-20050113-C00560
         		2,44 C 389,3/391,3 ESI
     72
    Figure US20050009864A1-20050113-C00561
         		2,51 C 403,4/405,4 ESI
     73
    Figure US20050009864A1-20050113-C00562
         		2,70 C 403,2/404,2 ESI
     74
    Figure US20050009864A1-20050113-C00563
         		2,30 C 460,4/462,4 ESI
     75
    Figure US20050009864A1-20050113-C00564
         		2,41 C 385,3/387,3 ESI
     76
    Figure US20050009864A1-20050113-C00565
         		2,49 C 399,3/401,3 ESI
     77
    Figure US20050009864A1-20050113-C00566
         		2,55 C 414,4/416,4 ESI
     78
    Figure US20050009864A1-20050113-C00567
         		1,72 B 378,3/380,3 ESI
     79
    Figure US20050009864A1-20050113-C00568
         		1,74 B 380,3/382,3 ESI
     80
    Figure US20050009864A1-20050113-C00569
         		1,75 B 378,3/380,3 ESI
     81
    Figure US20050009864A1-20050113-C00570
         		1,68 B 380,3/382,3 ESI
     82
    Figure US20050009864A1-20050113-C00571
         		1,71 B 399,0/400,0/ 401,0/402,0/ 403,0 ESI
     83
    Figure US20050009864A1-20050113-C00572
         		1,66 B 385,0/386,0/ 387,0 ESI
     84
    Figure US20050009864A1-20050113-C00573
         		1,69 B 399,0/400,0/ 401,0/402,0 ESI
     85
    Figure US20050009864A1-20050113-C00574
         		1,64 B 385,0/386,0/ 387,0/388,0 ESI
     86a
    Figure US20050009864A1-20050113-C00575
         		1,64 B 349,3/351,3 ESI (−)-enantiomer
     86b
    Figure US20050009864A1-20050113-C00576
         		1,63 B 349,3/351,3 ESI (+)-enantiomer
     87
    Figure US20050009864A1-20050113-C00577
         		1,97 B 439,0/441,1 ESI
     88
    Figure US20050009864A1-20050113-C00578
         		1,83 B 453,0/455,0 ESI
     88a
    Figure US20050009864A1-20050113-C00579
         		1,83 B 453,0/455,0 ESI
     89
    Figure US20050009864A1-20050113-C00580
         		2,01 B 531,0/533,0/ 534,9 ESI
     89a
    Figure US20050009864A1-20050113-C00581
         		2,02 B 531,0/533,0/ 534,9 ESI
     90
    Figure US20050009864A1-20050113-C00582
         		1,78 B 525,1/527,1 ESI
     90a
    Figure US20050009864A1-20050113-C00583
         		1,79 B 525,1/527,1 ESI
     91
    Figure US20050009864A1-20050113-C00584
         		1,63 B 465,1/467,1 ESI
     91a
    Figure US20050009864A1-20050113-C00585
         		1,64 B 465,1/467,1 ESI
     92
    Figure US20050009864A1-20050113-C00586
         		1,81 B 499,1/501,1/ 503,1 ESI
     92a
    Figure US20050009864A1-20050113-C00587
         		1,82 B 499,1/501,1/ 503,1 ESI
     93
    Figure US20050009864A1-20050113-C00588
         		1,99 B 439,0/441,1 ESI
     94
    Figure US20050009864A1-20050113-C00589
         		1,87 B 453,0/455,0 ESI
     94a
    Figure US20050009864A1-20050113-C00590
         		1,87 B 453,0/455,0 ESI
     95
    Figure US20050009864A1-20050113-C00591
         		2,01 B 531,0/533,0/ 535,0 ESI
     96
    Figure US20050009864A1-20050113-C00592
         		1,75 B 525,0/527,0 ESI
     96a
    Figure US20050009864A1-20050113-C00593
         		1,75 B 525,0/527,0 ESI
     97
    Figure US20050009864A1-20050113-C00594
         		1,66 B 465,0/467,0 ESI
     97a
    Figure US20050009864A1-20050113-C00595
         		1,66 B 465,0/467,0 ESI
     98
    Figure US20050009864A1-20050113-C00596
         		1,81 B 499,1/501,1/ 503,1 ESI
     99
    Figure US20050009864A1-20050113-C00597
         		405,1/407,1 ESI m.p.: 122° C.
    100
    Figure US20050009864A1-20050113-C00598
         		4,44 A 292,2/294,2 CI s. Ex. 2; Intermediate 4
     100a
    Figure US20050009864A1-20050113-C00599
         		s. Ex. 2; Intermediate 4a
     100b
    Figure US20050009864A1-20050113-C00600
         		s. Ex. 2; Intermediate 4b
    101
    Figure US20050009864A1-20050113-C00601
         		4,43 A 326,0/328,0 ESI
    102
    Figure US20050009864A1-20050113-C00602
         		4,23 A 306,1/308,0 ESI
    103
    Figure US20050009864A1-20050113-C00603
         		2,84 C 360,0 ESI
    104
    Figure US20050009864A1-20050113-C00604
         		2,79 C 320,0/322,0 ESI
    105
    Figure US20050009864A1-20050113-C00605
         		2,64 C 291,9/293,9 ESI
    106
    Figure US20050009864A1-20050113-C00606
         		4,26 A 310,0/312,0 ESI
    107
    Figure US20050009864A1-20050113-C00607
         		4,43 A 306,1/308,1 ESI
    108
    Figure US20050009864A1-20050113-C00608
         		4,11 A 292,0/294,0 ESI
    109
    Figure US20050009864A1-20050113-C00609
         		4,28 A 292,0/294,0 ESI
    110
    Figure US20050009864A1-20050113-C00610
         		4,05 A 302,0/304 ESI
    111
    Figure US20050009864A1-20050113-C00611
         		1,37 D 364,4/366,4 ESI
    112
    Figure US20050009864A1-20050113-C00612
         		1,44 D 378,4/380,4 ESI
    113
    Figure US20050009864A1-20050113-C00613
         		1,51 D 392,4/394,4 ESI
    114
    Figure US20050009864A1-20050113-C00614
         		1,51 D 378,3/380,3 ESI
    115
    Figure US20050009864A1-20050113-C00615
         		1,58 D 392,4/394,4 ESI
    116
    Figure US20050009864A1-20050113-C00616
         		1,04 D 435,5/437,5 ESI
    117
    Figure US20050009864A1-20050113-C00617
         		1,67 D 404,4/406,4 ESI
    118
    Figure US20050009864A1-20050113-C00618
         		2,08 D 412,3/414,3 ESI
    119
    Figure US20050009864A1-20050113-C00619
         		2,27 D 400,4/402,4 ESI
    120
    Figure US20050009864A1-20050113-C00620
         		2,37 D 400,4/402,4 ESI
    121
    Figure US20050009864A1-20050113-C00621
         		1,54 D 432,5/434,5 ESI
    122
    Figure US20050009864A1-20050113-C00622
         		1,70 D 428,5/430,5 ESI
    123
    Figure US20050009864A1-20050113-C00623
         		2,55 D 445,4/447,4 ESI
    124
    Figure US20050009864A1-20050113-C00624
         		2,43 D 428,5/430,5 ESI
    125
    Figure US20050009864A1-20050113-C00625
         		1,88 D 401,4/403,4 ESI
    126
    Figure US20050009864A1-20050113-C00626
         		2,31 D 496,5/498,5 ESI
    127
    Figure US20050009864A1-20050113-C00627
         		2,14 D 429,4/431,4 ESI
    128
    Figure US20050009864A1-20050113-C00628
         		2,07 D 401,4/403,4 ESI
    129
    Figure US20050009864A1-20050113-C00629
         		2,44 D 469,4/471,4 ESI
    130
    Figure US20050009864A1-20050113-C00630
         		1,55 D 378,4/380,4 ESI
    131
    Figure US20050009864A1-20050113-C00631
         		1.52 D 392,4/394,4 ESI
    132
    Figure US20050009864A1-20050113-C00632
         		1,63 D 378,3/380,3 ESI
    133
    Figure US20050009864A1-20050113-C00633
         		1,64 D 392,4/394,4 ESI
    134
    Figure US20050009864A1-20050113-C00634
         		1,14 D 435,5/437,5 ESI
    135
    Figure US20050009864A1-20050113-C00635
         		1,62 D 404,4/406,4 ESI
    136
    Figure US20050009864A1-20050113-C00636
         		2,16 D 412,3/414,3 ESI
    137
    Figure US20050009864A1-20050113-C00637
         		2,31 D 400,4/402,4 ESI
    138
    Figure US20050009864A1-20050113-C00638
         		2,41 D 400,4/402,4 ESI
    139
    Figure US20050009864A1-20050113-C00639
         		1,62 D 432,5/434,5 ESI
    140
    Figure US20050009864A1-20050113-C00640
         		1,75 D 428,5/430,5 ESI
    141
    Figure US20050009864A1-20050113-C00641
         		2,54 D 445,4/447,4 ESI
    142
    Figure US20050009864A1-20050113-C00642
         		2,50 D 428,5/430,5 ESI
    143
    Figure US20050009864A1-20050113-C00643
         		1,95 D 401,4/403,4 ESI
    144
    Figure US20050009864A1-20050113-C00644
         		2,34 D 496,5/498,5 ESI
    145
    Figure US20050009864A1-20050113-C00645
         		2,31 D 429,4/431,4 ESI
    146
    Figure US20050009864A1-20050113-C00646
         		2,11 D 401,4/403,4 ESI
    147
    Figure US20050009864A1-20050113-C00647
         		2,48 D 469,4/471,4 ESI
    148
    Figure US20050009864A1-20050113-C00648
         		2,36 B 394,2 ESI
    149
    Figure US20050009864A1-20050113-C00649
         		2,35 B 394,2 ESI
    150
    Figure US20050009864A1-20050113-C00650
         		2,35 B 394,2 ESI
    151
    Figure US20050009864A1-20050113-C00651
         		2,15 B 378,2 ESI
    152
    Figure US20050009864A1-20050113-C00652
         		1,64 B 433,3 ESI
    153
    Figure US20050009864A1-20050113-C00653
         		2,56 B 418,3 ESI
    154
    Figure US20050009864A1-20050113-C00654
         		2,16 B 420,2 ESI
    155
    Figure US20050009864A1-20050113-C00655
         		2,34 B 404,2 ESI
    156
    Figure US20050009864A1-20050113-C00656
         		2,43 B 406,2 ESI
    157
    Figure US20050009864A1-20050113-C00657
         		2,12 364,2 ESI
    158
    Figure US20050009864A1-20050113-C00658
         		1,65 B 421,2 ESI
    159
    Figure US20050009864A1-20050113-C00659
         		2,23 B 420,3 ESI
    160
    Figure US20050009864A1-20050113-C00660
         		2,25 B 434,3 ESI
    161
    Figure US20050009864A1-20050113-C00661
         		1,72 B 461,4 ESI
    162
    Figure US20050009864A1-20050113-C00662
         		1,68 B 449,4 ESI
    163
    Figure US20050009864A1-20050113-C00663
         		1,62 B 435,3 ESI
    164
    Figure US20050009864A1-20050113-C00664
         		1,71 B 435,3 ESI
    165
    Figure US20050009864A1-20050113-C00665
         		2,21 B 408,3 ESI
    166
    Figure US20050009864A1-20050113-C00666
         		1,88 B 427,3 ESI
    167
    Figure US20050009864A1-20050113-C00667
         		1,80 B 427,3 ESI
    168
    Figure US20050009864A1-20050113-C00668
         		1,59 B 433,3 ESI
    169
    Figure US20050009864A1-20050113-C00669
         		2,12 B 364,2 ESI
    170
    Figure US20050009864A1-20050113-C00670
         		2,12 B 378,2 ESI
    171
    Figure US20050009864A1-20050113-C00671
         		2,34 B 406,3 ESI
    172
    Figure US20050009864A1-20050113-C00672
         		2,44 B 418,3 ESI
    173
    Figure US20050009864A1-20050113-C00673
         		2,11 B 420,3 ESI
    174
    Figure US20050009864A1-20050113-C00674
         		2,25 B 404,3 ESI
    175
    Figure US20050009864A1-20050113-C00675
         		0,90 B 421,5 ESI
    176
    Figure US20050009864A1-20050113-C00676
         		1,52 B 433,3 ESI
    177
    Figure US20050009864A1-20050113-C00677
         		2,34 B 404,3 ESI
    178
    Figure US20050009864A1-20050113-C00678
         		2,11 B 364,2 ESI
    179
    Figure US20050009864A1-20050113-C00679
         		2,17 B 378,3 ESI
    180
    Figure US20050009864A1-20050113-C00680
         		2,51 B 406,3 ESI
    181
    Figure US20050009864A1-20050113-C00681
         		1,59 B 421,2 ESI
    182
    Figure US20050009864A1-20050113-C00682
         		2,47 B 418,2 ESI
    183
    Figure US20050009864A1-20050113-C00683
         		2,16 B 420,2 ESI
    184
    Figure US20050009864A1-20050113-C00684
         		2,02 B 335,2 ESI
    185
    Figure US20050009864A1-20050113-C00685
         		1,92 B 321,2 ESI
    186
    Figure US20050009864A1-20050113-C00686
         		1,05 C 378,4 ESI
    187
    Figure US20050009864A1-20050113-C00687
         		0,92 C 447,5 ESI
    188
    Figure US20050009864A1-20050113-C00688
         		1,10 C 392,5 ESI
    189
    Figure US20050009864A1-20050113-C00689
         		1,24 C 432,5 ESI
    190
    Figure US20050009864A1-20050113-C00690
         		1,10 C 434,5 ESI
    191
    Figure US20050009864A1-20050113-C00691
         		1,15 C 418,4 ESI
    192
    Figure US20050009864A1-20050113-C00692
         		0,93 C 435,4 ESI
    193
    Figure US20050009864A1-20050113-C00693
         		1,22 C 420,5 ESI
    194
    Figure US20050009864A1-20050113-C00694
         		2,04 C 335,4 ESI
    195
    Figure US20050009864A1-20050113-C00695
         		0,90 C 321,3 ESI
    196
    Figure US20050009864A1-20050113-C00696
         		2,48 B 418,3 ESI
    197
    Figure US20050009864A1-20050113-C00697
         		2,62 B 432,3 ESI
    198
    Figure US20050009864A1-20050113-C00698
         		2,32 B 392,3 ESI
    199
    Figure US20050009864A1-20050113-C00699
         		2,19 B 378,2 ESI
    200
    Figure US20050009864A1-20050113-C00700
         		2,16 B 434,3 ESI
    201
    Figure US20050009864A1-20050113-C00701
         		1,61 B 447,4 ESI
    202
    Figure US20050009864A1-20050113-C00702
         		1,59 B 435,3 ESI
    203
    Figure US20050009864A1-20050113-C00703
         		2,57 B 420,3 ESI
    204
    Figure US20050009864A1-20050113-C00704
         		1,71 B 422,2 ESI
    205
    Figure US20050009864A1-20050113-C00705
         		1,70 B 422,3 ESI
    206
    Figure US20050009864A1-20050113-C00706
         		1,68 B 422,3 ESI
    207
    Figure US20050009864A1-20050113-C00707
         		2,34 B 365,1 ESI
    208
    Figure US20050009864A1-20050113-C00708
         		1,18 C 379,4 ESI
    209
    Figure US20050009864A1-20050113-C00709
         		1,24 C 393,4 ESI
    210
    Figure US20050009864A1-20050113-C00710
         		1,38 C 421,5 ESI
    211
    Figure US20050009864A1-20050113-C00711
         		1,13 C 365,4 ESI
    212
    Figure US20050009864A1-20050113-C00712
         		1,26 C 393,4 ESI
    213
    Figure US20050009864A1-20050113-C00713
         		1,40 C 421,5 ESI
    214
    Figure US20050009864A1-20050113-C00714
         		1,20 C 379,4 ESI
     215a  215b
    Figure US20050009864A1-20050113-C00715
    Figure US20050009864A1-20050113-C00716
         		385,2 ESI
     216a  216b
    Figure US20050009864A1-20050113-C00717
    Figure US20050009864A1-20050113-C00718
         		378,1 ESI
    217
    Figure US20050009864A1-20050113-C00719
         		1,86 B 317,2 ESI
    218
    Figure US20050009864A1-20050113-C00720
         		1,27 C 370,2 ESI
    219
    Figure US20050009864A1-20050113-C00721
         		0,99 B1 394,1/396,2 ESI
    220
    Figure US20050009864A1-20050113-C00722
         		1,24 B1 364,1/366,1 ESI
    221
    Figure US20050009864A1-20050113-C00723
         		1,02 B1 336,1/338,1 ESI
  • Pharmacological Data:
  • Description of Test:
  • In this test, the recovery in the intracellular pH (pHi) after an acidification is ascertained, which is initiated if the NHE is capable of functioning, even under bicarbonate-free conditions. For this purpose, the pHi was determined using the pH-sensitive fluorescent dye BCECF (Calbiochem, the precursor BCECF-AM is employed).
  • The cells were initially loaded with BCECF. The BCECF fluorescence was determined in a “Ratio Fluorescence Spectrometer” (Photon Technology International, South Brunswick, N.J., USA) at excitation wavelengths of 505 and 440 nm and an emission wavelength of 535 nm and converted into the pHi using calibration curves. The cells were incubated in NH4Cl buffer (pH 7.4) (NH4Cl buffer: 115 mM NaCl, 20 mM NH4Cl, 5 mM KCl, 1 mM CaCl2, 1 mM MgSO4, 20 mM Hepes, 5 mM glucose, 1 mg/ml BSA; a pH of 7.4 is adjusted with 1 M NaOH) even during the BCECF loading. The intracellular acidification was induced by adding 975 μl of an NH4Cl-free buffer (see below) to 25 μl aliquots of the cells incubated in NH4Cl buffer. The subsequent rate of pH recovery was recorded for two minutes with NHE1, five minutes with NHE2 and three minutes with NHE3. To calculate the inhibitory potency of the tested substances, the cells were initially investigated in buffers with which a complete or absolutely no pH recovery took place. For complete pH recovery (100%), the cells were incubated in Na+-containing buffer (133.8 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 1.25 mM MgCl2, 0.97 mM Na2HPO4, 0.23 mM NaH2PO4, 5 mM Hepes, 5 mM glucose, a pH of 7.0 is adjusted with 1 M NaOH). To determine the 0% value, the cells were incubated in an Na+-free buffer (133.8 mM choline chloride, 4.7 mM KCl, 1.25 mM CaCl2, 1.25 mM MgCl2, 0.97 mM K2HPO4, 0.23 mM KH2PO4, 5 mM Hepes, 5 mM glucose, a pH of 7.0 is adjusted with 1 M NaOH). The substances to be tested were made up in the Na+-containing buffer. The recovery of the intracellular pH at each test concentration of a substance was expressed as a percentage of the maximum recovery. The IC50 value for the particular substance for the individual NHE subtypes was calculated from the pH recovery percentages using the Sigma-Plot program.
    TABLE 14
    Example IC50 [μM], (NHE3)
    1a 0.075
    2a 0.082
    2b 0.026
    6 0.670
    7 0.250
    10 1.000
    17 0.049
    21 0.814
    23 1.507
    24 0.340
    29 0.318
    36 0.274
    48 0.349
    51 0.215
    60 0.202
    64 0.507
    81 0.730
    87 0.418
    97 0.308
    113 0.279
    119 0.682
    144 0.695
    146 0.024
    153 0.602
    183 0.597
    199 0.252
    207 0.186

Claims (2)

1. A process for preparing compounds of formula I
Figure US20050009864A1-20050113-C00724
wherein:
R1, R2, R3 and R4 are independently of one another H, F, Cl, Br, I, CN, NO2, OH, NH2, CaH2a+1, CqqH2qq−1, OCbH2b+1, COOR10, OCOR10, COR10 or Ox—(CH2)y-phenyl; wherein
a and b are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CaH2a+1 and OCbH2b+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
qq is 3, 4, 5, 6, 7 or 8, wherein the group CqqH2qq−1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
R10 is H or CcH2c+1;
c is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CcH2c+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
x is zero or 1;
y is zero, 1, 2, 3 or 4; where the phenyl ring in the group Ox—(CH2)y-phenyl is unsubstituted or substituted by 1-3 independently chosen from F, Cl, Br, CN, NO2, OH, NH2 and CdH2d+1,
d is 1, 2, 3 or 4, wherein the group CdH2d+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
or
R1, R2, R3 and R4 are independently of one another chosen from a heteroaryl with at least one heteroatom chosen from 1, 2, 3 or 4 N atoms, 1 oxygen atom and 1 S atom, present as ring atoms;
or
R1, R2, R3 and R4 are independently of one another CONR11R12 or NR11R12; wherein
R11 and R12 are independently of one another H, CeH2e+1, CrrH2rr−1;
e is 1, 2, 3, 4, 5, 6, 7 or 8;
rr is 3, 4, 5, 6, 7, or 8, wherein the groups CeH2e+1 and CrrH2rr−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O or NR13;
R13 is H or CfH2f+1;
 f is 1, 2, 3 or 4, wherein the group CfH2f+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
or
R13 and a CH2 group of R11 or R12 together with the N atom to which they are bonded form a 5- or 6-membered ring;
or
R11 and R12 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
or
R11 and R12 are independently of one another COR14, CSR14 or SO2R14;
wherein
R14 is CgH2g+1;
g is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CgH2g+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms, and/or one or more CH2 groups are replaced by O or NR13;
or
R1, R2, R3 and R4 are independently of one another —Oh—SOj—R15, with
h is zero or 1;
i is zero, 1 or 2;
R15 is CkH2k+1, OH, OClH2l+1 or NR17R18;
k is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CkH2k+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
l is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group OClH2l+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
R17 and R18 are independently of one another H or CmH2m+1;
m is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CmH2m+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms and/or one or more CH2 groups are replaced by O, CO, CS or NR19;
 R19 is H or CnH2n+1;
 n is 1, 2, 3 or 4, wherein the group CnH2n+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
 or
 R19 and a CH2 group of R17 or R18 together with the N atom to which they are bonded form a 5- or 6-membered ring;
or
R17 and R18 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
but where R2 does not equal H in any of the foregoing definitions,
R5 is H, CpH2p+1, CssH2ss−1, COR20 or SO2R20; wherein
p is 1, 2, 3, 4, 5, 6, 7 or 8,
ss is 3, 4, 5, 6, 7 or 8,
R20 is CqH2q+1;
q is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CpH2p+1, CssH2ss−1 and CqH2q+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O or NR21;
R21 is H or CrH2r+1;
r is 1, 2, 3 or 4; wherein the group CrH2r+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
R6 is H;
R7, R8 and R9 are independently of one another —Ov—SOw—R23; wherein
v is zero or 1;
w is zero, 1 or 2;
R23 is CnnH2nn+1, CmmH2mm−1, OH, OCppH2pp+1 or NR25R26;
nn and pp are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8,
mm is 3, 4, 5, 6, 7 or 8, wherein the groups CnnH2nn+1, CmmH2mm−1 and OCppH2pp+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
R25 and R26 are independently of one another H, CN, CzH2z+1, or CzzH2zz−1;
z is 1, 2, 3, 4, 5, 6, 7 or 8;
zz is 3, 4, 5, 6, 7 or 8, wherein the group CzH2z+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms and, wherein the group CzH2z+1, is unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O, CO, CS or NR27;
R27 is H or CaaH2aa+1;
 aa is 1, 2, 3 or 4, wherein the group CaaH2aa+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
or
R27 and a CH2 group of R25 or R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
or
R25 and R26 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
or
R7, R8 and R9 are independently of one another NR32COR30, NR32CSR30 or NR32SObbR30;
R30 is H, CccH2cc+1, CyyH2yy−1, pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl or piperidinyl is unsubstituted or substituted where a CH2 group is replaced by O or NR33;
R32 and R33 are independently of one another H or ChH2h+1;
bb is 2 or 3;
cc is 1, 2, 3, 4, 5, 6, 7 or 8;
yy is 3, 4, 5, 6, 7 or 8;
h is 1, 2, 3, 4, 5, 6, 7 or 8,
wherein the group ChH2h+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms, and wherein the groups CccH2cc+1 and CyyH2yy−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by NR31 and/or one CH2 group are replaced by O;
R31 is H, CkkH2kk+1, COR65 or SO2 R65;
 kk is 1, 2, 3, or 4; wherein the group CkkH2kk+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms,
 R65 is H, or CxxH2xx+1;
 xx is 1, 2, 3 or 4, wherein the group CxxH2xx+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
or
R31 together with a CH2 group of R30 forms a 5-, 6- or 7-membered ring;
or
R30 is a 5- or 6-membered heteroaryl with at least one hetero atom chosen from 1, 2, 3 or 4 N atoms, zero, 1 S atom and 1 O atom, which is unsubstituted or substituted by up to three substituents chosen from F, Cl, Br, I, CooH2oo+1, and NR7OR71;
R70 and R71 are independently of one another H,
CuuH2uu+1 or COR72;
R72 is H, or CvvH2vv+1;
oo, uu and w are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CooH2oo+1, CuuH2uu+1 and CvvH2vv+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
or
R7, R8 and R9 are independently of one another H, F, Cl, Br, I, NO2, CN, OH, NH2, CeeH2ee+1, CwwH2ww−1, OCffH2ff+1, NR4OR41, CONR40R41, COOR42, COR42 or OCOR42,
ee and ff are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8;
ww is 3, 4, 5, 6, 7 or 8, wherein the groups CeeH2ee+1, CwwH2ww−1 and OCffH2ff+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
R40 and R41 are independently of one another H, CttH2tt+1 or C(NH)NH2;
tt is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CttH2tt+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or where one or more CH2 groups are replaced by O or NR44;
R44 is H or CggH2gg+1;
gg is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CggH2gg+1 is unnsubstituted or substituted where one or more H atoms are replaced by F atoms
or
R44 forms a 5- or 6-membered ring together with a (CH2) group of R40 or R41 and the N atom to which they are bound;
or
R40 and R41 with the N atom to which they are bonded form a 5- or 6-membered ring;
R42 is H or ChhH2hh+1;
hh is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group ChhH2hh+1 is unnsubstituted or substituted where one or more H atoms are replaced by F atoms;
with the proviso that two substituents chosen from the group R7, R8 and R9 can not simultaneously be OH and OCH3,
and that at least one of the substituents R7, R8 and R9 is chosen from CONR40R41, —Ov—SOw—R23, NR32COR30, NR32CSR30 and NR32SObbR30;
or a pharmaceutically acceptable salt thereof, or a trifluoroacetate thereof in any stereoisomeric form, or a mixture of any such compounds in any ratio;
which process comprises
converting the alcohol of formula VII in the presence of an acid, to the compound of formula I
Figure US20050009864A1-20050113-C00725
where, in the compounds of the formulae VII
R1 to R5 and R7 to R9 are each as defined in formula I.
2. A process for preparing compounds of formula I
Figure US20050009864A1-20050113-C00726
wherein:
R1, R2, R3 and R4 are independently of one another H, F, Cl, Br, I, CN, NO2, OH, NH2, CaH2a+1, CqqH2qq−1, OCbH2b+1, COOR10, OCOR10, COR10 or Ox—(CH2)y-Phenyl; wherein
a and b are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CaH2a+1 and OCbH2b+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
qq is 3, 4, 5, 6, 7 or 8, wherein the group CqqH2qq−1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
R10 is H or CcH2c+1;
c is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CcH2c+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
x is zero or 1;
y is zero, 1, 2, 3 or 4; where the phenyl ring in the group Ox—(CH2)y-phenyl is unsubstituted or substituted by 1-3 independently chosen from F, Cl, Br, CN, NO2, OH, NH2 and CdH2d+1,
d is 1, 2, 3 or 4, wherein the group CdH2d+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
or
R1, R2, R3 and R4 are independently of one another chosen from a heteroaryl with at least one heteroatom chosen from 1, 2, 3 or 4 N atoms, 1 oxygen atom and 1 S atom, present as ring atoms;
or
R1, R2, R3 and R4 are independently of one another CONR11R12 or NR11R12; wherein
R11 and R12 are independently of one another H, CeH2e+1, CrrH2rr−1;
e is 1, 2, 3, 4, 5, 6, 7 or 8;
rr is 3, 4, 5, 6, 7, or 8, wherein the groups CeH2e+1 and CrrH2rr−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O or NR13;
R13 is H or CfH2f+1;
 f is 1, 2, 3 or 4, wherein the group CfH2f+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
or
R13 and a CH2 group of R11 or R12 together with the N atom to which they are bonded form a 5- or 6-membered ring;
or
R11 and R12 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
or
R11 and R12 are independently of one another COR14, CSR14 or SO2R14;
wherein
R14 is CgH2g+1;
g is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CgH2g+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms, and/or one or more CH2 groups are replaced by O or NR13;
or
R1, R2, R3 and R4 are independently of one another —Oh—SOj—R15, with
h is zero or 1;
j is zero, 1 or 2;
R15 is CkH2k+1, OH, OClH2l+1 or NR17R18;
k is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CkH2k+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
l is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group OClH2l+1 is unsubsitituted or substituted where one or more H atoms are replaced by F atoms;
R17 and R18 are independently of one another H or CmH2m+1;
m is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CmH2m+1 is unsubstituted or substituted where one or more H atoms is replaced by F atoms and/or one or more CH2 groups are replaced by O, CO, CS or NR19;
 R19 is H or CnH2n+1;
 n is 1, 2, 3 or 4, wherein the group CnH2n+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
 or
 R19 and a CH2 group of R17 or R18 together with the N atom to which they are bonded form a 5- or 6-membered ring;
or
R17 and R18 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
but where R2 does not equal H in any of the foregoing definitions,
R5 is H, CpH2p+1, CssH2ss−1, COR20 or SO2R20; wherein
p is 1, 2, 3, 4, 5, 6, 7 or 8,
ss is 3, 4, 5, 6, 7 or 8,
R20 is CqH2q+1;
q is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CpH2p+1, CssH2ss−1 and CqH2q+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O or NR21;
R21 is H or CrH2r+1;
r is 1, 2, 3 or 4; wherein the group CrH2r+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
R6 is CsH2s+1,
s is 1, 2, 3, 4, 5, 6, 7 or 8;
R7, R8 and R9 are independently of one another —Ov—SOw—R23; wherein
v is zero or 1;
w is zero, 1 or 2;
R23 is CnnH2nn+1, CmmH2mm−1, OH, OCppH2pp+1 or NR25R26;
nn and pp are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8,
mm is 3, 4, 5, 6, 7 or 8, wherein the groups CnnH2nn+1, CmmH2mm−1 and OCppH2pp+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
R25 and R26 are independently of one another H, CN, CzH2z+1, or CzzH2zz−1;
z is 1, 2, 3, 4, 5, 6, 7 or 8;
zz is 3, 4, 5, 6, 7 or 8, wherein the group CzH2z+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms and, wherein the group CzH2z+1, is unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by O, CO, CS or NR27;
R27 is H or CaaH2aa+1;
 aa is 1, 2, 3 or 4, wherein the group CaaH2aa+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
or
R27 and a CH2 group of R25 or R26 together with the N atom to which they are bonded form a 5- or 6-membered ring;
or
R25 and R26 together with the N atom to which they are bonded form a 5-, 6- or 7-membered ring;
or
R7, R8 and R9 are independently of one another NR32COR30, NR32CSR30 or NR32SObbR30;
R30 is H, CccH2cc+1, CyyH2yy−1, pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl or piperidinyl is unsubstituted or substituted where a CH2 group is replaced by O or NR33;
R32 and R33 are independently of one another H or ChH2h+1;
bb is 2 or 3;
cc is 1, 2, 3, 4, 5, 6, 7 or 8;
yy is3,4,5,6,7or8;
h is 1, 2, 3, 4, 5, 6, 7 or 8,
wherein the group ChH2h+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms, and
wherein the groups CccH2cc+1 and CyyH2yy−1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or one or more CH2 groups are replaced by NR31 and/or one CH2 group are replaced by O;
R31 is H, CkkH2kk+1, COR65 or SO2 R65;
 kk is 1, 2, 3, or 4; wherein the group CkkH2kk+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms,
 R65 is H, or CxxH2xx+1;
 xx is 1, 2, 3 or 4, wherein the group CxxH2xx+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms;
or
R31 together with a CH2 group of R30 forms a 5-, 6- or 7-membered ring;
or
R30 is a 5- or 6-membered heteroaryl with at least one hetero atom chosen from 1, 2, 3 or 4 N atoms, zero, 1 S atom and 1 O atom, which is unsubstituted or substituted by up to three substituents chosen from F, Cl, Br, I, CooH2oo+1, and NR70R71;
R70 and R71 are independently of one another H, CuuH2uu+1 or COR72;
R72 is H, or CvvH2vv+1;
oo, uu and w are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8, wherein the groups CooH2oo+1, CuuH2uu+1 and CvvH2vv+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
or
R7, R8 and R9 are independently of one another H, F, Cl, Br, I, NO2, CN, OH, NH2, CeeH2ee+1, CwwH2ww−1, OCffH2ff+1, NR4OR41, CONR4OR41, COOR42, COR42 or OCOR42,
ee and ff are independently of one another 1, 2, 3, 4, 5, 6, 7 or 8;
ww is 3, 4, 5, 6, 7 or 8, wherein the groups CeeH2ee+1, CwwH2ww−1 and OCffH2ff+1 independently of one another are unsubstituted or substituted where one or more H atoms are replaced by F atoms;
R40 and R41 are independently of one another H, CttH2tt+1 or C(NH)NH2;
it is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CttH2tt+1 is unsubstituted or substituted where one or more H atoms are replaced by F atoms and/or where one or more CH2 groups are replaced by O or NR44;
R44 is H or CggH2gg+1;
gg is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group CggH2gg+1 is unnsubstituted or substituted where one or more H atoms are replaced by F atoms
or
R44 forms a 5- or 6-membered ring together with a (CH2) group of R40 or R41 and the N atom to which they are bound;
or
R40 and R41 with the N atom to which they are bonded form a 5- or 6-membered ring;
R42 is H or ChhH2hh+1;
hh is 1, 2, 3, 4, 5, 6, 7 or 8, wherein the group ChhH2hh+1 is unnsubstituted or substituted where one or more H atoms are replaced by F atoms;
with the proviso that two substituents chosen from the group R7, R8 and R9 can not simultaneously be OH and OCH3,
and that at least one of the substituents R7, R8 and R9 is chosen from CONR40R41, —Ov—SOw—R23, NR32COR30, NR32CSR30 and NR32SObbR30;
or a pharmaceutically acceptable salt thereof, or a trifluoroacetate thereof in any stereoisomeric form, or a mixture of any such compounds in any ratio;
which process comprises
converting the amide of formula XII to the compound of formula I
Figure US20050009864A1-20050113-C00727
where, in the compounds of the formulae XII
R1 to R9 are each as defined in formula I.
US10/866,843 2001-12-05 2004-06-14 Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them Abandoned US20050009864A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/866,843 US20050009864A1 (en) 2001-12-05 2004-06-14 Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10159714.2 2001-12-05
DE10159714 2001-12-05
US35351302P 2002-02-01 2002-02-01
US10/309,352 US6911453B2 (en) 2001-12-05 2002-12-04 Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
US10/866,843 US20050009864A1 (en) 2001-12-05 2004-06-14 Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/309,352 Division US6911453B2 (en) 2001-12-05 2002-12-04 Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them

Publications (1)

Publication Number Publication Date
US20050009864A1 true US20050009864A1 (en) 2005-01-13

Family

ID=31981875

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/309,352 Expired - Lifetime US6911453B2 (en) 2001-12-05 2002-12-04 Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
US10/866,843 Abandoned US20050009864A1 (en) 2001-12-05 2004-06-14 Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/309,352 Expired - Lifetime US6911453B2 (en) 2001-12-05 2002-12-04 Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them

Country Status (1)

Country Link
US (2) US6911453B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080132526A1 (en) * 2004-05-24 2008-06-05 Glaxo Group Limited Purine Derivative
US7985740B2 (en) 2005-07-19 2011-07-26 Glaxo Group Limited Purine derivatives as agonists of the adenosine A2A receptor
US9932331B2 (en) 2014-07-25 2018-04-03 Taisho Pharmaceutical Co., Ltd. Phenyl tetrahydroisoquinoline compound substituted with heteroaryl

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389306C (en) * 1999-11-03 2010-03-30 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
CA2415532C (en) * 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
MX2007000428A (en) 2004-07-15 2008-03-05 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin.
US20060111394A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US20060111385A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
NZ555501A (en) * 2004-11-24 2010-01-29 Medpointe Healthcare Inc Compositions comprising azelastine and methods of use thereof
MX2008000717A (en) * 2005-07-15 2008-03-18 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin.
AR071997A1 (en) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co CRYSTAL FORM OF 6 - ((4S) -2-METHYL-4- (2-NAFTIL) -1,2,3,4-TETRAHYDROISOQUINOLIN-7-IL) PIRIDAZIN-3-AMINA
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2384318B1 (en) * 2008-12-31 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN102638982B (en) * 2009-05-12 2015-07-08 百时美施贵宝公司 Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorohphenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
DK2429296T3 (en) * 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US20150336892A1 (en) 2012-08-21 2015-11-26 Ardelyx, Inc Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) * 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR102287207B1 (en) 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-binding compounds and methods for inhibiting phosphate transport
EA201991676A1 (en) 2017-01-09 2020-01-30 Арделикс, Инк. NHE-MEDIATED ANTI-PORT INHIBITORS
MX2019008170A (en) 2017-01-09 2020-02-07 Ardelyx Inc Compounds useful for treating gastrointestinal tract disorders.
EA202090438A1 (en) 2017-08-04 2020-06-15 Арделикс, Инк. Glycerretic Acid Derivatives for the Treatment of Hyperkalemia
AU2020218255A1 (en) 2019-02-07 2021-09-09 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224965A1 (en) * 2000-04-18 2004-11-11 Rolf Gericke 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666763A (en) 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same
JP4907817B2 (en) 1999-11-03 2012-04-04 エーエムアール テクノロジー インコーポレイテッド 4-Phenyl substituted tetrahydroisoquinolines and their use to block reuptake of norepinephrine, dopamine and serotonin
CA2389306C (en) 1999-11-03 2010-03-30 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224965A1 (en) * 2000-04-18 2004-11-11 Rolf Gericke 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080132526A1 (en) * 2004-05-24 2008-06-05 Glaxo Group Limited Purine Derivative
US7737126B2 (en) 2004-05-24 2010-06-15 Glaxo Group Limited Purine derivative
US7985740B2 (en) 2005-07-19 2011-07-26 Glaxo Group Limited Purine derivatives as agonists of the adenosine A2A receptor
US9932331B2 (en) 2014-07-25 2018-04-03 Taisho Pharmaceutical Co., Ltd. Phenyl tetrahydroisoquinoline compound substituted with heteroaryl

Also Published As

Publication number Publication date
US20040044211A1 (en) 2004-03-04
US6911453B2 (en) 2005-06-28

Similar Documents

Publication Publication Date Title
US6911453B2 (en) Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
JP4510457B2 (en) Substituted 4-phenyltetrahydroisoquinolines, process for their production, their use as pharmaceuticals, and medicaments containing them
US7790742B2 (en) Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions thereof, methods for their preparation and therapeutic use
US6703405B2 (en) Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
US7868003B2 (en) Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use
US20080070947A1 (en) Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
AU2004224242B2 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
US6737423B2 (en) Substituted heterocyclo-norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and medicaments comprising them
JP4495462B2 (en) Substituted 4-phenyltetrahydroisoquinolinium salts, processes for their preparation, their use as medicaments and medicaments containing them
EP1513834B1 (en) Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789

Effective date: 20050901

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH,GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789

Effective date: 20050901

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION